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Working Towards Alkaloid Macrocycles 
Brian Deegan 
 
This thesis will describe the project carried out over the previous 3 years. In this 
project synthesis and isolation of new macrocyclic compounds containing 2-(2-
hydroxyethoxy)phenol and a series of diacid dichlorides, both aromatic and aliphatic 
was achieved. The synthesis of an analogous set of macrocycles containing morphine 
in place of the 2-(2-hydroxyethoxy)phenol was attempted but unsuccessful.  
The theory behind this plan was that the reactivity of the two hydroxy groups on the 2-
(2-hydroxyethoxy)phenol and those on morphine will react in the same order. This 
gives the ability to selectively join two of the diol structures (morphine or 2-(2-
hydroxyethoxy)phenol) through the phenolic hydroxy group using a diacid dichloride 
and then close these structures to make the macrocycles using another diacid 
dichloride. This method worked well for the 2-(2-hydroxyethoxy)phenol based 
macrocycles but did not work for the morphine containing macrocycles. A variety of 
other methods where attempted for the synthesis and isolation of the morphine 
macrocycles but they were not successfully isolated. 
A sample of the compounds, both macrocyclic and the open structures, were tested for 
p-glycoprotein inhibition and also for toxicological screening against various bacterial 
species. From the results of this testing new compounds were designed, isolated and 
tested.  
All of the compounds isolated where tested for metal binding to a selection of metals 
and this too will be reported on.  
 
 ix
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Chapter 1 
Literature Review 
1.1 Chiral Crown ethers 
1.1.1 Naturally Occurring Chiral Crown Ethers 
Crown ethers contain a series of carbon units, alkyl or aromatic, linked by oxygen 
atoms. Lone pairs on oxygen can be used in binding of the crown to cations. The 
cations can be metallic or non-metallic such as protonated amines. Crown ethers are 
defined mainly by their shape, with the oxygen atoms forming the base of the crown 
and each of the carbon units being the points on the crown. 
Crown ethers are studied for different reasons ranging from their biological activity1 to 
catalysis2 and utilisation in sensors.3 All of these applications stem from their structure, 
which provides them with natural cavities suitable for a huge variety of functions, 
including antibacterial agents4 and sensors.3 Crown ether chemistry is a highly 
dynamic field of research with new crown ethers are constantly being developed and 
their properties investigated.5 Some chiral crown ethers have been synthesised as 
racemic mixtures or in very small enantiomeric excess (e.e.), and then require 
separation of the stereoisomers. Separation of enantiomers is very difficult as they 
share many of the same chemical and physical properties. One method to overcome 
this problem is to synthesise enantiomerically pure macrocycles. There are many 
examples of biologically active chiral crown ethers, including Nonactin, 1, Macrolactin 
A, 2, and Monensin B. Nonactin and Macrolactin A are naturally occurring molecules 
and have been studied by several natural product isolation and total synthesis groups. 
 
 
Figure 1: Structures of 1 and 2. 
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Nonactin is the lowest homologue of the family of macrotetrolide antibiotics that have 
been isolated from a variety of streptomyces cultures. Nonactin has been successfully 
synthesised without the use of biological reagents (bacteria, enzymes, fungi etc.) by 
Lee in 1996.6  
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Scheme 1: Synthesis of Nonactin 1 
Lee’s synthesis is extensive, with ten synthetic steps to prepare 4 and eleven steps to 
synthesise 3, the starting materials for the synthesis. This is followed by a further eight 
steps to synthesise Nonactin (1) (scheme 1). Lengthy (many step) reactions have major 
drawbacks. For example, a small decrease in yield at each step will overall give rise to 
a moderate to low yield. Also after each step if purification is not carried out the 
unwanted products from each step can undergo competing reactions in the following 
steps which leads to many impurities which can make the final purification very 
difficult. Nonactin is known as being a potent antibacterial.7 The structure of Nonactin, 
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as with many crown ethers, means that it acts as an ionophore. Nonactin has been 
proven effective against Gram positive bacteria, mycobacteria and fungi.7 
Another example of a naturally occurring chiral crown ether that has been synthesised 
in the laboratory is (–)-Macrolactin A, 2, by Jarosz et al.8 Macrolactin A exhibits a 
broad band of activity with significant antiviral and cancer cell cytotoxic properties 
and also has implications for controlling human HIV.  
 
Figure 2: The principal components for synthesis (–)-Macrolactin A 
The synthesis of 2 was carried out using four principal components (11, 12, 13 and 14) 
in thirteen steps from principle components and provides relatively low yields of 
product. Although each step in the reaction proceeds in high yields, with the exception 
of the cyclisation (26 %), there are thirteen steps in the synthesis resulting in a low 
overall yield (1.9 %).  
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Scheme 2: Synthesis of (-)-Macrolactin A, 2 
The overall yield increases to 5.1 % if the synthesis of the 4 principal components (11, 
12, 13 and 14) is not taken into account. Although this synthesis is successful the 
method is complicated with thirteen synthetic steps from principal components to the 
finished product. 
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Nigericin, 15, is a polyether which is available by fermentation of streptomyces sp. 
Although the structure is a linear (figure 3) configuration it has been shown to 
normally exist in a circular shape with head to tail hydrogen bonding between the 
terminal carboxylic acid and the terminal alcohol group.9  
 
Figure 3: Nigericin, 15 
Although this compound is not a crown ether it shares many of the properties of the 
crown ethers, i.e. it is a polyether ionophore and on complexation with a guest species 
it wraps around the guest forming the crown shape, with the oxygen atoms donating 
electron density to the cation guest species. Nigericin has not been synthesised 
successfully but some subunits have been prepared, e.g. the tetrahydropyran subunit.10 
It is currently being used as an antibiotic and is a highly active K+ and Pb+ ionophore. 
Nigericin is being considered as a treatment for Pb intoxication.11 
Another natural occurring chiral macrocycle is antascomicin A, (figure 4) which is 
produced by a strain of Micromonospora n. sp. A92-306401.12 Also shown in figure 4 
is 506BD, a synthetic variation of antascomicin A13 which has been synthesised in 
twenty-six steps with an overall yield of 0.23%. Both of these macrocycles are potent 
binders to FKBP12, and do not interfere with T-cell activation. They are both 
immunosuppressants and also inhibit the immunosuppressant activity of FK506 
(tacrolimus, 18) and rapamycin (19). Structures of 18 and 19 are given in figure 5.  
 
Figure 4: Antascomicin A and the synthetic variation 506BD 
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Both FK506 (tacrolimus) and rapamycin bind to FKBP12 and inhibit distinct signal 
transduction pathways in the T lymphocyte.13 Tacrolimus is produced by Streptomyces 
tsukubaensis and rapamycin is produced by Streptomyces hygroscopicus.14 
 
Figure 5: Tacrolimus and Rapamycin  
Tacrolimus and rapamycin are both immunosuppressive and of interest for cancer 
therapies. If antascomicin A and 506BD inhibit the immunosuppressant activity of 
tacrolimus and rapamycin then it is possible to find other compounds that will also 
inhibit the activity. As a consequence of this, both tacrolimus and rapamycin may 
become more interesting for cancer therapies, as they will not have the side-effects of 
being an immunosuppressant for the cancer patient.  
In 2000 West et al. reported the isolation and characterisation of peloruside A, 20 
(figure 6), which is a potent cytotoxic macrolide from the New Zealand marine sponge 
mycale sp.15 In 2008 Richard E. Taylor et al. published a review of the synthetic efforts 
in the successful synthesis of this macrocycle.16  
 
Figure 6: (+)-Peloruside A 
Previously, a report proclaimed peloruside A as a potent cytotoxic agent with 
paclitaxel-like microtubule-stabilizing activity17 and has also been shown to have 
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synergistic effects with taxoid site drugs including Taxol®, epothilone, discodermolide 
and eleuthorobin.18 
Weber et al. published the synthesis and biological data of fifty-six chiral 
macrocycles.19 These are not naturally occurring species but are derived from natural 
products. 21-32 are glutamate derived macrocycles and 33-76 are serine derived 
macrocycles. The synthesis of these macrocycles is shown in schemes 3 and 4.  
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Scheme 3: Synthesis of Macrocycles 21-32 
21-26 underwent hydrogenation with palladium/carbon catalyst followed by addition 
of the BocPhe group in the presence of EDC and HOBt to produce 27-32. 
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Scheme 4: Synthesis of Macrocycles 33-76 
27-32 and 55-76 showed activity towards the inhibition of human plasma renin. Renin 
is used by the body to help regulate blood pressure and so by controlling the activity of 
renin in the body some manipulation of blood pressure can be achieved. In the 
glutamate derived series (27-32) the thirteen membered ring structure (27) was more 
active as an inhibitor of renin than the fourteen membered analogue (28). In the serine 
derived series the fourteen membered rings were more active than the thirteen 
membered analogues, for example 65 was more active than 63. In both the glutamine 
and serine derived series where R≠H, 35-54 and 57-76, one diastereomer is invariably 
more active than the other, although which diastereomer is the more active depends on 
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the substituent. For example 30 was three times as active as its diastereomer 29 but 31 
was over a thousand fold more active than its diastereomer 30. 
 
1.1.2 Chiral 18-Crown-6 Ethers 
A review published in 199720 compiled five rules to be considered when designing 
chiral macrocycles as enantioselective host molecules. These rules were brought 
together with reference to enantiomeric recognition of amines but may apply to any 
chiral guest molecule. The rules are listed here:  
1) “in order to obtain effective enantiomeric recognition, a primary requirement is that 
chiral macrocyclic receptors form reasonably stable complexes with guest enantiomers 
so that the repulsive interactions can effectively lessen the stability of the complex of 
one enantiomer”:  
2) “the larger chiral barrier(s) of a macrocycle usually results in a larger degree of 
enantiomeric recognition” 
3) “The low conformational flexibility of diastereomeric complexes results in a high 
degree of enantiomeric recognition. Such limited conformational flexibility usually 
results from the rigidity of the macrocycles and the possibility of multipoint attractive 
interactions between host and guest molecules” 
4) “In order to have a high degree of enantiomeric recognition, the chiral macrocyclic 
compound should be stereochemically complementary with the guest enantiomers” 
5) “The macrocyclic receptors possessing C2, C3, and D2 symmetry show higher 
enantioselectivity than those of C1 and D3 symmetry”. 
The first rule for enantiomeric recognition requires that macrocycles must have the 
ability to bind to the target guest molecule. This basic requirement is the most 
important. If the host molecule (the macrocycle) cannot bind to the guest molecule it 
will not have the ability to distinguish between the enantiomers of the guest.   
The second rule means that as the bulkiness of the chiral substituent(s) increase the 
enantioselectivity of the chiral macrocycle will increase. This occurs because the large 
group will stericaly hinder binding of the unfavourable enantiomer. Also with this rule 
there is an upper limit. If the group is so large that it blocks the binding of the guest 
then enantiomeric recognition will be decreased. The maximum size the substituent at 
the chiral centre can be before a negative impact on enantiomeric recognition occurs is 
related to the size of the macrocycle and the target guest molecule.  
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The third rule specifies the lower the conformational flexibility of the macrocycle, the 
stronger the enantiomeric recognition will be. This indicates that if the macrocycle is 
rigid then its conformation will be unable to adjust to fit both enantiomers, e.g. if the 
macrocycle is rigid and binds to the S enantiomer strongly it will be unable to adjust 
enough to accommodate the R enantiomer leading to a weak binding of the R 
enantiomer.  
The fourth rule relates to stereochemical complementarity, this means that the 
structures of the host and target guest molecule should complement each other both 
structurally and chemically. In the host guest complex where the host molecule and 
guest molecule are in close proximity there should be groups which attract each other 
to strengthen the binding in the complex. Also any groups on either the guest or host 
that could hinder the binding in the guest to host should not interact at the binding site.  
The fifth rule states that macrocyclic receptors possessing C2, C3, and D2 symmetry 
show higher enantioselectivity than those of C1 and D3 symmetry. C1 symmetric 
macrocycles have limited steric hindrance to provide an effective chiral environment 
for enantiomer recognition. D3 symmetric macrocycles have the same chiral 
substituents in triplicate; one substituent is in each section of the macrocycle. This 
means that if one enantiomer can bind to the macrocycle, the other enantiomer will 
also bind to a similar extent.  
In 1991 four chiral 18-crown-6 ethers, 77, 78, 79 and 80, were synthesised using 
cyclohexane-1,2-diol derivatives as the source of chirality.21 
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Figure 6: Compounds 77, 78, 79 and 80 
Pig liver esterase (PLE) was used as the catalyst in the synthesis of the chiral 
cyclohexane-1,2-diols because PLE gave higher optical purity and was less 
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complicated than the chemical method. The three macrocycles that only contain one 
cyclohexane-1,2-diol, structures 77, 78 and 79, were synthesised by the reaction (under 
reflux conditions in THF) of the appropriate cyclohexane diol with 
pentaethyleneglycol bis(toluene-p-sulphonate) in the presence of NaH and KBF4. This 
gave yields ranging from 15 % to 62 %.  
 
Scheme 5: Synthesis of 80 
Cis-cyclohexane-1,2-diol was treated with dimethoxymethane, LiBr and toluene-p-
sulphonic acid to isolate 81. The synthesis of 80, 27 % yield, from 81 to the 
macrocycle is outlined in scheme 3. Chiral crown ethers, 77-80, have been tested for 
transport of chiral compounds through bulk liquid membranes, using two racemic 
guest species, 1,2-diphenylethylamine hydrochloride and methyl phenylglycinate 
hydrochloride. 79 and 80 show high enantiomeric selectivity for (S)-1,2-
diphenylethylamine with optical purities of 81 % and 70 %, respectively, being 
obtained.  This indicates that at least two phenyl units are required on these 
macrocycles to act as a significant chiral steric barrier for the guest species tested.  
In 1995 Peiffer et al. synthesised four chiral 18-crown-6 ethers, 85, 86, 87 and 88, 
using chiral glycols, which were obtained from the α–amino acids: L-valine, L-leucine, 
L-isoleucine and L-phenylalanine.22  
 12 
 
Figure 7: Compounds 85-88 
Crown ethers 85-88 were synthesised in two steps from the amino acid starting 
material. First the amino acids were converted to the corresponding chiral glycol by 
reaction with sodium nitrate/acetic acid and lithium aluminium hydride in 
tetrahydrofuran. Pentaethyleneglycol bis(toluene-p-sulphonate) underwent a 
condensation reaction with the glycol to give the four chiral crown ethers in yields 
from 28 % to 45 %. 85-88 were tested for the extraction of a number of radioelements 
both of α–emitting elements (Mn 54, Co 60, Sr 85, Cs 137 and Eu 152) and γ–emitting 
elements (Pu 231, Np 237 and Am 241). 85-88 gave positive results for the extraction 
of the actinides, although they were less efficient at extracting the actinides as the most 
commonly used extractant [(N,N-diisoprpyl) octo phenyl carbamoylmethylphosphine 
oxide] and were limited in their ability to extract both the alkaline earth metals and 
transition metals.  
Sharma produced a series of chiral 18-crown-6 ethers from D-xylose.23 This was 
attained in four to six steps from a D-xylose derivative, yielding four different chiral 
crown ethers in yields from 4 % to 9 %. Each of these crown ethers, 89-92, has eight 
chiral centres in their structures shown in figure 8. 
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Figure 8: Crown ethers 89-92 
89-91 were synthesised using the four step method outlined in scheme 4 from starting 
material, 93. Deprotection of the acetonide group in 95 yielded a mixture of three 
intermediates, 96, 97 and 98. 96, 97 and 98 underwent condensation with 
diethyleneglycol ditosylate in the presence of sodium hydride in dimethylsulphoxide, 
to furnish the chiral 18-crown-6 ethers 89, 90 and 91.  
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Scheme 6: synthesis of crown ethers 89, 90 and 91 
93 was treated with silver oxide and methyl iodide in dichloromethane at room 
temperature to produce 94, which underwent oxidisation with pyridinium dichromate 
and acetic anhydride in dichloromethane to produce 99. 99 was subjected to reduction 
with sodium borohydride to produce the ribo derivative, 100. 
 
 
Scheme 7: Synthesis of 100.  
Using 100 (in place of 94) the same reaction pathways was followed (scheme 6) 
producing the macrocycle product, 92. 
In 2002 Yamato et al. reported the synthesis of chiral 18-crown-6 ethers, 105r and 
105s, using stereoisomers of cyclohexane-1,2-diol. Their stability constants for 
potassium complexation in methanol in comparison to previously reported isomers 
101-10424 were also communicated. 
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Figure 9: Structures of Compounds 101-105 
Cyclohexene oxide, 106, was reacted with benzyl alcohol with a catalytic amount of 
NaH. This reaction results in a racemic mixture of trans-2-benzyloxycyclohexanol 
107, which is then acetylated using lipase enzyme.  
 
Scheme 8: Synthesis of 108r and 107s 
The lipase enzyme acetylated the (R)-alcohol producing the (R)-acetate (108r). 108r 
and (S)-alcohol (107s) were separated and 108r was hydrolyzed yielding the (R)-
alcohol 107r, thus enabling the enantiomers (107r and 107s) to be separated with an 
enantiomeric excess > 95 %. 107r and 107s were reacted with diethyleneglycol 
ditosylate followed by the removal of the benzyl groups by hydrogenation using Pd-C 
catalyst. The resulting diols were reacted with another equivalent of diethyleneglycol 
ditosylate to give the 18-crown-6 products 105s and 105r. 101-105 have been shown to 
have stability constants for K+ (log Ks) complexation in methanol at 25 °C of: 101) 
5.88; 102) 5.33; 103) 4.08; 104) 4.53; 105) 3.10,25 which show that the greater the 
number of cis cyclohexane rings in the crown ethers in this group the better the binding 
to potassium. 
Colera et al. synthesised six chiral 18-crown-6 ethers, 109-114, (figure 10) with 
lipophilic side chains.26 Three complexes (110, 112 and 114) have benzyl groups at the 
end of the lipophilic side chains and three complexes (109, 111 and 113) have the 
benzyl groups removed. 
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Figure 10: Structure 109-114 
(–)-2,3-O-Isopropylidene-D-threitol, 115, was used as the chiral starting material in the 
synthesis of 109-114. 115 was alkylated or benzylated yielding 116 and 117 
respectively, with 118 and 119 being prepared from 116 and 117 respectively via acid 
hydrolysis.  
 
Scheme 9: Synthesis of 120 and 121 
Diols, 118 and 119 were alkylated with 2-(2-iodoethoxy)tetrahydro-2H-pyran followed 
by the removal of the tetrahydropyran moiety furnishing 120 and 121 respectively. 120 
and 121, were each reacted with triethylene glycol di-O-tosylate to form the crown 
ethers 110 and 112 respectively. For the preparation of 114; 120 was mesylated and the 
mesylated product was reacted with another equivalent of 120. Each of the crown 
ethers, 110, 112 and 114, were hydrolysed to give crown ethers 109, 111 and 113 
respectively. 109-114 underwent complexation studies, their complexation constants 
were measured by 1H-NMR studies in CD3CN with two chiral alkylammonium 
picrates, sec-butylammonium picrate and α-methylbenylammonium picrate. From the 
studies carried out 109 and 110 both show good binding to the alkylammonium 
picrates and also exhibit enantiomeric recognition. 109 binds preferentially to R-sec-
butylammonium picrate over the S enantiomer with Log K values of 4.61 and 2.55 
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respectively and binds preferentially to R-α-methylbenylammonium picrate over the S 
enantiomer with Log K values of 5.42 and 2.24 respectively. 110 binds preferentially 
to R-sec-butylammonium picrate over the S enantiomer with Log K values of 4.91 and 
2.27 respectively and binds preferentially to R-α-methylbenylammonium picrate over 
the S enantiomer with Log K values of 5.08 and 2.65 respectively. 111-114 did not 
exhibit significant binding to the picrates nor significant enantiomeric recognition. This 
suggests that the presence of two lipophilic chains gave rise to the best conditions for 
both binding to the desired alkylammonium picrates and also for the enantiomeric 
recognition. 
 
1.1.3 Chiral Crown Ethers of Different Ring Sizes 
Chiral 20-crown-6 ether, 122, has been synthesised containing three carbohydrate 
residues.27 122 was synthesised in eight steps from diacetone-D-mannitol. Diacetone-
D-mannitol was allylated producing ethers 123 and 127. 123 and 127 were separated 
and individually underwent ozonolysis followed by reductive work up to yield diol 
products 124 and 128 respectively. 124 and 128 were protected using one equivalent of 
tert-butyldimethylsilyl chloride producing 125 and 129 respectively.  
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Scheme 10: Synthesis of 126 and 129 and structure of 122 
125 was tosylated in near quantitative yield affording 126, which was reacted with 129 
to form a longer chain with tbutyldimethylsilyl protecting groups at both ends. 
Deprotection then tosylation of both alcohol groups, followed by condensation reaction 
with (4R,4'R,5R,5'R)-4,4'-bi(1,3-dioxane)-5,5'-diol produced 122.  
Naemura et al. has reported the synthesis of two chiral crown ethers 130 and 131 using 
cis-4b,5,6,10b,11,12-hexahydrochrysene and cis-4b,5,9b,10-tetrahydroindeno[2,1-
a]indene, respectively (figure 11).28  
 
Figure 11: structures of Crown ethers 130 and 131 
The subunit cis-4b,5,9b,10-tetrahydroindeno[2,1-a]indene was reported in 1980 by 
Ogura et al.29 and cis-4b,5,6,10b,11,12-hexahydrochrysene was reported by Ramage et 
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al. in 1933.30 The reaction of cis-4b,5,6,10b,11,12-hexahydrochrysene with 
pentaethyleneglycol ditosylate in a mixture of sodium hydride and tetrahydrofuran 
produced 130 in 57 % yield. The same methodology using cis-4b,5,9b,10-
tetrahydroindeno[2,1-a]indene, in place of cis-4b,5,6,10b,11,12-hexahydrochrysene, 
provides the macrocycle 131 in 50 % yield. 130 and 131 were tested for enantiomeric 
recognition with 1,2-diphenylethylamine, 2-aminotetralin and methylphenylglycinate 
hydrochloride. The results show that 131 had better enantiomeric recognition than 130 
out of the two guest species, which signifies that the more rigid the subunit contained 
in these crown ethers the better the enantiomer recognition is for these particular guest 
species.  
In 1989 Kataky et al. synthesised a series of chiral 14-crown-4 ethers, 132-143, with 
the structures shown in figure 12.31 
 
Figure 12: Crown ethers 132-143 
1,10-Dichloro-4,7-dioxadecane reacted with (S)-1,4-bis(benzyloxy)butane-2,3-diol in 
the presence of lithium t-butoxide in t-butanol producing the disubstituted ether (132, 
scheme 11) in  51 % yield. 1,10-Dichloro-4,7-dioxadecane and 3-(benzyloxy)propane-
1,2-diol were used under the same methodology producing the monosubstituted ether 
(138, scheme 11) with the yield being unreported.  
 
Scheme 11: Synthesis of ethers 132 and 138 
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Hydrolysis was carried out on 132 and 138 removing the benzyl groups yielding ethers 
133 and 139.  133 and 139 were then tosylated yielding crowns 134 and 140. 
Substitution of the tosylate groups on 134 and 140 with nitrile groups produced 135 
and 141. Methanolysis on 135 and 141 gave the methyl esters 136 and 142. The methyl 
esters, 136 and 142, were converted to acid chlorides with phosphorous pentachloride 
in dichloromethane. The acid chloride of the disubstituted 14-crown-4 ether was then 
reacted with N,N-dibutylamine to form the bis-N,N-dibutylamide product, 137. The 
acid chloride of the single substituted 14-crown-4 ether was reacted with N,N-
dimethylamine to make the N,N-dimethylamide product, 143. These macrocycles were 
tested for Li+ selectivity in blood serum mimicking solution. The disubstituted bis-N,N-
dibutylamide crown ether proved best and superior to previously reported systems.  
A series of crown ethers have been synthesised using 1-phenylethane-1,2-diol and 2,4-
dimethyl-3-oxapentane-1,5-diol as chiral subunits, 144-147.32  
 
Figure 13: Crown Ethers 144-147 
Each of the macrocycles were synthesised using the same general procedures and the 
same elements, but by varying the order in which the steps in the general procedure 
were carried out and the elements added generated the different macrocycles. The 
components used in the synthesis were 2-phenyl-2-(tetrahydro-2H-pyran-2-
yloxy)ethanol (both R and S) (149); (S,S)-2,4-dimethyl-3-oxapentane-1,5-ditosylate 
(152); 1,3-bis(bromomethyl)-2,5-dimethoxybenzene (148), and 2,4-
dinitrophenylhydrazine. To synthesise 144 and 146, 1,3-bis(bromomethyl)-2,5-
dimethoxybenzene was reacted with 149 [(S) 149 for synthesis of 144 and (R) for 146] 
using sodium hydride producing 150. 150 was deprotected with methanol containing a 
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small amount of hydrochloric acid yielding 151. The deprotected product, (R or S) 151, 
was then reacted with (S,S)-2,4-dimethyl-3-oxapentane-1,5-ditosylate with sodium 
hydride and potassium borofluoride to create the enantiomers of 153. Demethylation 
was carried out on the enantiomers of 153 using ethanethiol and sodium hydride in 
dimethylformamide producing the enantiomers of this 154. 154 was then treated with 
cerium(IV)ammonium nitrate (CAN) followed by 2,4-dinitrophenylhydrazine to give 
target products 144 and 146.  The example synthetic pathway for 144 is shown in 
scheme 12. 
 
 
Scheme 12: Synthesis of 144 
The difference in the synthesis of crown ethers 145 and 147 is that 152 was used in the 
first step and 148 was used in the closing of the macrocycle. Binding tests were carried 
out on these macrocycles with 1-amino-2-propanol, 2-amino-1-propanol, 2-amino-3-
methyl-1-butanol and 2-amino-2-phenylehtanol. The results of these tests show that 
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macrocycles 144 and 146 show better enantiomeric selectivity than 145 and 147 for the 
series of aminoalcohols that were tested. Compound 144 was shown to have 
enantioselectivity for the R enantiomers of each of the aminoalcohols tests, with the 
most pronounced selectivity being seen for 2-amino-2-phenylehtanol with a log 
(KaR/KaS) value of 1.06. Compound 146 was shown to have enantioselectivity for the S 
enantiomers of each of the aminoalcohols tests, with the most pronounced selectivity 
observed for 2-amino-2-phenylehtanol with a log (KaS/KaR) value of 0.77. 
Hayward et al. synthesised a number of chiral crown ethers, 155, 156 and 157, using 
(+)-(1S,2S)-trans-cyclohexane-1,2-diol.33  
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Figure 14: Crown ethers 155 to157 
The trans cyclohexane-1,2-diol (158, scheme 13) was reacted with allyl bromide (159). 
The product (160) was subjected to ozonolysis with a reductive work-up to produce the 
‘half-crown’ diol (161).  
 
Scheme 13: synthesis of 161 
161 was tosylated and the tosylated product was reacted with an equivalent of 161 to 
give the dicyclohexane 18-crown-6 ether product (157). 161 was reacted with 2,2’-
oxybis(ethyl tosylate) to give the 15-crown-5 ether (155) and with pentaethyleneglycol 
ditosylate to give the mono-cyclohexane 18-crown-6 ether product (156). 
Vincent et al. reported the synthesis of eight chiral crown ethers containing α,α-
trehalose, 162-169.34  
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Figure 15: Crown ethers 162-169 
The crown ethers 162, 164, 166 and 168 were prepared via the reaction of the 
appropriately protected trehalose diol derivative with tetraethylene glycol ditosylate, 
giving the target products in yields ranging from 10 % to 70 %. The benzyl protecting 
groups were then removed by hydrogenation using palladium/carbon catalyst giving 
163, 165, 167 and 169 in yields of 60 % to 94 % for the deprotection step. 
A series of crown ethers have also been synthesised with D-glucose in the structure, 
170-178.35  
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Figure 16: Crown ethers 170-178 
The condensation of 2-hydroxyethyl 2,3,6-tri-O-benzyl-4-O-(2-hydroxyethyl)-α-D-
glucopyranoside, 185, and the appropriate poly(ethylene glycol)ditosylate produced 
170-178. 2-Hydroxyethyl-2,3,6-tri-O-benzyl-4-O-(2-hydroxyethyl)-α-D-
glucopyranoside was synthesised in five steps from allyl α-D-glucopyranoside, 179. 
Allyl α-D-glucopyranoside was reacted with benzaldehyde to synthesise 181. 181 was 
benzylated to protect the two remaining hydroxy groups, yielding 182. Reductive 
cleavage of 182 gave product 183 which has one free hydroxy group, which was 
reacted with allyl bromide to form 184. Compound 184 then underwent ozonolysis 
followed by reductive workup to give the target product, 2,3,6-tri-O-benzyl-4-O-(2-
hydroxyethyl)-α-D-glucopyranoside, 185. 
 
Scheme 14: Synthesis of 185 
Condensation of 185 with diethyleneglycol ditosylate gave crown ether 170, the same 
reaction with triethyleneglycol ditosylate gave crown ether 171 and the same reaction 
with 2,2'-(1,3-phenylenebis(oxy))bis(ethane-2,1-diyl) bis(4-methylbenzenesulfonate) 
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gave crown ether 172. Crown ethers 173, 174 and 175 were prepared by the 
hydrogenation of the protected crown ethers (170, 171 and 172 respectively) over 
palladium/carbon catalyst. Crown ethers 176, 177 and 178 were synthesised by the 
acetylation of the crown ethers 170, 171 and 172 respectively. Crown ether 171 has 
been shown to have enantiomeric selective catalyst properties for the Michael addition 
reaction of methyl phenylacetate with methyl acrylate utilising potassium tert-butoxide 
as the base. With one equivalent of 171, one equivalent potassium tert-butoxide, fifteen 
equivalents of methyl acrylate and forty equivalents of methyl phenylacetate the 
reaction resulted in 63 % e.e. (S) at -78 oC and 59 % e.e. (S) at -50 oC in toluene. But 
with one equivalent of 171 to five equivalents of potassium tert-butoxide with fifteen 
equivalents of methyl acrylate and twenty equivalents of methyl phenylacetate the 
reaction the reaction gave 47% e.e. (R) at 30oC.  The reasons for the variable 
preference of the one crown ether for both R and S configurations of dimethyl 2-
phenylpentanedioate in this reaction with changing conditions is not understood. 
Another series of chiral based crown ethers that also include carbohydrates as a source 
of the chirality have also been synthesised, 186-195.36,37 All these crown ethers have a 
hexaethyleneglycol, pentaethyleneglycol or tetraethyleneglycol chain attached to the 
carbohydrate derivative at both ends. They vary mainly in the location of the 
attachment to the carbohydrate and also in the carbohydrate derivative and are very 
similar in structure to crown ethers 170 and 171.  
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Figure17: Structures of crown ethers 186-195 
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Although products 186-195 are quite similar to those in figure 15 the method of 
synthesis is different for this series than for 170-178. The same general method is 
employed for each of these macrocycles (186-195). There are three different starting 
materials used, 196, 197 and 198.  
 
Figure 18: Structures of 196, 197 and 198. 
Crown ethers 186-191 were synthesised from 196, 192 was synthesised from 197 and 
193-195 were synthesised from 198. Each macrocycle was prepared using the same 
synthetic pathway. The 2-phenyl-1,3-dioxane group in each of the starting materials 
was reductively cleaved to give a benzyl protected alcohol and a free alcohol. This 
cleaved product was then etherified with bis(2-chloroethyl)ether to form ethylene 
glycol derivatives. For the synthesis of 195 the starting material (198) was reductively 
cleaved using lithium aluminium hydride and aluminium trichloride in 
dichloromethane and diethyl ether. The reductions of 196 and 197 were carried out 
using sodium cyanoborohydride in tetrahydrofuran followed by acidic work-up with 
hydrogen chloride in diethyl ether. The ethylene glycol derivatives were then 
alkoxylated with diethyleneglycol, triethyleneglycol or tetraethyleneglycol depending 
on the size of the ring being synthesised. The ring was closed via the elimination of 
phenol for 186-192 or elimination of benzenethiol for 193-194. Crown ethers 188 and 
189 were synthesised by deallylation of crown ethers 186 and 187 respectively. The 
reaction of 188 and 189 with chloro-diphenylphosphine with pyridine in 
tetrahydrofuran yielded 190 and 191. 190 and 191 were then reacted with 
Rh(COD)acac, the acac group is replaced by the two phosphine groups that are a part 
of the crown ether. This was done to synthesise chiral catalysts. Initial testing with 
these catalysts showed positive results for the possible use of these crown ethers as 
chiral catalysts for hydrogenation reactions of 2-acyl-N-2-dehydroamino acid 
derivatives.  
A series of chiral and meso-crown ethers have been synthesised using 
tetraoxaspiro(5,5)undecane and trioxa-azaspiro(5,5)undecane as the chiral subunit, 199 
to 214.38 Synthesis was carried out by the treatment of the tetraoxaspiro(5,5)undecane 
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(for crown ethers 199, 200, 201, 211 and 212) or trioxa-azaspiro(5,5)undecane (for 
crown ethers 202-210, 213 and 214) with hydride and then the slow addition of the 
required tosylate. There were sixteen different macrocycles synthesised in this series, 
with yields varying from 2 % to 55 % depending not only on the macrocycle being 
synthesised but also the hydride used. The crown ethers in this series can be grouped 
into two main groups; [1+1] cyclocondensation products (199-210), and [2+2] 
cyclocondensation products (211-214).  
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Figure 19: Crown ethers 199-214 
Crown ethers 211-214 were isolated in low yields, 2 % to 22 %, while 199-200 were 
isolated in higher yields, 6 % to 55 %. Crown ethers 202-204 were generated 
containing the structure trioxa-azaspiro(5,5)undecane. Compounds 203 and 204 were 
then reduced to give the benzylamine crown ethers 205 and 206 or reduced with a 
hindered hydride, lithium triethyl borohydride and then hydrolysed to give the free 
amine crown ethers 207 and 208. Crown ether 207 was then alkylated with ethyl 2-
bromoactate to yield 209 which was subjected to hydrolysis to give the free acid 210.  
Another series of chiral crown ethers have been synthesised using a spiro acetal 
subunit, 1,7-dioxaspiro(5,5)undecane ring system, as the chiral subunit, 215-220.39 The 
crown ethers in this series can be broken down into two main groups; those made with 
diaxial 1,7-dioxaspiro(5,5)undecane-3,5-diol, 215-217, and those made with 
diequatorial 1,7-dioxaspiro(5,5)undecane-3,5-diol, 218-220. The only variable within 
these groups is that of the size of the ring. 
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Figure 20: Structures 215-220 
The diaxial crown ethers, 215-217, were synthesised by the addition of tetraethylene 
glycol ditosylate, pentaethylene glycol ditosylate or hexaethylene glycol ditosylate to 
diaxial 1,7-dioxaspiro(5,5)undecane-3,5-diol giving the three crown ethers with yields 
of 48 % (215), 42 % (216) and 32 % (217). The diequatorial crown ethers, 218-220, 
were synthesised by the addition of tetraethylene glycol ditosylate, pentaethylene 
glycol ditosylate or hexaethylene glycol ditosylate to diequatorial 1,7-
dioxaspiro(5,5)undecane-3,5-diol resulting in yields of 34 % (218), 28 % (219) and 42 
% (220). The axial analogues exhibit more than 1000 fold better complexing ability to 
sodium and potassium than the equatorial analogues. Compounds 215 and 216 with 
n=1 and n=2 exhibit a higher binding affinity for potassium than 18-crown-6, with Log 
Ka values of 1.29 and 1.21 respectively compared to 0.83 for 18-crown-6. Although 
these macrocycles are chiral and were enantiomerically pure, no testing of chiral 
recognition was reported. 
Luk'yanenko et al. synthesised a series of chiral crown ethers using L-tartaric acid 
derivatives as chiral subunits, 221-232.40 Yields for this series ranged from 6 % to 45 
%. There were two main groups within the series, [1+1] (221-226) and [2+2] (227-
232) products. 
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Figure 21: Structure of crown ethers 221-232 
The synthesis of macrocycles 221-232 began with the protection of the alcohols in 
diethyl L-tartrate with benzaldehyde or pinacolone to give 233 and 234 (scheme 15) 
respectively. Reduction of 233 and 234 with lithium aluminium hydride furnished the 
diols 235 and 236. 
 
Scheme 15: Synthesis of 235 and 236 
The reaction of diols 235 and 236 with the appropriate polyethylene glycol ditosylate 
in the presence of sodium hydride and in dioxane gave the crown ether products. 221-
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223 and 227-229 were synthesised using 236. 224-226 and 230-232 were synthesised 
using 235. The analogous [1+1] and [2+2] crown ethers were isolated from the same 
reaction, e.g. 221 and 223 were synthesised in the same reaction and separated after. 
The enantioselectivity of these crown ethers with L- and D-valine methyl ester 
hydrochlorides were evaluated. The crown ethers that displayed the highest 
enantioselectivity were 223, 226 and 230. The most noteworthy characteristic of these 
macrocycles is that if only the ring size is considered when looking at 
enantioselectivity it shows that with increasing ring size there is an inversion of 
enantioselectivity. The reason for this is not fully understood but is likely to do with 
the differing structure and stoichiometry of the host-guest complex as ring size 
changes.  
A number of phenolic chiral crown ethers have been synthesised using (S)-(+)-
mandelic acid derivatives.41 There were twelve of these macrocycles synthesised (237-
248) with four different substituents on the crown ether ring.  
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Figure 22: Compounds 237-248 
Crown ethers 237-239 were synthesised from the same starting materials varying the 
poly(ethylene glycol) ditosylate for the different ring sizes. Compounds 237-239 were 
synthesised first then modified to produce the other crown ethers. The synthesis was 
done in six steps from starting material to the p-nitro phenolic crown ethers, 240-242. 
 31 
The mandelic acid derivative, mono THP protected 1-phenylethane-1,2-diol, was 
reacted with 5-bromo-1,3-bis(bromomethyl)-2-methoxybenzene. The tetrahydropyran 
was removed to leave the diol. Cyclisation with the appropriate poly(ethylene) glycol 
ditosylate followed by the reaction with diethylene glycol ditosylate gave 237 in 
overall yield of 42 %. Reaction with triethylene glycol ditosylate gave 238 in overall 
yield of 34 %. Reaction with tetraethylene glycol ditosylate gave 239 in overall yield 
of 24 %. Debromination was carried out with n-BuLi and water work-up to give the 
methoxy crown ether in overall yields of 25 % for 243, 21 % for 244 and 16 % for 245. 
Demethylation with sodium ethanethiolate gave the phenolic crown ether product in 
overall yields of 23 % for 246, 18 % for 247 and 4.8 % for 248. Macrocycles 246, 247 
and 248 were nitrated to give the p-nitro phenolic crown ethers in overall yields of 13 
% for 240, 6.2 % for 241 and 2.0 % for 242. The p-nitro phenolic crown ethers were 
tested for chiral recognition of secondary amines. Compound 241 showed best 
selectivity, with 240 being too small to accommodate a secondary amine and 242 being 
too large to efficiently inhibit the binding of the unwanted enantiomer.  
Karakaplan et al. synthesised a series of chiral crown ethers containing a (p-
methoxyphenoxy)methyl moiety, 249-253.42  
 
Figure 23: Crown ethers 249-253 
The chiral subunit, 254, was synthesised by the reaction of (S)-glycidol and p-
methoxyphenol with piperidine hydrochloride as catalyst.  
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Scheme 16: Synthesis of 255 
254 was used directly with triethylene glycol ditosylate to synthesise crown ether 249 
in 15 % yield and tetraethylene glycol ditosylate to synthesise crown ether 250 in 39 % 
yield. 254 was also used to synthesise the chiral precursor to the 18-crown-6 ethers 
(251, 252 and 253). 254 was reacted with 1-(tetrahydropyranyloxy)-2-[(p-
tolylsulfonyl)oxy]ethane to give the chiral triethylene glycol derivative, 255, which 
was deprotected followed by reaction with triethylene glycol ditosylate to give 251 in 
18 % yield. To synthesise crown ethers 252 and 253 the correct subunits had to be 
synthesised. The benzo-subunit was produced via the tosylation of 1,2-bis-(2-
hydroxyethoxy)benzene and the product of this reaction was then reacted with chiral 
triethylene glycol derivative to give the crown ether 252 in 12 % yield. The naphtho 
subunit was synthesised by the reaction of 2,3-dihydroxynaphthalene and ethylene 
oxide. The product of this reaction was tosylated followed by reaction with the chiral 
triethylene glycol derivative to give 253 in 12 % yield. 250-253 were then tested for 
binding and enantioselectivity, by UV spectroscopy titration, towards two amino acid 
ester hydrochloride salts, alanine methyl ester hydrochloride and phenylalanine methyl 
ester hydrochloride. Compound 250 exhibited the strongest binding and best 
enantioselectivity towards alanine methyl ester hydrochloride with a Log (KaL/KaD) 
value of 0.76, while it showed no enantioselectivity towards phenylalanine methyl 
ester hydrochloride. Compound 253 exhibited the strongest binding and best 
enantioselectivity towards phenylalanine methyl ester hydrochloride with log (KaD/KaL) 
value of 0.38 with poor recognition of alanine methyl ester hydrochloride. Both 251 
and 252 did not exhibit enantioselectivity for either of the amino acid ester 
hydrochloride salts tested.  
Lingenfelter et al. reported the synthesis of a series of chiral 20-crown-6 ethers using 
binaphthyl derivatives as chiral subunits.43 The general structure for these chiral crown 
ethers is shown in figure 24 below, both (R) and (S) enantiomers were synthesised and 
 33 
the only differences between the structures is the substituents on the binaphthyl 
derivatives. 
 
Figure 24: Structure of crown ethers 256-265 
The synthesis of the crown ether was done by the addition of pentaethylene glycol 
ditosylate to 2,2’-dihydroxy-1,1’-binaphthyl for crown ether 256, with, 3,3’-dimethly-
2,2’-dihydroxy-1,1’-binaphthyl for crown ether 257 and with  3,3’-dimethoxymethyl-
2,2’-dihydroxy-1,1’-binaphthyl for crown ether 258. The methoxy of the 
methoxymethyl group in 258 was then substituted with phenoxy to produce 259, with 
p-methoxyphenoxy to produce 260, with phenylsulfane to produce 261 and with 
benzylsulfane to produce 262. The methoxy of the methoxymethyl group in 258 was 
also converted into a cyano group from which the 2-phenyl-1,3,4-oxadiazole, 263,  was 
synthesised and then the 2-phenyl-1,3,4-oxadiazole could be replaced with a phenyl 
group to produce 264 and with pentamethylphenyl to produce 265. 256-265 were then 
tested for chiral recognition towards two guests, phenylalanine methyl ester perchlorate 
salt and valine methyl ester perchlorate salt. 264 has the highest chiral recognition 
towards the guests tested, with substantially higher recognition towards the 
phenylalanine methyl ester perchlorate salt with an enantiomer distribution constant 
(EDC) of 19.5 with D-phenylalanine methyl ester perchlorate salt being the preferred 
guest. 256 showed the least chiral recognition towards the valine methyl ester 
perchlorate salt with an EDC of 1.1 and was only slightly better for the chiral 
recognition of the phenylalanine methyl ester perchlorate salt with an EDC of 1.6. 
Two chiral crown ethers have been synthesised with a biphenanthryl subunit 
containing the chiral centre, 266 and 267.44  
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Figure 25: Structures of 266 and 267 
266 and 267 were synthesised in 4 steps, the first three steps identical for both 
macrocycles. The synthesis started with the oxidation of 9-phenanthrylmagnesium 
bromide with t-butyl perbenzoate and the hydrolysis of the t-butyl ester to give 9-
phenanthrol. Oxidative coupling on the 9-phenanthrol to make 10,10’-dihydroxy-9,9’-
biphenanthryl, produced a racemic mixture, which was then purified into the pure (R) 
and (S) enantiomers. The (S) enantiomer underwent a condensation reaction with 
pentaethyleneglycol ditosylate to give 266 in 22 % overall yield. The (R) enantiomer 
was reacted with diethyleneglycol ditosylate to give 267 in 12.5 % overall yield. 266 
and 267 were then tested for chiral recognition with three chiral guest molecules, 
methyl (±)-phenylglycinate, (±)-1-phenylethylamine hydrochloride and (±)-1,2-
diphenylethylamine hydrochloride. 266 was shown to have better enantiomeric 
selectivity for each guest species tested.  
Chiral polymeric crown ethers, (R) and (S) enantiomers of a chiral 21-crown-6 ether, 
have been synthesised containing binaphthyl subunits, 268 and 269.45 
 
Figure 26: Structures of 268 and 269 
The synthesis of the polymer crown ether products was done by cationic catalysis, of 
(S) or (R) 2,2’-bis[2-(2-vinylethoxy)ethoxy-1,1’-binaphthyl. Different catalysts and 
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solvent combinations were used to try to optimise the yield of the polymer. The yields 
obtained for the (S) polymer range from 23.7 % to 40 % and for the (R) polymer range 
from 35.9 % to 89.4 %. The use of boron trifluoride etherate as the catalyst in 
nitroethane gave the highest yields for both enantiomers. The (S) or (R) polymeric 
crown ethers gave values of optical rotation that are very similar but in opposite 
directions. The (R) polymer exhibits chiral recognition close to that of the non-
polymeric (R) binaphthyl 20-crown-6 reported by Cram et al.43 
 
1.1.4 Chiral Aza-Crown Ethers 
A series of eleven chiral pyridine-18-crown-6 ethers have been synthesised, 270-280, 
with all macrocycles reported being the (S,S) isomer.46 The general structure of 270-
278 is the same, differing only in the substituents on the crown ether ring. 279 and 280 
have the same general structure as each other and are different from the other nine 
macrocycles in the series. 270, 273 and 276 were synthesised first and then modified to 
yield 271, 272, 274, 275, 277 and 278. This was done by the method shown in scheme 
17 below. Aza-crowns 279 and 280 were synthesised by the method shown in scheme 
18.  
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Scheme 17: Synthesis 270-278 
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Scheme 18: Synthesis 279-280 
Binding studies were carried out by NMR with [α-(1-naphthyl)ethyl]ammonium 
perchlorate and 270, 273, 274, 276, 277 and 278. Log K values of 270 were measured 
with [α-(1-naphthyl)ethyl]ammonium perchlorate in 50/50 deuterated 
chloroform/deuterated methanol and Log K values were too low to measure accurately 
and in deuterated nitromethane the Log (KR/KS) was found to be 0.2. Log K values of 
273 were measured with [α-(1-naphthyl)ethyl]ammonium perchlorate in 50/50 
deuterated chloroform/deuterated methanol and Log KR was found to be 0.7 and Log 
KS was too low to measure accurately. Log K values of 274 were measured with [α-(1-
naphthyl)ethyl]ammonium perchlorate in 50/50 deuterated chloroform/deuterated 
methanol and Log (KR/KS) was found to be 0.37. Log K values of 276 were measured 
with [α-(1-naphthyl)ethyl]ammonium perchlorate in 50/50 deuterated 
chloroform/deuterated methanol the Log K values were too low to measure accurately 
and in deuterated nitromethane Log (KR/KS) was found to be 0.2. Log K values of 277 
were measured with [α-(1-naphthyl)ethyl]ammonium perchlorate in 50/50 deuterated 
chloroform/deuterated methanol and Log (KR/KS) was found to be 0.2. Log K values of 
278 were measured with [α-(1-naphthyl)ethyl]ammonium perchlorate in 50/50 
deuterated chloroform/deuterated methanol and Log (KS/KR) was found to be 0.1 and 
in deuterated nitromethane the Log K values were too high to measure accurately. 
Two chiral monoaza-15-crown-5 ethers have been synthesised from L-valinol, 281 and 
282.47,48 
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Figure 27: Aza-crown ethers 281 and 282 
281 and 282 were synthesised in four steps, starting with the reduction of L-valine, 
283, to L-valinol, 284. Valinol was then benzylated to form the N-benzyl amino 
alcohol, 285. This product was then reacted with ethylene oxide to give the diol, 286, 
which could be used in the final step of the synthesis of the monoaza-15-crown-5 
ethers.  
Scheme 19: Synthesis of 286 
286 was then employed in a condensation with triethylene glycol ditosylate to 
synthesise aza-crown ether 281 or 1,2-bis(2-tosylethoxy)benzene to synthesise aza-
crown ether 282. Binding studies were carried out with phenylmethylammonium 
perchlorate and naphthylmethylammoniun perchlorate. The data showed that both 281 
and 282 display enantiomeric recognition of phenylethylammonium perchlorate with 
log (KaR/KaS) values of 0.50 and 0.26 respectively and naphthylmethylammoniun 
perchlorate with log (KaS/KaR) values of 1.5 and 1.0 respectively. 
One triaza-18-crown-6 ether, 288, and one diaza-12-crown-4 ether, 287, have been 
synthesised by Lee et al.49 
 
Figure 28: Aza-Crown ethers 287 and 288 
288, was synthesised in 11 steps, starting with (R)-1-benzylglycerol, 289. The primary 
hydroxy group was selectively protected with TBDPS. Allylation was carried out on 
the secondary alcohol to give 290. The allyl group in 290 was converted into a 
hydroxyethyl group in two stages. Firstly dehydroxylation of the allyl group utilising 
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osmium oxide, followed by diol cleavage using lead acetate and reductive work-up 
using sodium borohydride, to give 291.  
 
Scheme 20: Synthesis of 291 
The alcohol group on 291 was tosylated and then reacted with 2-(2-
tosylaminoethoxy)ethanol. Debenzylation followed by mesylation of the alcohol 
groups and reacting with 2-(2-(tosylamino)ethoxy)-N-tosylethanamine gave the 
TBDPS protected 18-crown-6. Deprotection with tetrabutylammoniun fluoride gave 
288 in 14 % yield. For the synthesis of the diaza-12-crown-4 ether, 291 was 
debenzylated and the diol was tosylated. This ditosylate was then reacted with 2-(2-
(tosylamino)ethoxy)-N-tosylethanamine to give 287 in 37 % yield.  
Cage-annulated chiral aza-crown ethers, 292-295, have been successfully synthesised 
utilising the reaction of the chiral diamines with diacid chlorides.50 Of the two diacid 
chlorides used one was commercially available, 2,6-pyridinedicarbonyl dichloride, and 
the other had to be synthesised. The synthesis of the acid chloride was carried out in 
four steps (scheme 21) from the starting material pentacyclo 
[5.4.0.02,6.03,10.05,9]undecane-8,11-dione, 296. 296 was first allylated with ally 
magnesium bromide, then dehydrated using p-toluene sulphonic acid. Ozonolysis in 
dry methanol was then carried out on the product of the dehydration reaction, followed 
by oxidative work-up, with hydrogen peroxide in methanoic acid to give the diacid, 
5,5-Dicarboxymethyl-4-oxahexacyclo[5.4.1.02,6.05,10.05,9.08,11]dodecane. Treatment of 
the diacid with oxalyl chloride resulted in the diacid chloride product, 297.  
Scheme 21: Synthesis of 297 
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Figure 29: Crown ethers 292-295 
Cyclisation was carried out at high dilution (2.28 mM) with the appropriate chiral 
diamine and yields of the products varied from 25 % to 43 %. The enantioselectivity of 
these macrocycles was tested by U-tube transport studies with monitoring by optical 
rotation. The guest molecule for these studies was phenylglycine methyl ester 
hydrochloride. Results from this testing show high rate of transport (12 % h-1) but with 
poor enantioselectivity.  
Another series of chiral aza-crown ethers using pentacyclo-undecane-8,11-dione were 
synthesised, 298-300.51 The main difference in the structure of crown ethers 294-298 is 
an amine in 298-300 and an amide in 294 and 295. 
 
Figure 30: Structures of crown ethers 298-300 
298-300 were synthesised with 297 and with 2-substitued-2-(methylamino)ethanol. 
The substituents on the 2-substitued-2-(methylamino)ethanol became the R groups on 
the macrocycles shown in figure 30. The product of this reaction was then reacted with 
α,α-dibromo-o-xylene to give the aza-crown ether product in yields of 17 % for 298, 
42 % for 299 and 35 % for 300. Crown ethers 298 and 299 were shown to act as 
catalysts for the Michael addition reaction of 2-nitropropane to chalcone, giving low 
yield but an enantiomeric excess of up to 92 %.   
A number of enantiomerically pure chiral phenazino-crown ethers have been 
synthesised, 301-309.52  
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Figure 31: Aza-crown ethers 301-309 
Each of the (R,R) crown ethers and crown ether 304 (S,S) (figure 31), were synthesised 
from phenazine-1,9-diol with the appropriate ditosylate, with yields ranging from 12 % 
to 58 %. The other (S,S) crown ethers were synthesised from 1,9-dichlorophenazine 
and the appropriate diols with yields ranging from 14 % to 22 %. From tests carried out 
it was shown that all the (R,R) phenazino-crown ethers act as better chiral selectors 
than pyridino-18-crown-6 ethers for the perchlorate salts of PEA and NEA.  
A series of chiral diaza-crown ethers (310-317) were synthesised53 using 
enantiomerically pure trans-1,2-diaminocyclohexane. 
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Figure 32: Aza-crown ethers 310-317 
310-317 were synthesised by the reaction of R,R-trans-1,2-diaminocyclohexane with 
the correct ether linked dialdehyde, which ether linked dialdehyde used depends on the 
value of n. Crown ethers 310 and 311 were synthesised without solvent and gave yields 
of 89 % and 95 % respectively. Crown ethers 312 and 313 were synthesised in solution 
and both gave yields of 95 %. Crown ethers 310-313 were reduced to give crown 
ethers 314-317 in yields of 80 % for 314, 91 % for 315, 92 % for 316 and 91 % for 
317.  
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Chiral diaza-crown ether, 323, has been made from L-threonine, 318.54  
 
Scheme 22: Synthesis of diaza-crown ether 323 
This was a six step synthesis with 22 % total yield. The first step was benzylation of L-
threonine, 318, producing 319, which was reduced with lithium aluminium hydride to 
yield the diol 320. 320 was reacted with diethylene glycol dichloride, which reacted 
solely with the primary alcohol to give 321. 321 underwent deprotection with 
Pearlman’s catalyst resulting in amine 322. 322 was treated with sodium iodide, 
sodium carbonate under reflux in acetonitrile followed by addition of benzyl bromide 
to yield the macrocycle 323. No testing of the binding abilities of 323 was reported.  
 
1.2 P-glycoprotein Inhibitors 
As part of the work of this project several compounds were tested as P-gp inhibitors. 
The positive results obtained from the initial testing incited some development work. 
This investigation lead to compounds which displayed improved activity as P-gp 
inhibitors. This work will be detailed in chapter five, but featured here is the 
introduction into the concept of P-gp inhibition.  
P-glycoprotein (P-gp) is a multidrug efflux pump; it is one of the membrane bound 
glycoproteins that can cause multidrug resistance (MDR). P-gp keeps a wide variety of 
foreign substances, e.g. toxic agents and drugs, from being absorbed. P-gp plays an 
important role in the cell but they have been known to over express in cancer cells and 
as such decrease the concentration of chemotherapeutics in these cells, which in turn 
allows the cancer cells to survive. P-gp inhibitors are of increasing interest because 
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they potentially have multiple drug resistance reversing activity, by inhibiting the 
action of P-gp, and also can be made to have little or no biological impact on healthy 
cells. This can have implications for the treatment of diseases such as cancer and HIV, 
as P-gp is able to confer resistance by detecting binding and moving a wide variety of 
hydrophobic and amphipathic compounds, including many anticancer drugs and HIV-
protease inhibitors from inside to the outside of the cell.55 P-gp inhibitors are also 
known as chemosensitizers and P-gp modulators. P-gp inhibitors can be grouped into 
seven classes based on their structural features. These classes are calcium channel 
blockers, calmodulin antagonists, protein kinase C inhibitors (PKCIs), natural products 
such as steroids, cyclic peptides, flavanoids and miscellaneous compounds. 
Miscellaneous compounds are the P-gp inhibitors that don’t fit into any of the other 
classes. P-gp inhibitors can also be broadly separated into three categories based on 
their interaction with P-gp: high-affinity substrates of the pump; efficient inhibitors of 
ATP hydrolysis coupled P-gp transport and; partial substrates/inhibitors.  Most 
chemosensitizers display their MDR reversal activities by competitively binding to the 
drug binding sites on P-gp or non-competitively binding to the modulatory site.  
Studies have indicated that a chemosensitizer with potential for clinical use should 
meet the following requirements: the compound should have a minimum log P value of 
2.92; the compound should have a main chain length of not less than 18 atoms; should 
have a high EHOMO value; and should have a minimum of one tertiary nitrogen.55 
Although some compounds without a tertiary nitrogen atom do act as P-gp inhibitors, it 
is thought that the tertiary nitrogen is indispensable for the compound to be a highly 
efficient p-pg inhibitor. 
(R)-Verapamil, 324, is regarded as the standard P-gp inhibitor to which the mechanism 
and potency of all subsequently discovered P-gp inhibitors are compared to. (R)-
Verapamil both inhibits P-gp if actively pumping and stimulates P-gp if it is inactive 56.  
 
Figure 33: (R)-Verapamil 
(R)-Verapamil is a sodium and calcium channel blocker. It binds reversibly to P-gp and 
inhibits the binding of many chemotherapeutic agents and other inhibitors of P-gp.  
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Figure 34: Ro11-2933 
 (R)-Verapamil is not the most potent P-gp inhibitor, in fact an analogue of (R)-
Verapamil, Ro11-2933, 325, was found to be ten times more potent than (R)-
Verapamil in reversing resistance to doxorubicin.57  
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Figure 35: Flupentixol 
Calmodulin antagonists are another class of P-gp inhibitors, which includes 
flupentixol, 326. Both the cis and trans isomers of flupentixol are P-gp inhibitors but 
the trans isomer is about four-fold more potent than the cis isomer.58 
 
Figure 36: R101933 
Also included in this class of P-gp inhibitors is R101933, 327 (figure 36). R101933 is 
undergoing clinical trials, and was reported in 2002 as being in phase II/III clinical 
study.59  
Staurosporine, 328, and CGP42151, 3279 are two PKCIs that that appear to bind to 
both ATP binding site (ABS) and steroid-binding hydrophobic region (SBHR).  
 
Figure 37: Staurosporine and CGP42151 
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P-gp has been shown to bind reversibly to most steroids, the more hydrophilic steroids 
are more easily transported and tend to be less useful as P-gp inhibitors. The more 
hydrophobic (lipophilic) steroids tend to be transported less efficiently and as such are 
more useful as P-gp inhibitors. Progesterone, 330, a hormone that occurs naturally in 
humans, was found to bind to P-gp but appeared not to be transported by P-gp,60 this 
indicated the possibility of use as a P-gp inhibitor but from testing it was found to be 
less effective than (R)-Verapamil.  
O
O
H
H
H
330
  
Figure 38: Progesterone 
Other steroidal P-gp inhibitors have been tested, such as megestrol acetate and RU486, 
which have proved to be more effective inhibitors of P-gp than progesterone but only 
as effective as (R)-Verapamil. Flavanoids have also been reported to be P-gp inhibitors 
that bind to ABS and a vicinal SBHR within a cytosolic domain of P-gp.61 One such 
example of this is galangin, 332. 
  
Figure 39: Galangin 
Cyclic peptides, CysA, and macrolide compounds, tacrolimus, 333, and sirolimus, are 
immunosuppressants used in organ transplantation and can also act as P-gp 
inhibitors.61 
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Figure 40: Tacrolimus 
PSC-833, 334, is a cyclosporine analogue that is an effective P-gp inhibitor. It has been 
in two phase III clinical studies, one reported in 200262 and one in 2006.63 
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Figure 41: PSC-833 
Polycyclic alkaloids have also been reported to act as P-gp inhibitors, but because of 
their cytotoxicity or other intrinsic pharmacological effects almost all of them have 
been proven to be unsuitable for clinical use as P-gp inhibitors. Also polymer 
excipients like poly(ethylene)-glycol (PEG300) (20 %, v/v) was reported to produce 
complete inhibition of P-gp in Caco-2 and MDR1-MDCK cell monolayers.64 
In this short review of P-gp inhibitors a few illustrative examples of P-gp inhibitors 
have been given. These examples show the diversity of the structures which have been 
shown to act as P-gp inhibitors. To date a complete structure activity relationship study 
of each class of P-gp inhibitors has not been carried out. Instead Wang et al. has 
compiled a list of requirements that potential P-gp inhibitors should have. This list has 
been compiled for a large group of compounds that has been split into seven classes 
and is not specific to any one class. There are proven exceptions to this list of 
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requirements including PEG300 which does not have any tertiary nitrogen. Within the 
examples given in this review there are two macrocycles which are of different ring 
size and structural backbone highlighting the possibility that other macrocycles may 
also act as P-pg inhibitors. Within the classes of P-gp inhibitors there is the calcium 
blockers classification; therefore it is possible that compounds which bind to calcium 
may affect the calcium channel.  
 
1.3 Conclusion 
In this chapter it has been shown that the typical synthesis of chiral crowns and aza-
crowns is long and can often result low yields. Chapter two will demonstrate the efforts 
in this project towards the development of a short method for the synthesis of achiral 
macrocycles with high yields for the optimised derivatives. Chapter three will describe 
the efforts to apply the short methods to the synthesis of the chiral crown ethers 
containing opiates. Binding studies with some of the chiral crown ethers and studies 
using these crowns as catalysts have also been outlined. The binding studies carried out 
in this project are described in chapter four.  
Also a brief review with some illustrative examples of P-gp inhibitors has been given. 
A selection of the products synthesised in this project were tested for their activity as 
P-gp inhibitors. This work will be detailed in chapter five of this thesis.  
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Chapter 2 
Synthesis of Macrocyclic compounds containing the 2-(2-
hydroxyethoxy)phenol moiety and the precursors to these macrocycles 
 
2.1 Introduction: 
This chapter details the synthesis of a series of novel macrocycles and their precursors. 
The synthesis of these compounds was performed with the idea that the methods 
developed for their synthesis could then be employed in the preparation of the 
analogous alkaloid containing macrocycles. Using this approach, the time of the 
method development for the alkaloid containing derivatives was expected to be 
significantly reduced. The goal of the project was the synthesis of alkaloid containing 
crown ethers but prior to their attempted synthesis a model study was carried out. The 
method development could be carried out with 2-(2-hydroxyethoxy)phenol, 336, 
because both the alkaloid derivative, i.e. morphine, and 2-(2-hydroxyethoxy)phenol 
have two alcohol groups which are expected react in the same preferential order. 
Figure 42 shows the structural similarities between morphine and the 2-(2-
hydroxyethoxy)phenol.  
 
Figure 42: Morphine and 2-(2-hydroxyethoxy)phenol 
Although 336 is a subunit of 335, the pentacyclic 335 is more rigid in structure. The 
increased rigidity of 335 may lead to difficulties in the macrocyclisation reaction if a 
flexible backbone is required. This would require extra method development for the 
synthesis of the macrocycles containing the morphine moiety. Despite this limitation 
336 was selected as the model compound. 
Although the macrocycles and the bis-alcohols and bis-phenols to be discussed in this 
chapter were primarily to be synthesised as a method development tool, they are novel 
compounds in there own right. Their potential uses were examined later in the project 
through metal binding and biological analysis, the testing methods and results from 
these tests will be discussed in chapters four and chapter five respectively. The bis-
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alcohols and bis-phenols, compounds 338-347, also underwent the same testing as the 
crown ethers and results will be discussed in the same chapters.  
Also discussed in this chapter is the optimisation of the synthesis of compound 360. 
This optimisation was carried out so that the optimised method for the synthesis of this 
compound could be employed in the synthesis of the analogous alkaloid macrocycle.  
 
2.2 Synthesis of the bis-alcohols 338-344:  
There were seven diacid dichlorides used to synthesise the bis-alcohols; terephthaloyl 
dichloride, isophthaloyl dichloride, phthaloyl dichloride, 2,2-dimethylmalonyl 
dichloride, diglycolyl dichloride and 2,6-pyridine dicarbonyl dichloride were 
commercially available and while furan-2,5-dicarbonyl dichloride was synthesised.  
Furan-2,5-dicarbonyl dichloride was synthesised by the dehydration of mucic acid to 
give the diacid65 followed by chlorination with thionyl chloride under reflux to yield 
the dichloride species. 
Seven bis alcohols (338-344) containing different linkers between the phenolic 
hydroxy groups were generated. The structure of each of these compounds and their 
synthesis is given in scheme 23.  
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Scheme 23: The synthesis of the seven bis-alcohols.  
338-344 were generated via the reaction of a diacid dichloride with the 2-(2-
hydroxyethoxy)phenol at -15 oC in the presence of triethylamine under nitrogen.  
Yields of the bis-alcohols ranged from 29 % to 93 %. 339 (93 % yield) gave the 
highest isolated yield with purification via recrystallisation. 341 (29 % yield), which 
gave the lowest yield, and 343 (60 % yield) required column chromatography on a 
silica stationary phase. 338 (54 % yield), 340 (67 % yield), 342 (34 % yield) and 344 
(76 % yield) required column chromatography on a silica stationary phase followed by 
recrystallisation for purification.  
 
2.3 Synthesis of the macrocycles from bis-alcohols in section 2.2. 
From each of the bis-alcohols, 338-344, attempts were made to synthesise at least one 
macrocycle. From this there was a series of seven macrocycles successfully isolated. 
The structures of these seven macrocycles are given in figure 43.  
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Figure 43: Macrocycles made from the bis-alcohols. 
A general methodology for the synthesis of the macrocycles was employed; reactions 
were carried out under high dilution conditions in the presence of a base and under a 
nitrogen atmosphere. The base for each of the successful reactions was triethylamine. 
Three macrocycles were successfully synthesised from bis(2-(2-
hydroxyethoxy)phenyl) phthalate, 338. Reaction of 338 with phthaloyl dichloride, 
isophthaloyl dichloride and terephthaloyl dichloride yielded 348 (3.2 %), 349 (1.9 %) 
and 350 (3.7 %) respectively. Two macrocycles were successfully synthesised from 
bis(2-(2-hydroxyethoxy)phenyl) isophthalate, 339. Reaction of 339 with isophthaloyl 
dichloride and phthaloyl dichloride yielded 351 (4.4 %) and 352 (3.5 %) respectively. 
Bis(2-(2-Hydroxyethoxy)phenyl) terephthalate, 340, was reacted with terephthaloyl 
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dichloride to yield 353 (2.5 %) and bis(2-(2-hydroxyethoxy)phenyl) furan-2,5-
dicarboxylate was reacted with furan-2,5-dicarbonyl dichloride to yield 354 (12 %). 
Each of these compounds were isolated and characterised by NMR, high resolution 
MS, FTIR and melting point. The remaining material from each of the reactions is a 
mixture of polymer and unreacted starting material.  
There were six macrocycles (figure 44) that were not successfully isolated via method 
using the bis-alcohols. The material isolated from these reactions was polymeric 
structures and unreacted starting materials.  
 
Figure 44: Macrocycles not isolated by this method 
For each attempt the same general method used in the synthesis of 348-354 was 
utilised. The changes that were made to the general method included variation of the 
base used, concentration of starting materials, temperature and the purification 
methods in attempts to isolate these six macrocycles. Each attempted synthesis was 
carried out using five equivalents of the following bases: triethylamine; sodium 
carbonate; potassium carbonate; and dimethyl amino pyridine. The attempted 
syntheses were also carried out at room temperature, -15 oC and in refluxing 
dichloromethane (40 oC). The concentrations used were 10 mmol, 40 mmol and 80 
mmol. Samples from each reaction were taken and attempts were made to purify them 
via recrystallisation, column chromatography and distillation using a Kugelrohr 
apparatus. After numerous unsuccessful attempts at the synthesis of these macrocycles 
it was decided to synthesise these macrocycles by different methods. These 
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macrocycles were isolated by other methods discussed later in this chapter, sections 2.5 
and 2.6.  
 
2.4 Synthesis of the bis-phenols, 346, 347, 355 and 356:  
Four bis-phenols were synthesised as shown in scheme 24. Bis(2-(2-
hydroxyphenoxy)ethyl) 2,2-dimethylmalonate, 346,  was the first prepared. 346 was 
prioritised as results obtained from the biological screening of 357 and 343, to be 
discussed in chapter 5, made 346 an important target as part of a structure activity 
relationship study. 346 was utilised to make 357 which served as a comparison of 
methods to the methods for the synthesis of the same macrocycle discussed in sections 
2.3 and 2.6. Subsequently, bis(2-(2-hydroxyphenoxy)ethyl) terephthalate, 347, bis(2-
(2-hydroxyphenoxy)ethyl) isophthalate, 355, and bis(2-(2-hydroxyphenoxy)ethyl) 
furan-2,5-dicarboxylate, 356, were synthesised by the same method as bis(2-(2-
hydroxyphenoxy)ethyl) 2,2-dimethylmalonate, 346.  
The method used for synthesis of these products (scheme 24) started with the 
protection of the phenol with the triethylsilyl (TES) protecting group. The synthesis 
involved reacting TES triflate with 2-(2-hydroxyethoxy)phenol under nitrogen 
atmosphere at -15 oC in the presence of triethylamine. 
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Scheme 24: The synthesis of the bis-phenols 
345 was then reacted with a diacid dichloride and the resulting intermediates had 
column chromatography on a silica stationary phase with a 3:1 diethylether:chloroform 
mobile carried out to increase purity but were not isolated pure. The TES protected 
intermediates were subjected to acidic deprotection to give the target bis-phenols.  
 
2.5 Synthesis of macrocycles 350, 352, 353 and 357 from bis-phenols 346 and 347.  
Four macrocycles, 350, 352, 353 and 357, were synthesised from the bis-phenols for 
comparison of yields with the previous method outlined in section 2.3. If the yields 
from this method were higher than attained in section 2.3 it may be an alternative route 
for the generation of the alkaloid macrocycles. The method used in this section, 
scheme 25, was essentially the same as that used for synthesising the macrocycles from 
the bis-alcohols, the main difference being the starting material. 
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Scheme 25:  Synthesis of compounds 350, 352, 353 and 357  
The yields obtained for 353, 350 and 357 by this method are higher than that presented 
in section 2.3. For 353 the yield increased from 2.5 % to 7 % and 350 increased from 
3.7 % to 6 %. The most significant difference is that 357, which was not isolated from 
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the method in section 2.3, was successfully isolated in 25 % yield.  For the final 
macrocycle isolated by this method, 352, the yield was slightly less, decreasing from 
3.5 % to 3.1 %. Attempts were also made at the isolation of 361 via this method but all 
attempts were unsuccessful.  
 
2.6 One pot synthesis 
Using the one pot method for the synthesis of the macrocycles, 2-(2-
hydroxyethoxy)phenol is reacted with half an equivalent of a diacid dichloride and 
then after an allotted time another half equivalent of a diacid dichloride is added to the 
reaction. The synthesis outlined out in this section was undertaken for two reasons; 1) 
as a comparison to the previous methods, sections 2.3 and 2.5, and 2) to try to 
synthesise some of the macrocycles that had not been successful by the previous 
methods.  
A total of ten macrocycles, 351, 352, 353, 354, 357, 358, 359, 360, 361 and 362, were 
successfully synthesised by this method. Scheme 26 gives the general method 
employed using the example of 358. Five of the ten macrocycles, 358, 359, 360, 361 
and 362 (figure 45) were only synthesised by this method and attempts to isolate them 
via the methods in sections 2.3 and 2.5 failed.  
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Figure 45: Five macrocycles isolated solely by the one pot method 
Each of the macrocycles in figure 45 were isolated and characterised by NMR, high 
resolution MS, FTIR and melting point, with the exception of compound 361 which 
was sparingly soluble in all available solvents (acetone, acetonitrile, benzene, butanol, 
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carbon tetrachloride, chloroform, cyclohexane, 1,2-dichloroethane, dichloromethane, 
diethylether, N,N-dimethylformamide, dimethylsulphoxide, 1,4-dioxane, ethanol, 
ethylacetate, hexane, methanol, pentane, petroleum ether, propanol, pyridine, 
tetrahydrofuran, toluene, water and xylene) and as such the 13C NMR could not be 
recorded. 
Scheme 26 shows the synthetic pathway of a macrocycle, 358. All the other derivatives 
in this section were synthesised via the same general method with variation of the 
dichlorides and the base used, as detailed in the experimental section of this chapter.  
 
Scheme 26: Synthesis of 358 
The five macrocycles synthesised via this method and in sections 2.3 and 2.5 are 351, 
352, 353, 354 and 357. Their yields are 23 %, 16 %, 2.5 %, 9 % and 2.5 % 
respectively. A significant improvement in yield was seen for 351 and 352 via method. 
353 was isolated in equivalent yields to that obtained in section 2.3. A decreased yield 
of 354 and 357 was recorded in this section, although this decrease was less significant 
for compound 354 than for compound 357. 
The first attempt at the synthesis of 357 resulted in a yield of 2.1 % (0.015 mmol, 8 
mg). The X-Ray crystal structure showed that the target product was not synthesised 
and instead compound 363 was isolated, as shown in scheme 27 below. Due to the 
small amount of 363 obtained there was not enough material to record the other data 
required (melting point, mass spectrum and infra-red spectrum). In order to record the 
full characterisation data the synthesis was repeated on a larger scale, with a yield of 
2.5 % (0.12 mmol, 57 mg) recorded, reported in the experimental section.  
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Scheme 27: Synthesis of 357 and 363 
Both proton and carbon NMR of the product from repeated synthesis were recorded 
and agreed with the NMR data from the original synthesis. From this the full 
characterisation data (NMR, IR, HRMS and melting point) was recorded.  
The predicted values of the NMR, both 1H and 13C, for compounds 357 and 363 are 
listed in the table 1 below alongside the NMR data recorded from the product. 
Predictions were carried out using ChemBioDraw Ultra Version 11.0.1 © 1986-2007 
CambridgeSoft.  
 
 63 
 357 363 Product 
Atom 
Number 
1H 
Prediction 
13C 
Prediction 
1H 
Prediction 
13C 
Prediction 1H 13C 
1 1.37 22.8 1.42 22.8 1.53 20.96* 
2  51.3  51.7  50.95* 
3  171.5  171.5  170.81 
4  142.0  142.0  142.82 
5 7.18 120.6 7.18 120.6 124.45 
6 6.98 120.7 6.98 120.7 124.69 
7 7.15 126.1 7.15 126.1 127.33 
8 6.96 114.8 6.96 114.8 123.25 
9  153.9  153.9 
7.02-
7.14 150.77 
10 4.22 67.0 4.33 71.9 4.05 64.03 
11 4.50 67.3 4.50 67.3 4.48 72.54 
12  174.5  174.5  172.70 
13  52.1    50.95* 
14 1.47 22.8   1.53 20.96* 
Table 1: Predicted values for 1H and 13C NMR of macrocycles 357 and 363 compared 
to that recorded for the product. * Individual peaks are not observed for Carbon 1 and 
14 and for Carbon 2 and 13 in the product. 
From the NMR predictions, 357 and 363 are quite similar by NMR, but there are 
differences predicted in both carbon and proton NMR. Most notably there should be an 
extra peak in the proton NMR spectra of 357 over that of 363 for H14 and also in the 
carbon NMR spectra for C13. C13 in structure 357 is different from that of C2 357 
because of its location is between two ester groups synthesised from the aliphatic 
alcohol groups of 2-(2-hydroxyethoxy)phenol and C2 is between two ester groups 
synthesised from the phenols of 2-(2-hydroxyethoxy)phenol. Each of these peaks 
should differ from that of C2 in 363 as this carbon is located between two different 
ester groups, one of the phenol and the other from the aliphatic alcohol. Also the peaks 
for H’s 10 and 11 should be closer to each other in 363 relative to 357 with the peaks 
for C’s 10 and 11 should be closer to each other in 357 relative to 363. From 
comparison of the predicted NMR spectra of both products with that of the isolated 
product it appears that the product isolated was 363, as the number of peaks is in 
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accordance with the predicted number of peaks for 363. Although the NMR spectra are 
predicted to be very similar and could appear to be the same, as indicated by the 
prediction of C1 and C14 of 357 being identical to C1 of 363 although the predicted 
values for the hydrogens on these carbons are predicted to be different.  
As the NMR spectra of 357 and 363 appear to be the same, the next method to show 
the difference would be mass spectrometry, as there is a clear difference in the mass of 
the two macrocycles. The exact mass of 357 has been calculated to 500.1682 amu and 
the exact mass of 363 has been calculated to exactly half of that of 357 at 250.0841 
amu. The mass spectrum of the first sample that was submitted for X-ray, was not 
recorded as the entire sample went for X-ray. The compound isolated from the second 
synthesis was purified and submitted for time of flight, mass spectrometry. The exact 
mass was recorded at 501.1746 amu which is within error of the calculated mass of 
protonated 357, 501.1755 amu, as seen in figure 46 below.  
 
Figure 46: TOF MS of 357.  
This indicates that although there may be a small impurity of 363 in the sample the 
sample was mainly the expected product, 357. Attempts were made, unsuccessfully, to 
grow crystals of this product from the slow evaporation of the following solvents (both 
as mixed solvent systems and individual solvents): chloroform, hexane, 
dichloromethane, acetonitrile, acetone, ethylacetate, diethylether and cyclohexane. 
We postulated that 363 is a minor product and then repeated the synthesis to try to 
isolate 363 in enough yield for full characterisation. Multiple attempts, using the same 
method, to generate 363 again failed. Each time the mass spectrum, although at a lower 
resolution using an Agilent Technologies 6110 Quadrapole LC-MS, indicated the 
presence of 357 as the product. The X-Ray data will be discussed in section 2.9. 
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2.7 Optimisation of the one pot synthesis of compound 353:  
At this stage of the project the optimisation of the one pot synthesis of 353 was 
undertaken as this improved method could then be utilised in attempts to isolate the 
analogous macrocycle containing the morphine moiety.  
Optimisation was carried out by changing the reaction conditions and repeating the 
reaction until a reasonable yield was isolated and proved repeatable. After a series of 
reactions were carried out the data from these reactions was used in Design Expert® 
version 6.0.10 from Stat-Ease Inc. This is a statistical anyalysis program that carrys out 
calculations on results obtained from previous synthesis and then suggests optimial 
conditions to try. The reaction is outlined in scheme 28 below.  
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Scheme 28: Optimisation of the synthesis of 353 
The same general method was employed as outlined earlier in section 2.6 with 
variation of temperature, concentration, type of base, amount of base, and time 
individually and in conjunction with one another until the reaction was deemed to be 
reproducible and of high yield.  
The general method for optimisation of yield of 353 is outlined below: 
2-(2-Hydroxyethoxy)phenol (154 mg, 1.00 mmol) was dissolved in dry DCM (10.0 
mL) at room temperature under nitrogen and then chilled to -15 oC. Dry base [table 2 
(A)] is added while stirring and maintaining the temperature at -15oC. Terephthaloyl 
dichloride (100 mg, 0.50 mmol) was then dissolved in dry DCM (5.0 mL) and added 
to the reaction mixture. The reaction mixture was then stirred for 1 hour and after 
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which it was allowed to warm to room temperature and was stirred for sixteen hours, 
as this was the same time scale in which the intermediate product,  bis(2-(2-
hydroxyethoxy)phenyl)terephthalate, was synthesised. Dry base [table 2 (B)] and dry 
DCM [table 2 (C)] were then added to the reaction flask. The contents of the flask 
were heated or cooled to the required temperature set in table 2. Terephthaloyl 
dichloride (100 mg, 0.50 mmol) was dissolved in dry DCM indicated [table 2 (D)] and 
added slowly to the reaction flask. This reaction mixture was then stirred for a time 
dictated in table 2. The reaction was quenched via addition of DI water (10.0 mL) and 
warmed to room temperature and stirred for ten minutes. The reaction mixture was 
then transferred to a separation funnel and the organic and aqueous layers were 
separated. An NMR of the crude products was recorded, and from this an 
approximation of yield, by ratio of product to unwanted side-products, was made, the 
products of the higher yielding reactions were then purified by column 
chromatography on a silica stationary phase to give pure isolated yields. The unwanted 
side-products where the intermediate, bis(2-(2-hydroxyethoxy)phenyl)terephthalate, 
and some polymer product. These isolated yields are given in table 2. 
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Base used 
 
Equivalents base 
used 
 Reaction Ratio Product: 
polymer: 340 
A B A B 
Volume 
DCM added  
at C 
Volume 
DCM added  
at D 
Temp. 
(oC) 
Time  
(h) 
A 1:0.9:0.5 3.2 3.2 70 15 -15 3 
B 1:2:0.5 3.2 3.2 0 15 -78 3 
C 1:1:4 3.2 3.2 70 15 -78 3 
D 1:1:0.3 3.2 3.2 70 15 RT 3 
E 1:1:0.5 
NEt3 
3.6 3.6 80 105 RT 3 
F 0:0:1 K2CO3 2.8 2.8 70 15 RT 3 
G 1:1:0.2 NEt3 K2CO3 2.4 2.8 70 15 RT 3 
H 1:1:12 Cs2CO3 2.2 2.2 45 50 RT 3 
I 1:1.5:4 NEt3 Cs2CO3 2.2 2.2 40 55 RT 3 
J 1:3:4 tetramethylethane-
1,2-diamine 
2.8 2.8 40 55 RT 3 
K 1:2.5:12 iPr2NH 2.8 2.8 40 55 RT 3 
L 1:2:3.4 iPr2NH NEt3 4.2 2.2 40 55 RT 3 
M 4:3:8 iPr2NH 2.8 2.8 40 55 RT 24 
N 4:1.6:2.4 Na2CO3 2.8 2.8 40 55 RT 3 
O 1:1:1 NEt3 Na2CO3 2.2 2.8 40 55 RT 3 
P 1:0:2.5 5.6 5.6 40 55 RT 3 
Q 1:1:20 2.8 2.8 40 55 RT 24 
R 1:0.4:1.2 2.8 2.8 40 55 -15 3 
S 1:0.3:0.6 2.8 2.8 40 55 40 3 
T 1:0:1.5 2.8 2.8 0 15 RT 3 
U 1:0:1.3 2.8 2.8 40 55 RT 3 
V 1:0:8 2.8 2.8 100 85 RT 3 
W 1:2:2 5.6 5.6 0 15 40 3 
X 1:0.3:0.3 5.6 5.6 40 45 40 3 
Y 1:0.2:2.2 2.8 2.8 0 15 40 3 
Z 1:0.2:0 4.2 4.2 60 50 40 3 
AA 1:0:13 17 17 70 65 40 3 
AB 1:0.2:3.8 11 11 60 50 40 3 
AC 1:0:30 
Na2CO3 
18 18 60 50 40 3 
AD 1:0.5:0.2 2.5 2.5 60 50 40 3 
AE 1:1:3 0.8 0.8 60 50 40 3 
AF 1:0.9:0.9 3.6 3.6 60 50 40 3 
AG 1:1:0.4 2.5 2.5 35 50 40 3 
AH 1:1:0.1 
NEt3 
2.5 2.5 75 50 40 3 
Table 2: Conditions screened in optimisation of the synthesis of 353 
Reaction Approximate yield from ratios on 
NMR of first attempt at the reaction 
Yield isolated 
A 41.6% 38.2% 
D 43.5% 28.3% 
E 40.0% 14.8% 
X 62.5% 0% 
Z 83.0% 0% 
AD 58.8% 44% 
Table 3: Isolated yields from optimisation reactions. 
The target product was not recovered from the columns of the crude products from 
reactions X and Z, even though by TLC the product should have eluted from the 
column with the same Rf as achieved with the products from the other reactions. 
Reactions X and Z were repeated a further three times and each time the reactions 
failed to produce the same ratio of product to the intermediate and the polymer as was 
achieved in the first reaction, with approximate yields from NMR being less than 20% 
for each repeated attempt at the synthesis. This shows that the reactions X and Z were 
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not reproducible and for this reason it was decided to use triethylamine as the base for 
optimisation as the product was isolatable when triethylamine was used as seen in 
reactions A, D and E. Reaction AD was repeated in triplicate and the isolated yield 
given in table 3 was the average of the three reactions (individual yields were 44.2 %, 
45.3 % and 42.5 %) and this has a standard deviation of 1.4 %. This indicates that 
although the reaction is not ideal, as a higher yield may be isolatable using different 
conditions, the reaction is repeatable with significantly higher yield than that of the 
original method, 2.5 %. For this reason the conditions used in reaction AD were chosen 
for use in the synthesis of the morphine macrocycle with terephthaloyl dichloride.  
 
2.8 Optimisation of bis(2-(2-hydroxyphenoxy)ethyl) 2,2-dimethylmalonate, 346:  
When bis(2-(2-hydroxyphenoxy)ethyl) 2,2-dimethylmalonate was initially tested as a 
P-glycoprotein inhibitor the results indicated this could be a potent inhibitor of the P-
glycoprotein efflux pump, see section 5.2.2. As such, more of the compound was 
required for testing, and the decision was taken to optimise the synthesis of this 
derivative.  
 
Scheme 29: Reaction Pathway for the synthesis of 346 
The first step optimised was the protection of 2-(2-hydroxyethoxy)phenol. Triethylsilyl 
triflate was added to 2-(2-hydroxyethoxy)phenol in the presence of triethylamine in dry 
dichloromethane under an inert atmosphere. It was found that using the same reaction 
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conditions and extending the reaction time to forty-eight hours from twenty-four hours 
the yield increased from an initial yield 48 % of to 97 %.  
The next step was the optimisation of the synthesis of triethylsilyl protected bis(2-(2-
hydroxyphenoxy)ethyl) 2,2-dimethylmalonate. The optimisation investigated the 
effects of time, volume of dichloromethane and the amount of triethylamine used. 
After only four experiments by increasing the reaction time from four to forty-eight 
hours, reducing the concentration of the dichloride and increasing the number of 
equivalents of triethylamine from 2.85 to 3.2 (see table 4) the yield was increased from 
77 % to 95 % (triplicate results of 92 %, 95 % and 95 %). 
Time 
(hours) 
Volume (mL) of 
dichloromethane per mmol 
dimethylmalonyl chloride 
Equivalents 
triethylamine to 345  
Yield (%) 
4 24 2.85 77 
6 17 2.56 66 
24 21 3.20 79 
48 21 3.20 95 
Table 4: Conditions for optimisation of triethylsilyl protected bis(2-(2-
hydroxyphenoxy)ethyl) 2,2-dimethylmalonate 
At this stage of the optimisation the triethylsilyl protected bis(2-(2-
hydroxyphenoxy)ethyl) 2,2-dimethylmalonate could now be isolated in 92 % overall 
yield which is a significant improvement on the 33 % noted earlier. The final step is 
the selective removal of the triethylsilyl protection groups. Acidic conditions are used 
so care has to be taken not to break the ester bonds. TES deprotection was monitored 
by TLC every ten minutes until the protected bis(2-(2-hydroxyphenoxy)ethyl) 2,2-
dimethylmalonate was no longer present in solution. The reactions were then stopped 
and the target product purified. It is important that the reaction can be stopped and the 
target product separated from the deprotection reagent quickly as the continuation of 
the reaction could break the ester bonds. Table 5 lists the conditions tried for the 
deprotection step and the yields isolated from each reaction. 
The results in table 5 show that the best conditions for this reaction when using 4:1 
acetic acid:water at 40 oC. This method is postulated to be the best for three principle 
reasons: 1) The acetic acid is an effective reagent for the hydrolysis of the silyl-ester 
bond but not so strong as to easily hydrolyse the ester bond. 2) The product is a solid 
which is not very soluble in water, therefore when the deprotection is complete and the 
dichloromethane is added the product separates from the acid quickly while the acid is 
quenched. This differs from reactions 1 and 2 in which the product can be held in 
 70 
solution with the acetic acid and water by the tetrahydrofuran  allowing the acetic long 
to hydrolyse the ester bond. 3) The purification is less complicated that that of the 
methods using 2,3-dichloro-5,6-dicyanobenzoquinone (which also gave higher yields 
than obtained by the original method), as this reagent is partially soluble in 
dichloromethane and has to be separated by column chromatography, whereas the 
purification after reaction 10 (table 5) was a recrystallisation.  
 
Reaction Deprotection conditions Temp. Work-up Yield 
1 8:8:1 acetic acid: tetrahydrofuran: water RT 
Addition of Na2CO3 
saturated water and  
dichloromethane 
23 
2 6:6:1 acetic acid: tetrahydrofuran: water RT 
Addition of Na2CO3 
saturated water and  
dichloromethane 
20 
3 1:1 Tetrachloromethane: 
methanol sonication 40
oC 
Remove from sonication 
bath and removed 
solvents under vacuo 
22 
4 
20 mol% 2,3-Dichloro-5,6-
dicyanobenzoquinone in 
9:1 acetonitrile: water 
RT 
Addition of DCM for 
separation of reactions 
from the product 
47 
5 
20 mol% 2,3-Dichloro-5,6-
dicyanobenzoquinone in 
4:1 tetrahydrofuran: water 
RT 
Addition of DCM for 
separation of reactions 
from the product 
51 
6 2 equivalents potassium fluoride in acetonitrile 80
oC 
Addition of H2O 
extraction with 
dichloromethane 
18 
7 2 equivalents potassium fluoride in acetonitrile RT 
Addition of H2O 
extraction with 
dichloromethane 
0 
8 
2 equivalents potassium 
fluoride and 2 equivalents 18-
crown-6 in acetonitrile 
80oC 
Addition of H2O 
extraction with 
dichloromethane 
23 
9 
2 equivalents potassium 
fluoride and 2 equivalents 18-
crown-6 in acetonitrile 
RT 
Addition of H2O 
extraction with 
dichloromethane 
0 
10 4:1 acetic acid: water 40oC 
Addition of Na2CO3 
saturated water and  
dichloromethane 
67 
11 tetrabutylammoniun fluoride 1M in tetrahydrofuran RT 
Addition of H2O 
extraction with 
dichloromethane 
0 
Table 5: Conditions for optimisation of deprotection of triethylsilyl protected bis(2-(2-
hydroxyphenoxy)ethyl) 2,2-dimethylmalonate 
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From the optimisation of the synthesis of bis(2-(2-hydroxyphenoxy)ethyl) 2,2-
dimethylmalonate the overall yield is now 62 % repeatable which is a significant 
improvement on the 8 % under the original conditions.  Scheme 30 shows the 
optimised method versus the original procedure for the synthesis of 346.  
 
Scheme 30: Optimised synthesis of 346, overall yield 62% 
 
2.9: X-Rays of 352, 353, 363 and 343: 
An understanding of the interactions in the crystals of a potential ion receptor can 
provide valuable information on the bonding mode and binding sites of “host” 
molecules in solution studies.36 The crystallographic analysis of therapeutic 
compounds has also proven invaluable to chemists and biologists in understanding the 
key binding sites and modes of action of these therapeutic agents.66 From the X-ray 
crystallographic analysis of the macrocyclic structures 352, 353 and 363, the cavity 
sizes of the cyclic species were estimated using Mercury 1.4.2 software. This data was 
based on solid state and it must be emphasised that the macrocycles may undergo 
significant conformational changes when in solution or when binding to guest species. 
However the X-ray data regarding the cavity size of the macrocycles can be used to 
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estimate which of the guest species might have a significant chance of binding to the 
macrocycle. In this project the guest species of interest are metal cations. The full data 
for each of the compounds, in their .cif format files, is given on CD in the appendix. 
By comparing trends in X-ray data with actual trends of metal cation binding this may 
lead to a more accurate predictive model for future work. 
 
2.9.1: Discussion of the X-Ray Crystal Structure of 352 
Crystals suitable for single crystal X-ray crystallographic determination of 352 were 
grown by slow evaporation from chloroform:hexane (1:2), yielding colourless block 
shaped crystals.  
Selected bond distances, torsion angles and angles of non-hydrogen atoms are given in 
table 6. Table 7 gives selected measurements across the cavity of the macrocycle 
which are illustrative of the cavity size. Figure 47 shows perspective views of the 
crystal structure and figure 48 shows the crystal structure with atomic numbering. 
Figure 47: X-Ray crystal structure of 352 from various aspects 
The presence of the four phenyl rings, severely restrict the flexibility commonly 
recognized for ethereal aliphatic crown ethers. The structure takes on the form of a 
flattened and slightly deformed ellipsoid.  
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Figure 48: X-Ray crystal structure of 352 
Bond lengths Estimated standard deviation 
C(4)–C(8) 1.485 Å 2 
C(17)–C(18) 1.492 Å 2 
C(14)–O(5) 1.3666 Å 18 
O(2)–C(32) 1.4026 Å 17 
O(5)–C(15) 1.4334 Å 18 
C(16)–O(7) 1.4443 Å 18 
O(9)–C(25) 1.4454 Å 19 
Bond angles Estimated standard deviation 
C(1)–O(2)–C(32) 116.51° 11 
C(7)–C(2)–C(1) 122.31° 14 
O(4)-C(9)-C(14) 121.87° 13 
O(7)-C(17)-C(18) 112.21° 13 
C(27)-O(10)-C(26) 116.51° 12 
C(16)-C(15)-O(5) 109.86° 13 
Torsion angles Estimated standard deviation 
C(10)–C(9)–C(14)–O(5) 177.57° 13 
O(10)–C(27)–C(32)–C(31) –177.50° 13 
O(2)–C(1)–C(2)–C(3) –172.58° 13 
C(3)–C(4)–C(8)–O(4) 151.51° 13 
O(3)-C(8)-C(4)-C(3) 13.0° 2 
O(1)-C(1)-C(2)-C(3) 5.8° 2 
O(7)-C(17)-C(18)-C(19) 1.9° 2 
O(9)-C(24)-C(21)-C(22) –164. 93° 13 
O(6)-C(17)-C(18)-C(19) –179.23° 15 
O(8)-C(24)-C(21)-C(22) 14.9° 2 
Table 6: Representative bond lengths, bond angles and torsion angles of 352. 
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Macrocycle 352 crystallizes in the monoclinic space group P21/c with four independent 
molecules per asymmetric unit. The bond length for C(4)–C(8) is 1.485 Å and for 
C(17)–C(18) is 1.492 Å as to be expected as these bonds are similar in nature with the 
most obvious difference being a meta substituent to the C(4)-C(8) bond and there being 
a substituent in the para position to the (C17)-(C18) bond in their corresponding phenyl 
rings. For O(5)–C(15) the bond length is 1.4334 Å with C(15) being sp3 hybridised and 
for C(14)–O(5) the bond length is slightly shorter at 1.3666 Å with this reduced bond 
length caused by the sp2 hybridisation of C(14). Bonds C(16)–O(7) and O(9)–C(25)are 
almost the same distances at 1.4443 Å and 1.4454 Å respectively showing that as 
expected oxygens 7 and 9 are similar as are carbons 16 and 25.  
The angle for C(10)–C(9)–C(14) is 121.41° and is close to the C(31)–C(32)–C(27) 
angle of 121.66°. However, torsion angles for C(10)–C(9)–C(14)–O(5) and O(10)–
C(27)–C(32)–C(31) are 177.57° and –176.02° respectively. This gives an indication 
that the compound is not completely symmetrical in the solid state. The asymmetrical 
state of the  molecule in the crystal is also shown by comparison between  torsion 
angle values associated with the isophthalate unit are similar and equal to 151.51° for 
C(3)–C(4)–C(8)–O(4) and –172.58° for O(2)–C(1)–C(2)–C(3).  
From – To Distance (Å) 
O1 – O7 7.2 
O4 – O5 2.8 
O3 – O7 3.3 
C2 – C20 3.6 
O2 – O9 4.6 
O2 – O7 8.0 
O4 – O9 8.8 
O5 – O10 10.1 
C16 – C27 11.1 
Table 7: Dimensions of the cavity of 352. 
Table 7 details intramolecular distances which are indicative the size of the cavity of 
macrocycle 352.  
 
2.9.2: Discussion of the X-ray crystal structure of Compound 353 
Crystals suitable for single crystal X-ray crystallographic determination of 353 were 
grown by slow evaporation from chloroform:hexane (1:1), yielding colourless block 
shaped crystals.  
Selected bond distances, torsion angles and angles of non-hydrogen atoms are given in 
table 8. Table 9 gives selected measurements across the cavity of the macrocycle 
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which are illustrative of the cavity size. Figure 49 shows perspective views of the 
crystal structure and figure 50 shows the crystal structure with atomic numbering.  
 
 
 
Figure 49: X-Ray crystal structure of 353 from various aspects 
Compound 353 contains four phenyl rings. These rings and the carbonyl groups 
deform the structure, severely restricting the flexibility commonly recognized for 
crown ethers. The structure takes on the form of a flattened and slightly deformed 
ellipsoid. (cf. 352) 
 
 
Figure 50: X-Ray crystal structure of 353 
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Bond lengths Estimated standard deviation 
C(25)–C(30) 1.393 Å 2 
C(16)-C(11) 1.398 Å 2 
O(5)-C(10) 1.4291 Å 18 
O(10)–C(31) 1.4320 Å  18 
C(17)-C(18) 1.488 Å 2 
C(21)-C(24) 1.491 Å 2 
Bond angles Estimated standard deviation 
C(11)–C(16)–O(7) 119.39° 13 
C(30)–C(25)–O(9) 118.79° 13 
O(10)–C(31)–C(32) 107.89° 12 
C(2)–C(1)–O(2) 112.52° 13 
C(16)–C(11)–O(5) 116.26° 13 
O(4)–C(9)–C(10) 107.68° 12 
Torsion angles Estimated standard deviation 
O(5)–C(11)–C(16)–O(7) –0.8° 2 
O(9)–C(25)–C(30)–O(10) 1.06° 19 
O(3)–C(8)–O(4)–C(9) –6.0° 2 
C(32)–O(2)–C(1)–O(1) –0.1°  2 
C(5)–C(8)–O(4)–C(9) 173.56 12 
O(6)–C(17)–C(18)–C(23) 152.02 15 
C(20)–C(21)–C(24)–O(8) 173.36 15 
O(10)–C(31)–C(32)–O(2) 60.52 17 
C(5)–C(8)–O(4)–C(9) 173.56 12 
O(4)–C(9)–C(10)–O(5) 53.87 16 
Table 8: Representative bond lengths, bond angles and torsion angles of 353. 
 
Macrocycle 353 crystallizes in the monoclinic space group P21/c with four independent 
molecules per asymmetric unit. The bond length for C(25)–C(30) is 1.393 Å and for 
C(16)-C(11) is 1.398 Å. Bonds O(5)–C(10) and O(10)–C(31) are almost the same 
distances at 1.4291 Å and 1.4320 Å respectively. The angle for C(11)–C(16)–O(7) is 
119.39° and is close to the C(30)–C(25)–O(9) angle of 118.79°. However, torsion 
angles for O(5)–C(11)–C(16)–O(7) and O(9)–C(25)–C(30)–O(10) are –0.8° and 1.06° 
respectively. This gives an indication that the compound is not completely symmetrical 
in the solid state as although the similar bond on each side of the crystal have very 
similar bond lengths and angles, as expected, they differ in torsion angle which would 
no be expected for a symmetrical molecule. Also demonstrating the asymmetrical 
nature of the crystal structure is the comparison between torsion angle values 
associated with the terephthalate unit are similar and equal –6.0° for O(3)–C(8)–O(4)–
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C(9) and –0.1° for C(32)–O(2)–C(1)–O(1), although the bond angles and lengths are 
similar to each other. 
From - To Distance (Å) 
O1 – O7 7.7 
O1 – O10 3.1 
O4 – O8 7.6 
C8 – C20 3.5 
O2 – O9 4.5 
O4 – O7 4.7 
O4 – O9 8.4 
O5 – O10 10.1 
C10 – C30 11.7 
Table 9: Dimensions of the cavity of 353. 
Table 9 above shows some distances indicating the size of the cavity of macrocycle 
353.  
 
2.9.3: Discussion of the X-ray crystal structure of 363 
Crystals suitable for single crystal X-ray crystallographic determination of 363 were 
grown by slow evaporation from chloroform:hexane (1:3), yielding colourless block 
shaped crystals.  
Selected bond distances, torsion angles and angles of non-hydrogen atoms are given in 
table 10. Table 11 gives selected measurements across the cavity of the macrocycle 
which are illustrative of the cavity size. Figure 51 shows perspective views of the 
crystal structure and figure 52 shows the crystal structure with the atomic numbering.  
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Figure 51: X-Ray crystal structure of 363 from various aspects 
363 contains a ten membered ring with seven carbon and 3 oxygen atoms and one 
phenyl ring. The phenyl ring and the carbonyl groups restrict the flexibility commonly 
seen in crown ethers causing deformation of the structure. The ten membered ring 
takes on the form of a flattened and slightly deformed ellipsoid. 
 
 
 
Figure 52: X-Ray crystal structure of 363 
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Bond lengths Estimated standard deviation 
O(3)–C(3) 1.198 Å 3 
C(7)–O(5) 1.185 Å 2 
C(1)–C(2) 1.514 Å 3 
C(8)–C(13) 1.397 Å 3 
C(3)–C(4) 1.529 Å 3 
C(4)–C(5) 1.532 Å 3 
Bond angles Estimated standard deviation 
C(3)–O(2)–C(2) 116.69° 16 
C(7)–O(4)–C(8) 118.17° 15 
C(13)–C(8)–O(4) 118.63° 16 
C(6)–C(4)–C(5) 110.95° 16 
C(3)–C(4)–C(7) 103.17° 15 
O(5)–C(7)–O(4) 124.44° 17 
Torsion angles Estimated standard deviation 
C(2)–O(2)–C(3)–O(3) –25.6° 3 
O(5)–C(7)–O(4)–C(8) –11.3° 3 
C(13)–O(1)–C(1)–C(2) 146.37° 16 
C(3)–C(4)–C(7)–O(4) –53.89° 18 
O(4)-C(8)-C(13)-O(1) 8.6° 3 
O(4)–C(8)–C(9)–C(10) 175.31° 18 
C(11)–C(12)–C(13)–O(1) 176.71° 18 
C(9)-C(10)-C(11)-C(12) 0.7° 3 
C(9)-C(8)-C(13)-C(12) 0.6° 3 
Table 10: Representative bond lengths, bond angles and torsion angles of 363. 
Macrocycle 363 crystallizes in the monoclinic space group P21 with four independent 
molecules per asymmetric unit. The bond length for C(1)–C(2) is 1.514 Å and for 
C(8)–C(13) is 1.397 Å. Bonds O(3)–C(3) and C(7)–O(5) are almost the same distances 
at 1.198 Å and 1.185 Å respectively. The angle for C(3)–O(2)–C(2) is 116.69° and is 
close to the C(7)–O(4)–C(8) angle of 118.17°. Each of these differences is to be 
expected because of the hybridisation of the atoms involved in the bonds and the 
differences between the aromatic and alkyl carbons.  The aromatic ring and hence it’s 
substituents are non-planar as demonstrated by the torsion angles of O(4)-C(8)-C(13)-
O(1),  C(9)-C(8)-C(13)-C(12) and O(4)–C(8)–C(9)–C(10), this is caused by the stress 
from the larger 10 membered ring. 
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From – To Distance (Å) 
O1 – O2 2.8 
O1 – O4 2.8 
O2 – O4 3.0 
C2 – C8 4.0 
C1 – C4 4.0 
C4 – C13 4.3 
Table 11: Dimensions of the cavity of 363 
 
2.9.4: Discussion of the X-ray crystal structure of 343 
Crystals suitable for single crystal X-ray crystallographic determination of 352 were 
grown by slow evaporation from chloroform:hexane (1:2), yielding colourless needle 
shaped crystals.  
Selected bond distances, torsion angles and angles of non-hydrogen atoms are given in 
table 12. Figure 53 shows perspective views of the crystal structure and figure 54 
shows the crystal structure with atomic numbering. 
  
  
Figure 53: X-Ray crystal structure of 343 from various aspects 
343 was synthesised as a precursor to macrocycle 357 and as such is different from 
each of the other crystal structures as they are each macrocycles and have a ring. 343 is 
a branched molecule with the main chain containing seventeen atoms.  
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Figure 54: X-Ray crystal structure of 343 with atomic numbering 
 
Bond lengths Estimated standard deviation 
C(20)–C(21) 1.496 Å 3 
C(14)–O(6) 1.409 Å 2 
C(1)–C(2) 1.481 Å 3 
C(8)–O(3) 1.412 Å 2 
C(3)–C(8) 1.388 Å 3 
C(10)–C(12) 1.529 Å 3 
Bond angles Estimated standard deviation 
C(3)–O(2)–C(2) 116.9° 1 
C(20)–O(7)–C(19) 118.6° 1 
C(1)–C(2)–O(2) 105.8° 2 
C(11)–C(10)–C(12) 111.5° 2 
C(9)–C(10)–C(13) 108.3° 1 
C(15)–C(16)–C(17) 119.6° 2 
Torsion angles Estimated standard deviation 
C(21)–C(20)–O(7)–C(19) –167.9° 2 
C(1)–C(2)–O(2)–C(3) –154.9° 2 
O(3)–C(9)–C(10)–C(13) –65.0° 2 
C(19)–C(14)–O(6)–C(13) 69.8° 2 
C(15)–C(16)–C(17)–C(18) –2.8° 3 
C(4)–C(5)–C(6)–C(7) –0.5° 3 
Table 12: Representative bond lengths, bond angles and torsion angles of 343. 
Compound 343 crystallizes in the monoclinic space group Pna21 with four independent 
molecules per asymmetric unit. Each of the bond lengths and angles are within normal 
levels and there are no significant differences between similar bonds in varying 
locations within the crystal. However, there are variations of torsion angles for similar 
groups across the crystal; examples include C(1)–C(2)–O(2)–C(3) and C(21)–C(20)–
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O(7)–C(19)  with angles of –154.9° and –167.9° respectively and the two aromatic 
rings are also none planar with torsion angles of –2.8° and –0.5° measured across 
C(15)–C(16)–C(17)–C(18) and C(4)–C(5)–C(6)–C(7) respectively. The aromatic ring 
containing C(15)–C(16)–C(17)–C(18) has the lager torsion angle indicating that it is 
under more strain than the other aromatic ring in the crystal. Although the most 
favourable torsion angle for an alkyl chain is ±60°, ±120° or 180° for steric reasons, 
with the ideal situation giving a torsion angle of 180° between the two largest groups at 
either end of a chain. So in the case of C(1)–C(2)–O(2)–C(3) or C(21)–C(20)–O(7)–
C(19) the most favourable torsion angle is 180°, therefore C(1)–C(2)–O(2)–C(3) is 
under increased strain with the C(1)-C(2) bond being at 154.9° in the anticlockwise 
direction to O(2)-C(3) bond.  
With the crystal of 343 each molecule is hydrogen bonded to two separate molecules 
through the hydroxy groups containing the oxygen atoms O1 and O8. O1 acts as a 
hydrogen bond acceptor and H8 (the hydrogen atom on O8) acts as a hydrogen bond 
donor, the bond length is 2.043Å. These hydrogen bonds are depicted in figure 55 
below.  
 
Figure 55: X-ray crystal structure of 343 depicting the hydrogen bond interactions 
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2.10: Differentiation between Structural Isomers: 
In this section of the thesis the differentiation of the isomers is discussed. This 
differentiation is very important for two reasons. Firstly, so the correct isomers are 
identified and thus the data reported within this thesis is correct; and secondly because 
one pair of isomers, 343 and 346 are biologically active and if work is to continue 
using 343 and 346 to develop compounds with higher activity then it is of utmost 
importance to unambiguously identify the different isomers. 
 
2.10.1: Differentiation between Structural Isomers 343 and 346:  
The structures of 343 and 346 (figure 56) show that these two compounds are isomers 
and it is possible under the right conditions that there could be an intermolecular 
transesterification reaction transforming one product into the other.  
 
Figure 56: Side by side comparison of 343 and 346.  
Although the phenol in the starting material, 2-(2-hydroxyethoxy)phenol, should be 
more reactive than the aliphatic alcohol this will invariably mean that the less reactive 
aliphatic alcohol will form the more stable product. The method of synthesis of both 
343 and 346 is based on the reactivity of the phenol compared to aliphatic alcohol. On 
the addition of one equivalent of dimethyl malonyl dichloride to two equivalents of 2-
(2-hydroxyethoxy)phenol then the first product to form is expected be 343 because the 
phenol is more reactive than the aliphatic alcohol. However, the diacid dichloride may 
also react with the aliphatic alcohol to form 346. According to Cheruvallath et al.67 fast 
mechanical stirring and slow addition of the diacid dichloride is the most important 
factor for determining the product of the reaction, although acetic anhydride was added 
to form the ester instead of dimethyl malonyl dichloride.  
Also it is possible to get intermolecular transesterification. This process would lead to 
343 and 346 being interchangeable, but most notable would also lead to the creation of 
new product 364 as shown in figure 57 below. 
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Figure 57: Structure of 364 
For transesterification to occur the new ester bond formed should be more stable than 
the original ester bond. In the case of 364 and 346 they are both more stable than 343 
so the possibility exists for this intermolecular transesterification to occur. In the 
plethora of published transesterification reactions a catalyst (acid and base) is used. 
Some of the more alkali catalysts for this reaction are metal hydroxides, carbonates and 
metal alkoxides, sulphuric, sulphonic or hydrochloric acids are the most commonly 
used acid catalysts.68 The alkali catalysts are most commonly used because there is a 
faster reaction time and moderate conditions can be used, with typical reaction 
temperatures of 60 oC to 70 oC. Although temperatures for acidic catalysed 
transesterification are typically less, 55 oC to 80 oC, the acid catalysts is typically a 
strong acid.  
For the synthesis of 343 mild basic conditions were used, with the addition of 
triethylamine to react with the hydrogen chloride produced as a by-product of the 
reaction. This may act as a catalyst for the transesterification reaction, either as the free 
base or as the conjugate acid, although this is not likely to a great extent with the 
highest temperature being used for this reaction being room temperature.  
For the synthesis of 346 both alkali and acidic conditions were used, depending on the 
stage of the synthesis (basic conditions for esterification step and acidic conditions for 
the deprotection step). Although this may increase the likelihood of the 
transesterification reaction occurring the difference in the NMR, both 1H and 13C, to 
that of the 343 strongly indicates that the structure is different from that of 343.  Table 
13 below shows the actual versus predicted 1H and 13C NMR of 343 and 346. 
Predictions were carried out using ChemBioDraw Ultra Version 11.0.1 © 1986-2007 
CambridgeSoft. 
One of the clear differences between 343 and 346 is the presence of two phenol groups 
in 346 and none in 343, this has a basic wet chemistry test which shows the presence of 
a phenol and not of an aliphatic alcohol. This test is the addition of aqueous iron(III) 
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chloride to a solution of the compound being tested. Using this test 343 gave negative 
results for the presence on a phenol, the iron(III) chloride solution staying yellow. The 
same test gave a positive result for the presence of phenol on 346, with the iron(III) 
chloride solution turning purple on contact with the solution of 346. 
The most compelling evidence that 343 was successfully isolated and identified is the 
X-ray crystal structure. The X-ray structure is discussed in section 2.9.4. This structure 
agrees with the NMR assignments made for 343.  Figures 58 and 59 below show the 
proton NMR spectra of 343 and 346 respectively. 
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Table 13: Actual versus predicted 1H and 13C NMR of 343, 346 and predicted NMR 
values of 364.  
At no stage of the synthesis was a product isolated whose NMR matched (or nearly 
matched) the predicted values for 364 in the table above 
Atom  
Number 
343 1H 
Actual 
(Predicted) 
346 1H 
Actual 
(Predicted) 
343 13C 
Actual 
(Predicted) 
346 13C 
Actual 
(Predicted) 
364  
Predicted 
1H (13C) 
1 1.71(1.37) 1.67(1.47) 23.19(22.8) 22.08(22.8) 1.42(22.8) 
2   50.45(50.0) 49.36(50.8) (50.4) 
3   170.90(172.1) 169.91(171.1) (172.1) 
4   139.63(142.0) 149.06(148.8) (142.0) 
5 7.15(7.18) 6.86-
6.82(6.84) 
121.18(120.6) 120.07(116.5) 7.18(120.6) 
6 6.88-6.92 
(6.98) 
7.08(6.84) 122.44(120.7) 121.35(121.7) 6.98(120.7) 
7 7.02(7.15) 6.86-
6.82(6.90) 
127.33(126.1) 126.28(121.9) 7.15(126.1) 
8 6.88-6.92 
(6.96) 
6.98(6.82) 113.6(114.8) 112.58(115.8) 6.96(114.8) 
9   150.11(153.9) 138.54(145.6) (153.9) 
10 4.04(4.33) 3.94(4.42) 70.29(69.5) 69.14(66.7) 4.33(69.5) 
11 3.71(3.70) 3.64(4.45) 61.03(60.9) 59.87(62.6) 3.69(60.9) 
12     (171.1) 
13     4.45(62.6) 
14     4.42(66.7) 
15     (145.6) 
16     6.82(115.8) 
17     6.90(121.1) 
18     6.84(121.7) 
19     6.84(116.5) 
20     (148.8) 
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Figure 58: 1H NMR of 343. 
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Figure 59: 1H NMR of 346. 
Shown in figures 58 and 59 are the 1H NMR spectra of 343 and 346, which are clearly 
spectra of different compounds. The singlets for the methyl groups, H1 on both 
structures in figure 56 above, are different by 0.04 ppm, also each of the peaks for the 
CH2 groups, H’s 10 and 11, are different, as are the peaks in the aromatic region. The 
sum of these differences is a clear indicator that the two compounds are different from 
each other. Together with the X-ray of 343 we submit this is strong evidence of the 
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correct assignment of 343 and 346. Also the peaks for H’s 10 and 11 on 343 closely 
match that of the same group in 2-(2-hydroxyethoxy)phenyl acetate reported by 
Cheruvallath et al.67 The 13C NMR of each of these compounds is different, as shown 
below in figures 60 and 61.  
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Figure 60: 13C NMR of 343. 
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Figure 61: 13C NMR of 346 
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Seen in figure 60 and 61 above the 13C NMR spectra of 343 and 346 are clearly of 
different spectra showing that they are also significantly different compounds, the 
peaks for the methyl groups, C1 of 343 is at 23.19 ppm and is at 22.08 ppm for C1 of 
346. For C2 they are at 50.45 ppm and 49.26 ppm respectively. Each of the other peaks 
also differ across the spectrum. The sum of all these differences, 1H NMR, 13C NMR, 
the iron(III) chloride wet chemistry test and X-ray crystallography provides clear 
evidence that both 343 and 346 have been synthesised and correctly identified.  
 
2.10.2: Differentiation between Structural Isomers 339 and 355: 
339 and 355 (figure 62) are isomers and it is possible under the right conditions that 
there could be an intermolecular transesterification reaction transforming one product 
into the other.  
 
Figure 62: Side by side comparison of 339 and 355. 
The arguments for and against the possibility of the transesterification reaction 
occurring have been made in section 2.10.1, as such these arguments will be referred to 
when evaluating the evidence dividing to establish that 339 and 355 have been 
correctly synthesised and identified.  
The intermolecular transesterification would lead to 339 and 355 being 
interchangeable, but most notably would also lead to the creation of new product 365 
as shown in figure 63 below. 
 
Figure 63: Structure of 365 
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The first test to be discussed here is the wet chemistry test using iron(III) chloride to 
test for the presence for the phenol groups. In this case compound 339 tested negative 
for the presence of the phenol with the iron(III) chloride solution remaining yellow and 
355 tested positive with the iron(III) chloride solution turning purple.  
The 1H and 13C NMR spectra for 339 and 355 are shown in the figures 64 to 67 below. 
Below these figures in table 14 are a list of the actual versus predicted 1H and 13C 
NMR of 339 and 355 and the predicted peaks for 365. Predictions were carried out 
using ChemBioDraw Ultra Version 11.0.1 © 1986-2007 CambridgeSoft. 
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Figure 65: 1H NMR of 355 
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Figure 66: 13C NMR of 339 
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Figure 67: 13C NMR of 355 
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Table 14: Actual versus predicted 1H and 13C NMR of 339, 355 and predicted NMR 
values of 366 
In the case of 339 the predicted 1H-NMR closely matches the actual data recorded for 
the hydrogens on the two aliphatic carbons, H’s 12 and 13. Although it is not an exact 
Atom  
Number 
339 1H 
Actual 
(Predicted) 
355 1H 
Actual 
(Predicted) 
339 13C 
Actual 
(Predicted) 
355 13C 
Actual 
(Predicted) 
366  
Predicted 
1H (13C) 
1 7.62(7.64) 7.46(7.56) 129.31(128.5) 128.89(128.5) 7.60(128.5) 
2 8.40(8.47) 8.16(8.26) 135.21(135.5) 134.29(134.2) 8.43(134.6) 
3   131.93(130.1) 130.22(131.1) 8.30(135.1) 
4 8.99(8.62) 8.63(8.28) 130.03(130.6) 130.94(129.8) (130.1) 
5   164.18(166.3) 166.71(166.9) (131.1) 
6   140.17(138.5) 146.15(148.8) 8.45(130.2) 
7 7.12-7.21 
(7.26) 
6.74-6.88  
(6.84) 
121.50(120.6) 115.09(116.5) (166.9) 
8 6.98-6.94 
(7.08) 
6.74-6.88  
(6.84) 
122.79(120.7) 120.18(121.7) (166.2) 
9 7.12-7.21 
(7.24) 
6.74-6.88 
 (6.90) 
127.22(126.1) 122.40(121.9) 4.62(63.9) 
10 6.98-6.94 
(7.06) 
6.74-6.88 
(6.82) 
114.01(114.8) 112.50(115.8) (138.5) 
11   149.90(153.9) 145.48(145.6) 4.60(66.7) 
12 4.12(4.33) 4.32(4.60) 70.37(69.5) 67.51(66.7) 7.26(120.6) 
13 3.75(3.69) 4.66(4.62) 61.01(60.9) 63.53(63.7) (145.6) 
14     7.08(120.7) 
15     6.82(115.8) 
16     7.24(126.1) 
17     6.90(121.9) 
18     7.06(114.8) 
19     6.84(121.7) 
20     (153.9) 
21     6.84(116.5) 
22     4.63(69.5) 
23     (148.8) 
24     3.69(60.9) 
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match it is in the correct area and more importantly is significantly different from that 
of the equivalent hydrogens on 355, H’s 12 and 13. One other significantly different 
hydrogen from these isomers is H4. In 339 H4 is ortho to two ester groups, each 
synthesised from a phenol; H4 in 355 is ortho to two ester groups, each synthesised 
from an aliphatic alcohol. H4 is predicted to be further downfield in the NMR 
spectrum of 339 than in the NMR spectrum of 355 due to the effects of the phenolic 
esters and of the aliphatic esters. Although in each spectra H4 appears further 
downfield than predicted it is clear in the spectrum of 339 that H4 is significantly 
further downfield than in the spectrum of 355. Hydrogens H12, H13 and H14 are the 
most significant hydrogens for differentiating the two structures by NMR, as they are 
the hydrogens that will change most significantly between the isomers.  
The 13C NMR spectra of these two compounds are also significantly different, with the 
NMR of 339 more closely matching the predicted values for many of the carbons. Also 
it must be noted that again none of the intermediate product 366 was isolated. 
Also to be taken into account here is the macrocycle 352, page 55, which has been 
synthesised using 339 as a starting material. Compound 339 was dissolved in 
dichloromethane and then triethylamine was added before being linked between the 
aliphatic alcohols using terephthaloyl dichloride. Further to this is that 352 was made 
using the one pot method in with 2-(2-hydroxyethoxy)phenol was first linked using the 
isophthaloyl dichloride to form the intermediate and then extra base (triethylamine) 
added before the addition of terephthaloyl dichloride to form the macrocycle. The 
structure of this macrocycle has been proven by X-ray crystallography, and confirms 
that 339 must have been formed in both methodologies in order to obtain 352 as the 
product. The fact that this macrocycle has formed and not the isomer, 358, shows that 
not only did 339 from but was also stable to the extra base present.  
When the NMR data is taken into account, with the wet chemistry test and the X-ray of 
macrocycle 352 and the fact that the same methodology was used in the synthesis of 
these compounds as was used in 343 and 346 it has been proven that compounds 339 
and 355 have been successfully isolated and correctly identified.  
 
2.10.3: Differentiation between Structural Isomers 342 and 356: 
342 and 356 (figure 68) are isomers and it is possible under the right conditions that 
there could be an intermolecular transesterification reaction transforming one product 
into the other.  
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Figure 68: Comparison of 342 and 356 
The arguments for and against the possibility of the transesterification reaction 
occurring have been made in section 2.10.1, as such these arguments will be referred to 
when evaluating the evidence to establish that 342 and 356 have been correctly 
synthesised and identified.  
As before, sections 2.10.1 and 2.20.2, it is possible to get intermolecular 
transesterification but this process would lead to 342 and 356 being interchangeable, 
but most notably would also lead to the creation of new product 366 as shown in figure 
69 below. 
 
Figure 69: Structure of 366 
The first test to be discussed here is the wet chemistry test using iron(III) chloride to 
test for the presence for the phenol groups. In this case compound 342 tested negative 
for the presence of the phenol with the iron(III) chloride solution remaining yellow and 
356 tested positive with the iron(III) chloride solution turning purple.  
The 1H and 13C NMR spectra for 342 and 356 are shown in the figures 70 to 73 below. 
Below these figures in table 15 are a list of the actual versus predicted 1H and 13C 
NMR of 342 and 356 and the predicted peaks for 366. Predictions were carried out 
using ChemBioDraw Ultra Version 11.0.1 © 1986-2007 CambridgeSoft. 
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Figure 70: 1H NMR of 342 
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Figure 71: 1H NMR of 356 
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Figure 72: 13C NMR of 342 
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Figure 73: 13C NMR of 356 
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Table 15: Actual versus predicted 1H and 13C NMR of 342, 356 and predicted 
NMR values of 366. 
The NMR spectra of both 342 and 356 closely match the predicted 1H and 13C 
NMR values for the two CH2 moieties, positions 10 and 11. Although exact match 
was not observed it is in the correct area and demonstrates both are significantly 
different. Although the recorded data more closely resembles the predicted data for 
Atom  
Number 
342 1H 
Actual 
(Predicted) 
356 1H 
Actual 
(Predicted) 
342 13C 
Actual 
(Predicted) 
362 13C 
Actual 
(Predicted) 
366  
Predicted 
1H (13C) 
1 7.43(7.81) 7.41(7.78) 121.55(120.6) 119.16(119.4) 7.72(119.4) 
2   146.54(150.6) 146.34(146.9) (148.4) 
3   155.94(177.6) 157.34(158.9) (158.9) 
4   139.44(138.5) 147.09(148.8) 4.62(61.5) 
5 7.21-7.13 
(7.18) 
6.79(6.84) 120.23(120.6) 115.89(116.5) 4.60(66.1) 
6 6.98-6.94 
(6.98)  
6.79(6.84) 122.73(120.7) 119.29(121.7) (145.6) 
7 7.21-7.13 
(7.15) 
6.96(6.90) 127.51(126.1) 121.80(121.9) 6.82(115.8) 
8 6.98-6.94 
(6.96)  
6.71-6.74 
(6.82) 
114.21(114.8) 114.82(115.8) 6.90(121.9) 
9   149.79(153.9) 146.06(145.6) 6.84(121.7) 
10 4.12(4.33)  4.29(4.60) 70.53(69.5) 66.67(66.1) 6.84(116.5) 
11 3.79(3.69) 4.61(4.62) 61.04(60.9) 64.10(61.5) (148.8) 
12     7.87(120.6) 
13     (149.1) 
14     (177.6) 
15     (138.5) 
16     7.18(120.6) 
17     6.98(120.7) 
18      7.15(126.1) 
19     6.96(114.8) 
20     (153.9) 
21     4.33(69.5) 
22     3.69(60.9) 
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compound 342 rather than for compound 356 they have still been shown to be 
significantly different and also dissimilar from the predicted NMR of 366. These 
CH2 moieties are the key for differentiating the two structures by NMR, as they are 
the hydrogens that will change most significantly and are also less likely to be 
complicated multiplets as seen in the aromatic regions.   
When the NMR data is taken into account, with the wet chemistry test and the fact 
that the same methodology was used in the synthesis of these compounds as was 
used in each of the other pairs of isomers it seems almost certain that compounds 
339 and 355 have been successfully isolated and correctly identified.  
 
2.10.4: Differentiation between Structural Isomers 340 and 347: 
The possibility exists that under the right conditions 340 and 347 (figure 74) can 
undergo an intermolecular transesterification reaction transforming one product 
into the other, as previously outlined with the isomers in section 2.10.1.  
 
Figure 74: Side by side comparison of 340 and 347.  
The arguments for and against the possibility of the transesterification reaction 
occurring have been made in section 2.10.1, as such these arguments will be 
referred to when evaluating the evidence dividing to establish that 340 and 347 
have been correctly synthesised and identified.  
The intermolecular transesterification but this process would lead to 340 and 347 
being interchangeable, but most notably would also lead to the creation of new 
product 367 as shown in figure 75 below. 
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Figure 75: Structure of 367 
The first test to be discussed here is a wet chemistry assay using iron(III) chloride 
to check for the presence for the phenol groups. In this case compound 340 gave 
negative results for the presence of the phenol with the iron(III) chloride solution 
remaining yellow and 347 gave positive results with the iron(III) chloride solution 
turning purple showing there was  phenol present.  
The 1H and 13C NMR spectra for 340 and 347 are shown in the figures 76 to 79 
below. Below these figures in table 16 is a list of the actual versus predicted 1H 
and 13C NMR of 340 and 347 and the predicted peaks for 367. Predictions were 
carried out using ChemBioDraw Ultra Version 11.0.1 © 1986-2007 
CambridgeSoft. 
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Figure 76: 1H NMR of 340. 
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Figure 78: 13C NMR of 340.  
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Figure 79: 13C NMR of 347
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Table 16: Actual versus predicted 1H and 13C NMR of 340 and 347 and the predicted 
peaks for 367. 
In the case of 340 and 347 the predicted 1H-NMR doest not match the actual data 
recorded for H10 and H11. Although the aromatic hydrogens of 347 closely match the 
Atom  
Number 
340 1H 
Actual 
(Predicted) 
347 1H 
Actual 
(Predicted) 
340 13C 
Actual 
(Predicted) 
347 13C 
Actual 
(Predicted) 
367 
Predicted 
1H (13C) 
1 8.28(8.04) 8.08(7.83) 130.49(130.2) 129.79(129.8) 8.00(130.2) 
2   133.64(135.4) 133.70(134.4) 7.87(129.8) 
3   164.20(166.2) 166.77(166.9) (134.5) 
4   140.15(138.5) 146.15(148.8) (135.3) 
5 7.20(7.26) 6.89-6.75 
(6.84) 
122.73(120.6) 115.09(116.5) (166.2) 
6 6.99-6.95 
(7.08) 
6.89-6.75 
(6.84) 
121.55(120.7) 120.18(121.7) (138.5) 
7 7.14(7.24) 6.89-6.75 
(6.90) 
127.30(126.1) 122.47(121.9) 7.26(120.6) 
8 6.99-6.95 
(7.06) 
6.89-6.75 
(6.82) 
114.05(114.8) 112.49(115.8) 7.08(120.7) 
9   149.86(153.9) 145.46(145.6) 7.24(126.1) 
10 3.75(4.33) 4.33(4.60) 70.37(69.5) 67.49(66.7) 7.06(114.8) 
11 4.13(4.69) 4.66(4.62) 61.04(60.9) 63.67(63.9) (153.9) 
12     4.33(69.5) 
13     3.69(60.9) 
14     (166.9) 
15     4.62(63.9) 
16     4.60(66.7) 
17     (145.6) 
18     6.82(115.8) 
19     6.90(121.9) 
20     6.84(121.7) 
21     6.84(116.5) 
22     (148.8) 
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predicted values, it is hard to be certain how closely they match as they are in a very 
narrow region of the spectrum and all overlap. Also the aliphatic hydrogens, H10 and 
H11, in 347 appear closer together than in 340, which matches the predicted pattern. 
This is not the ideal situation from the proton NMR as the aliphatic peaks are a more 
definitive indicator of the species as discussed above. H1 in the spectra of both 340 and 
347 appear as a singlet above 8 ppm, again as with H10 and H11, they do not match 
the predicted chemical shift closely but instead appear in the predicted pattern with in 
their relative spectra. H1 in the spectrum of 340 appearing further downfield than H1in 
the spectrum of 347. This is important as these hydrogens differ significantly between 
the two isomers.  
The 13C NMR spectra of these two compounds are also significantly different and each 
closely matches the predicted values for many of the carbons. Again these are not exact 
matches but are very close for almost all carbons in 340 and 347. Also it must be noted 
that again none of the intermediate product 367 was isolated. 
Also to be taken into account here are the macrocycles 352 and 358, page 55. 352 has 
been synthesised, fully characterised and the X-ray crystal structure reported. 
Macrocycle 358 is the isomer of 352 and although no X-ray crystal data has been 
recorded, for 358, it has been successfully isolated. Although this was not successfully 
synthesised directly from 340, 358 was synthesised via the one pot method in which 
340 had to form in the reaction vessel and then react with isophthaloyl dichloride to 
form the macrocycle (358). This is known to have happened because if 2-(2-
hydroxyethoxy)phenol did not react with terephthaloyl dichloride first and then with 
isophthaloyl dichloride but instead reacted with isophthaloyl dichloride first, it would 
then have made 339 as the intermediate and formed macrocycle 352 as the product, as 
339 has already been reported to be stable to the conditions for the synthesis of the 
macrocyclisation reaction. From this evidence it is known that 340 is formed 
preferentially to 347. 
When the NMR data is considered, with the wet chemistry test, the X-ray of 
macrocycle 352 and the fact that the same synthetic methodology was used for the 
synthesis each of the other isomeric pairs, it has been proven that compounds 340 and 
347 have been unambiguously prepared. 
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2.11: Conclusion: 
Thirteen novel crown ethers and eleven new precursors (both bis-alcohols and bis-
phenols) were successfully synthesised and isolated. Six of these macrocycles were 
synthesised by at least 2 methods.  
Sections 2.2 and 2.4 detail the isolation of the eleven precursors, seven bis-alcohols 
and four bis-phenols. Section 2.2 details the synthesis of the bis-alcohols 338-344 and 
Section 2.4 outlines the preparation of the bis-phenols 346, 347, 355 and 356. 
Sections 2.3, 2.5 and 2.6 discuss the formation of thirteen macrocycles. In section 2.3 
the synthesis of seven macrocycles (348-354) made from the bis-alcohols was outlined. 
Section 2.5 addressed the synthesis of four macrocycles (350, 352, 353 and 357) from 
the bis-phenols. Section 2.6 discuses the one pot method used for the preparation of ten 
macrocycles (351-354 and 357-362) from 2-(2-hydroxyethoxy)phenol.  
348 and 349 were isolated solely in section 2.3. 358-362 were only successfully 
prepared by the one pot synthesis, section 2.6. Each of the other macrocycles were 
synthesised by more then one method.  
350 was successfully isolated by the methods in sections 2.3 and 2.5, with the latter 
giving the better yield (6 %). 351 and 354 were isolated in sections 2.3 and 2.6. 351 
was isolated in higher yield (23 %) in section 2.6, the one pot method, while 354 was 
isolated in higher yield (12 %) in section 2.3 closing the bis-alcohol with the diacid 
dichloride. 352 and 353 were successfully isolated by all three methods. 352 was 
isolated in it’s highest yield from the one pot method, 16 % compared to 3.5 % for 
each of the other methods, but 353 was isolated in it’s highest yield (7 %), pre-
optimisation, from the method utilising the bis-phenol to make the macrocycle, section 
2.5. 357 was isolated in sections 2.5 and 2.6, with significantly higher yield (25 %) 
being isolated in section 2.5.  
The one pot synthesis of 353 was optimised with the goal of using this optimised 
method to synthesise the analogous morphine containing macrocycle. This 
optimisation increased the yield from 2.5 % to 44 %. The use of this method for the 
synthesis of the morphine containing macrocycle will be discussed in chapter 3. 
The results from the general synthesis and the optimisation of 353 suggest that the 
controlling factors for the isolatable yields of the macrocycles are related to 
temperature, time, concentration and equivalents of base used and not the general 
method used, as there was no clear general method which gave higher yields than each 
of the other methods.  
 106 
The synthesis of bis(2-(2-hydroxyphenoxy)ethyl) 2,2-dimethylmalonate, 346, was also 
optimised. This was done after biological testing indicated that 346 acted as a P-gp 
inhibitor. The yield for this compound was increased from 7 % to 62 %. The results of 
the biological testing will be discussed in chapter 5. 
From the X-ray crystallographic data representative measurements of the cavity sizes 
in 352, 353 and 363 have been presented. These measurements are based purely on 
physical size of the cavity in the solid state and do not take into account the 
rigidity/flexibility of the “hosts”, the charge on any potential guests and the stability of 
the host-guest complex and therefore cannot be used as a predictable guide as to what 
guest species may bind to the macrocycles.  
Using a combination of data from wet chemistry testing, NMR spectra, X-ray 
crystallography it has been clearly demonstrated that the isomers have been 
unequivocally identified.  
In conclusion it has been demonstrated that a library of bis-alcohols, bis-phenols and 
macrocycles have been prepared. The macrocyclisation can be optimised to 
satisfactory yields and gram quantities of the model compounds can be obtained for 
screening.  
 
Experimental: 
All chemicals were purchased from Sigma/Aldrich and used as received. When 
necessary, solvents were purified prior to use and stored under nitrogen. 
Dichloromethane was distilled over CaH2 and triethylamine was distilled and stored 
over potassium hydroxide pellets. Commercial grade reagents were used without 
further purification. Davisil 60A silica gel was used for thin layer and column flash 
chromatography. Melting points were determined using a Stuart melting point, SMP3, 
apparatus and are uncorrected. Infrared spectra were recorded on Perkin Elmer FT-IR 
spectrum GX spectrometer. Liquid chromatography time-of-flight mass spectrometry 
was recorded on a Waters Corp. Liquid Chromatography-Time of flight mass 
spectrometer from Micromass MS Technologies Centre. NMR spectra were obtained 
on a Bruker AC 400 NMR spectrometer operating at 400 MHz for 1H NMR and 100 
MHz for 13C NMR. The 1H and 13C NMR chemical shifts (ppm) are relative to 
tetramethylsilane. All coupling constants (J) are in Hertz. 
 
 
 107 
Furan-2,5-dicarbonyl dichloride, 337:66       
 
Mucic acid (10.0 g, 57.6 mmol) and p-toluenesulfonic acid monohydrate (31.7 g, 166.6 
mmol) were stirred together at 140 oC for 2 hours. The reaction mixture was then 
cooled to 98 oC and aqueous 4 % calcium chloride solution (600 mL) was added and 
then heated to reflux with stirring for 1 hour. The resulting solution was then filtered 
and concentrated hydrochloric acid (200 mL) was added and left for twenty four hours 
at room temperature. This gave the furan-2,5-diacid as a pale red solid isolated by 
filtration.  
This solid was then dried under vacuum and heated to reflux in excess thionyl chloride 
(26 mL) for sixteen hours. The excess thionyl chloride, sulfurochloridous acid and 
sulfurous acid (by-products of the reaction) were removed under vacuum to give the 
target product (12 %, 1.385 g, 7.177 mmol) as a pale red solid. As this product was an 
intermediate the exact mass was not recorded. The 1H NMR and 13C NMR are in 
agreement with the literature.66  
1H NMR (CDCl3): δ(ppm) 7.95 (2H, s, H2) 
13C NMR (CDCl3): δ(ppm) 155.90 (C3), 149.34 (C1), 123.28 (C2) 
IR (KBr disc): σ(cm-1) 1812, 1549, 1507, 1384, 1201, 636 
MP: 80-81 oC 
 
Bis(2-(2-Hydroxyethoxy)phenyl) phthalate, 338:  
 
2-(2-Hydroxyethoxy)phenol (4.04 g, 20.0 mmol) was dissolved in dichloromethane 
(300 mL) at room temperature under a nitrogen atmosphere. To this was added 
triethylamine (10.0 mL, 72 mmol) and then chilled to -15 oC. The phthaloyl dichloride 
(1.44 mL, 10.0 mmol) was dissolved in dichloromethane (100 mL) and added slowly 
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to the mixture. After one hour at -15 oC the reaction was allowed to warm to room 
temperature and stirred for sixteen hours. The reaction was then quenched by the 
addition of DI water (DI H2O) (10.0 mL), stirred for 20 minutes and then separated. 
The organic layer was washed with DI H2O (30.0 mL X 3), dried over magnesium 
sulphate and the solvent was evaporated in vacuo. The product was purified by column 
chromatography on a silica stationary phase using 2:1 diethylether:dichloromethane, 
followed by recrystallisation from chloroform:hexane to obtain the pure product as a 
colourless solid (2.35 g, 54 %, 5.36 mmol). 
1H NMR (CDCl3): δ(ppm) 7.63 (2H, dd, J = 3.4, 1.8 Hz, H2), 7.63 (2H, dd, J = 3.4, 1.8 
Hz, H1), 716 (2H, td, J = 8.0, 1.6 Hz, H6), 7.09 (2H, dd, J = 8.0, 1.6 Hz, H8), 6.95 (2H, 
dd, J = 8.0, 1.2 Hz, H9), 6.90 (2H, td, J = 8.0, 1.2 Hz, H7), 4.04 (4H, t, J = 4.4 Hz, 
H11), 3.71 (4H, t, J = 4.4 Hz, H12), (2H, br s, H13). 
13C NMR (CDCl3): δ(ppm) 166.46 (C4), 150.40 (C10), 139.66 (C5), 131.88 (C1), 
131.57 (C3), 129.73 (C2), 127.37 (C8), 122.75 (C7), 121.11 (C6), 113.60 (C9), 70.36 
(C11), 61.05 (C12) 
IR (KBr disc): σ(cm-1) 3430, 3068, 2943, 2878, 1722, 1607, 1572, 1458, 1410, 1267, 
1180, 1109, 1076, 1056.  
M.P.: 105-107 oC 
Calculated exact mass for product: (C24H22O8) 438.1315 
Calculated exact mass for product + sodium: (C24H22O8Na+) 461.1207 
Found: HRMS (EI, 70 eV) 461.1204 
 
Bis(2-(2-Hydroxyethoxy)phenyl) isophthalate, 339:  
 
2-(2-Hydroxyethoxy)phenol (4.04 g, 20.0 mmol) was dissolved in dichloromethane 
(300 mL) at room temperature under a nitrogen atmosphere. Triethylamine (10.0 mL, 
72 mmol) was added and the mixture was then cooled to -15 oC. Isophthaloyl 
dichloride (2.01 g, 10.0 mmol) was dissolved in dichloromethane (100 mL) and added 
slowly to the mixture. After one hour at -15 oC the reaction was allowed to warm to 
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room temperature and stirred for sixteen hours. The reaction was quenched by the 
addition of DI water (10.0 mL) stirred for 20 minutes and separated. The organic layer 
was washed with DI H20 (30.0 mL X 3), dried over magnesium sulphate and the 
solvent was evaporated in vacuo. The product was purified by column chromatography 
on a silica stationary phase using 2:1 diethylether:dichloromethane followed by 
recrystallisation from chloroform:hexane to obtain the pure product as a colourless 
solid (93 %, 4.069 g, 9.30 mmol).  
1H NMR (CDCl3): δ(ppm) 8.99 (1H, s, H4), 8.40 (2H, dd, J = 2.8 Hz, H2), 7.62 (1H, t, 
J = 2.8 Hz, H1), 7.21-7.12 (4H, m, H’s 7 and 9), 6.98-6.94 (4H, m, H’s 8 and 10), 4.12 
(4H, t, J = 4.4 Hz, H12), 3.75 (4H, t, J = 4.4 Hz, H13) 
13C NMR (CDCl3): δ(ppm) 164.18 (C5), 149.90 (C11), 140.17 (C6), 135.21 (C2), 
131.93 (C3), 130.03 (C4), 129.31 (C1), 127.22 (C9), 122.79 (C8), 121.50 (C7), 
114.01(C10), 70.37 (C12), 61.01 (C13). 
IR (KBr disc): σ(cm-1) 3518, 3407, 3045, 2960, 2363, 1736, 1702, 1611, 1597, 1504, 
1459, 1314, 1263, 1246, 1142, 1110, 1034. 
MP: 124-126 oC 
Calculated exact mass for product: (C24H22O8) 438.1315 
Calculated exact mass for product + proton: (C24H22O8H+) 439.1387 
Found: HRMS (EI, 70 eV) 439.1396 
 
Bis(2-(2-Hydroxyethoxy)phenyl)terephthalate, 340:  
6
7
8
9
4
5
O
O
10
11
OH
12
6
7
8
9
4
5
O
O
10
11
OH
12
1 1
2
11
2
3 3
O O
 
2-(2-Hydroxyethoxy)phenol (4.04 g, 20.0 mmol) was dissolved in dichloromethane 
(300 mL) at room temperature under a nitrogen atmosphere. To this was added 
triethylamine (10.0 mL, 72 mmol) and the mixture was cooled to -15 oC. Terephthaloyl 
dichloride (2.01 g, 10.0 mmol) was dissolved in dichloromethane (100 mL) and added 
slowly to the mixture. After one hour at -15 oC the reaction was allowed to warm to 
room temperature and stirred for sixteen hours. The reaction was quenched by the 
addition of DI water (10.0 mL) stirred for 20 minutes and then separated. The organic 
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layer washed with DI H20 (30.0 mL X 3), dried over magnesium sulphate and the 
solvent was evaporated in vacuo. The product was purified by column chromatography 
on a silica stationary phase using 1:1 diethyl ether:dichloromethane giving the product 
as a colourless solid (67 %, 2.94 g, 6.70 mmol). 
1H NMR (CDCl3): δ(ppm) 8.28 (4H, s, H1), 7.20 (2H, dt, J = 8.0, 1.6 Hz H 7), 7.14 
(2H, dd, J = 8.4, 1.6 Hz H 5), 6.99-6.95 (4H, m, H’s 6 and 8), 4.13 (4H, t, J = 4.4 Hz, 
H11), 3.75 (4H, t, J = 4.4 Hz, H10). 
13C NMR (CDCl3): δ(ppm) 164.20 (C3), 149.86 (C9), 140.15 (C4), 133.64 (C2), 
130.49 (C1), 127.30 (C7), 122.73 (C5), 121.55 (C6), 114.05 (C8), 70.37 (C10), 61.04 
(C11). 
IR (KBr disc): σ(cm-1)3449, 2963, 2365, 1736, 1607, 1458, 1407, 1261, 1179, 1102, 
1068, 1015. 
MP: 199-201 oC 
Calculated exact mass for product: (C24H22O8) 438.1315 
Calculated exact mass for product + proton: (C24H22O8H+) 439.1387 
Found: HRMS (EI, 70 eV) 439.1396 
 
Bis(2-(2-Hydroxyethoxy)phenyl)pyridine-2,6-dicarboxylate, 341:  
 
2-(2-Hydroxyethoxy)phenol (308 mg, 2.00 mmol) was dissolved in dichloromethane 
(20.0 mL) at room temperature under a nitrogen atmosphere. Triethylamine was added 
(1.0 mL, 7.2 mmol) and the mixture was cooled to -15 oC. 2,6-Pyridine dicarbonyl 
dichloride (204 mg, 1.00 mmol) was dissolved in dichloromethane (20.0 mL) and 
added slowly to the mixture. After one hour at -15 oC the reaction was allowed to 
warm to room temperature and stirred for sixteen hours. The reaction was quenched by 
the addition of DI water (10.0 mL) stirred for 20 minutes and then separated. The 
organic layer washed with DI H20 (30.0 mL X 3), dried over magnesium sulphate and 
the solvent was evaporated in vacuo. The product was purified by column 
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chromatography on a silica stationary phase using 1:1 ethylacetate:dichloromethane 
giving the product as a colourless solid (29 %, 0.128g, 0.29 mmol). 
NMR (CDCl3): δ(ppm) 8.25 (2H, d, J = 8.0 Hz, H2), 7.96 (1H, t, J = 1.6 Hz, H1), 6.87-
6.72 (8H, m, H’s 6, 7, 8 and 9), 4.74 (4H, t, J = 4.8 Hz, H11), 4.35 (4H, t, J = 4.8 Hz, 
H12).  
13C NMR (CD3CN): δ(ppm) 164.43 (C4), 147.82 (C10), 146.57 (C3), 145.49 (C1), 
138.44 (C5), 128.52 (C2), 122.53 (C8), 120.02 (C7), 115.59 (C6), 113.13 (C9), 67.34 
(C11), 64.12 (C12). 
IR (KBr disc): σ(cm-1) 3498, 2961, 2365, 1730, 1637, 1596, 1504, 1458, 1404, 1374, 
1323, 1246, 1175, 1141, 1112, 1083, 1064, 1035. 
MP: 109-111 oC  
Calculated exact mass for product: (C23H21NO8) 439.1267 
Calculated exact mass for product + proton: (C23H21NO8H+) 440.1340 
Found: HRMS (EI, 70 eV) 440.1348 
 
Bis(2-(2-Hydroxyethoxy)phenyl)furan-2,5-dicarboxylate, 342:  
 
2-(2-Hydroxyethoxy)phenol (4.04 g, 20.0 mmol) was dissolved in dichloromethane 
(300 mL) at room temperature under a nitrogen atmosphere. Triethylamine (10.0 mL, 
72 mmol) was added and the mixture was cooled to -15 oC. 2,5-Furan dicarbonyl 
dichloride (2.029 g, 10.0 mmol) was dissolved in dichloromethane (100 mL) and added 
slowly to the mixture. After one hour at -15 oC the reaction was allowed to warm to 
room temperature and stirred for sixteen hours. The reaction was quenched by the 
addition of DI water (10.0 mL) stirred for 20 minutes and then separated. The organic 
layer was washed with DI H20 (30.0 mL X 3), dried over magnesium sulphate and the 
solvent was evaporated in vacuo. The product was purified by column chromatography 
on a silica stationary phase using 1:1 ethylacetate:dichloromethane, followed by 
recrystallisation from chloroform:hexane to obtain the pure product as a colourless 
solid (1.46 g, 34 %, 3.41 mmol). 
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1H NMR (CDCl3): δ(ppm) 7.43 (2H, s, H1), 7.21-7.13 (4H, m, H’s 5 and 7), 6.98-6.94 
(4H, m, H’s 6 and 8), 4.12 (4H, t, J = 4.4 Hz, H10), 3.79 (4H, t, J = 4.4 Hz, H11) 
13C NMR (CDCl3): δ(ppm) 155.94 (C3), 149.79 (C9), 146.54 (C2), 139.44 (C4), 
127.51 (C7), 122.73 (C6), 121.55 (C1), 120.23 (C5), 114.21 (C8), 70.53 (C10), 61.04 
(C11).   
IR (KBr disc): σ(cm-1) 3371, 3127, 1713, 1688, 1583, 1505, 1468, 1438, 1357, 1326, 
1305, 1281, 1265, 1223, 1168, 1132, 1112, 1063, 1047, 1023, 1006. 
MP: 143-144 oC 
Calculated exact mass for product: (C22H20O9) 428.1107 
Calculated exact mass for product + sodium: (C22H20O9Na+) 451.1000 
Found: HRMS (EI, 70 eV) 451.1005 
 
Bis(2-(2-Hydroxyethoxy)phenyl)-2,2-dimethylmalonate, 343:  
 
2-(2-Hydroxyethoxy)phenol (1.823 g, 11.84 mmol) was dissolved in dichloromethane 
(140 mL) at room temperature under a nitrogen atmosphere. Triethylamine (4.5 mL, 32 
mmol) was added and the mixture was cooled to -15 oC. Dimethylmalonyl chloride 
(1.00 g, 5.92 mmol) was dissolved in dichloromethane (30 mL) and added slowly to 
the mixture. After one hour at -15 oC the reaction was allowed to warm to room 
temperature and stirred for sixteen hours. The reaction was quenched by the addition of 
DI water (10.0 mL) stirred for 20 minutes and then separated. The organic layer was 
washed with DI H20 (30.0 mL X 3), dried over magnesium sulphate and the solvent 
was evaporated in vacuo. The product was purified by column chromatography on a 
silica stationary phase using 1:1 ethylacetate:chloroform to isolate the product (60 %, 
1.10 g, 2.72 mmol) as a colourless solid. 
1H NMR (CDCl3): δ(ppm) 7.15 (2H, td, J = 8.4, 1.6 Hz, H5), 7.02 (2H, dd, J = 8.8, 1.6 
Hz, H7), 6.92-6.88 (4H, m, H’s 6 and 8), 4.04 (4H, t, J = 4.4 Hz, H10), 3.71 (4H, t, J = 
4.4 Hz, H11), 1.71 (6H, s, H1). 
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13C NMR (CDCl3): δ(ppm) 170.91 (C3), 150.11 (C9) 139.63 (C4), 127.33 (C7), 122.44 
(C6), 121.18 (C5), 113.60 (C8) 70.29 (C10), 61.03 (C11), 50.45 (C2), 23.19 (C1). 
IR (KBr disc): σ(cm-1) 3531, 3451, 2996, 2954, 2924, 2878, 2363, 1754, 1607, 1504, 
1459, 1391, 1309, 1292, 1254, 1213, 1181, 1144, 1099, 1067, 1032. 
MP: 102-104 oC 
Calculated exact mass for product: (C21H22O8) 404.1471 
Calculated exact mass for product + proton: (C21H22O8H+) 405.1544 
Found: HRMS (EI, 70 eV) 405.1549 
 
Bis(2-(2-Hydroxyethoxy)phenyl)diglycolate, 344:  
 
2-(2-Hydroxyethoxy)phenol (4.04 g, 20.0 mmol) was dissolved in dichloromethane 
(300 mL) at room temperature under a nitrogen atmosphere. Triethylamine (10.0 mL, 
72 mmol) was added and the mixture was cooled to -15 oC. Diglycolyl dichloride (1.71 
g, 10.0 mmol) was dissolved in dichloromethane (100 mL) and added slowly to the 
mixture. After one hour at -15 oC the reaction was allowed to warm to room 
temperature and stirred for sixteen hours. The reaction was quenched by the addition of 
DI water (10.0 mL) stirred for 20 minutes and then separated. The organic layer was 
washed with DI H20 (30.0 mL X 3), dried over magnesium sulphate and the solvent 
was evaporated in vacuo. The product was purified by column chromatography on a 
silica stationary phase using 2:1 ether:dichloromethane, followed by recrystallisation 
from chloroform:hexane to isolate the pure product (76 %, 3.10 g, 7.63 mmol) as a 
colourless solid. 
1H NMR (CDCl3): δ(ppm) 6.88-6.73 (8H, m, H’s 4 to 7), 4.47 (4H, t, J = 4.2 Hz, H9), 
4.21 (4H, s, H1), 4.19 (4H, t, J = 4.2 Hz, H10). 
13C NMR (CDCl3): δ(ppm) 169.75 (C2), 146.12 (C8), 145.34 (C3), 122.50 (C6), 
120.19 (C5), 115.19 (C4), 112.56 (C7), 68.25 (C9), 67.24 (C1), 63.14 (C10). 
IR (KBr disc): σ(cm-1) 3502, 3074, 2969, 2363, 1757, 1746, 1655, 1596, 1504, 1460, 
1388, 1276, 1247, 1233, 1195, 1136, 1065, 1052, 1030. 
MP: 67-69 oC 
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Calculated exact mass for product: (C20H22O9) 406.1264 
Calculated exact mass for product + proton: (C20H22O9H+) 407.1337 
Found: HRMS (EI, 70 eV) 407.1342 
 
Synthesis of the macrocycles from the bis-alcohols: 
Synthesis of 2,3,6,7,10,11,17,18-tetrabenzo-1,4,9,12,15,20-hexaoxacyclodoeicosa-
2,6,10,17-tetraene-5,8,16,19-tetraone, 348: 
 
Bis(2-(2-Hydroxyethoxy)phenyl)phthalate, 338, (0.438 g, 1.00 mmol) was dissolved in 
dry dichloromethane (25.0 mL) at room temperature and chilled to -15 oC. Dry 
triethylamine (0.7 mL, 5.0 mmol) was added. Phthaloyl dichloride (0.1426 mL, 1 
mmol) was dissolved in dry dichloromethane (5.0 mL) and added slowly to the 
reaction mixture. The reaction mixture was stirred for 1 hour at -15 oC.  After this 
period the reaction mixture was allowed to warm to room temperature and was stirred 
at sixteen hours. After this time had elapsed the reaction was quenched by adding 
distilled water (20.0 mL) and stirring for ten minutes. The reaction mixture was 
transferred to a separation funnel and the organic and aqueous layers were separated. 
The organic layer was washed with distilled water (50.0 mL X3), and followed by 
saturated ammonium chloride solution (50.0 mL) and with saturated sodium chloride 
solution (50.0 mL). The organic layer was dried over magnesium sulphate and the 
solvent in vacuo. The product was purified by column chromatography on a silica 
stationary phase with 2:1 diethylether:dichloromethane followed by recrystallisation 
from chloroform:hexane to give the final pure product (3.2 %, 18 mg, 0.032 mmol) as 
a colourless solid.  
1H NMR (CDCl3): δ(ppm) 7.78 (2H, dd, J = 5.7, 3.3 Hz, H2), 7.49 (2H, dd, J = 5.7, 3.3 
Hz, H15), 7.35-7.31 (4H, m, H’s 1 and 16), 7.19-7.12 (4H, m, H’s 6 and 8), 6.96 (2H, 
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dd, J = 8.2, 1.2 Hz, H7), 6.92 (2H, td, J = 7.7, 1.4 Hz, H9), 4.28 (4H, t, J = 4.2 Hz, 
H12), 4.15 (4H, t, J = 4.2 Hz, H11) 
13C NMR (CDCl3): δ(ppm) 167.22 (C13), 165.21 (C4), 150.38 (C10), 140.42 (C5), 
131.70 (C1), 131.41 (C16), 131.30 (C3), 130.89 (C14), 129.80 (C2), 128.76 (C15), 
127.08 (C8), 123.04 (C7), 121.62 (C6), 114.35 (C9), 66.69 (C11), 63.61 (C12). 
IR (KBr disc): σ(cm-1) 3445, 3040, 2929, 2878, 1734, 1606, 1581, 1505, 1452, 1434, 
1414, 1403, 1372, 1256, 1191, 1162, 1111, 1050. 
MP: 122-124 oC 
Calculated exact mass for product: (C32H24O10) 568.1369 
Calculated exact mass for product + proton: (C32H24O10H+) 569.1442 
Found: HRMS (EI, 70 eV) 569.1464 
 
Synthesis of 2,3,6,7,10,11,17,19-tetrabenzo-1,4,9,12,15,21-hexaoxacyclotrieicosa-
2,6,10,17-tetraene-5,8,16,20-tetraone, 349: 
 
Bis(2-(2-Hydroxyethoxy)phenyl)phthalate, 338, (0.438 g, 1.00 mmol) was dissolved in 
dry dichloromethane (25.0 mL) at room temperature and chilled to -15 oC. Dry 
triethylamine (0.7 mL, 5.0 mmol) was added. Isophthaloyl dichloride (0.201 g, 1.00 
mmol) was dissolved in dry dichloromethane (5.0 mL) and added slowly to the 
reaction mixture. The reaction mixture was stirred for 1 hour at -15 oC.  The reaction 
mixture was allowed to warm to room temperature and was stirred for sixteen hours. 
After this time the reaction was quenched by adding distilled water (20.0 mL) and 
stirring for ten minutes. The reaction mixture was transferred to a separation funnel 
and the organic and aqueous layers were separated. The organic layer was washed with 
distilled water (50.0 mL X3), and saturated ammonium chloride solution (50.0 mL) 
and with saturated sodium chloride solution (50.0 mL). The organic layer was dried 
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over magnesium sulphate and then the solvent was removed in vacuo. The product was 
purified by column chromatography on a silica stationary phase with 3:1 diethyl 
ether:chloroform followed by recrystallisation from chloroform:hexane to isolate the 
pure product (1.9 %, 11 mg, 0.019 mmol) as a colourless solid.  
1H NMR (CDCl3): δ(ppm) 8.26 (1H, s, H16), 8.09 (2H, d, J = 7.6 Hz, H15), 7.68 (2H, 
dd, J = 3.4, 5.3 Hz, H2), 7.40 (1H, t, J = 7.7 Hz, H17), 7.28-7.22 (4H, m, H’s 1 and 6), 
7.17 (2H, d, J = 8.0 Hz, H8), 7.12 (2H, d, J = 8.0 Hz, H7), 7.02 (2H, t, J = 7.5 Hz, H9), 
4.59 (4H, br d, J = 2.8 Hz, H12), 4.33 (4H, br s, H11) 
13C NMR (CDCl3): δ(ppm)  165.78 (C13), 164.82 (C4), 150.05 (C10), 141.39 (C5), 
134.04 (C15), 131.15 (C1), 131.00 (C3), 130.12 (C14), 130.02 (C16), 129.25 (C2), 
127.96 (C17), 127.00 (C6), 122.95 (C9), 122.48 (C8), 115.96 (C7), 67.80 (C11), 63.71 
(C12). 
IR (KBr disc): σ(cm-1) 3079, 2942, 1780, 1723, 1606, 1501, 1453, 1407, 1378, 1254, 
1190, 1143, 1105, 1084, 1044. 
MP: 223.5-225 oC 
Calculated exact mass for product: (C32H24O10) 568.1369 
Calculated exact mass for product + proton: (C32H24O10H+) 569.1442 
Found: HRMS (EI, 70 eV) 569.1464 
 
Synthesis of 2,3,6,7,10,11,17,20-tetrabenzo-1,4,9,12,15,22-hexaoxacyclotetraeicosa-
2,6,10,17,19-pentaene-5,8,16,21-tetraone, 350:  
 
Bis(2-(2-hydroxyethoxy)phenyl)phthalate, 338, (0.438 g, 1.00 mmol) was dissolved in 
dry dichloromethane (25.0 mL) at room temperature and chilled to -15 oC. Dry 
triethylamine (0.7 mL, 5.0 mmol) was added. Terephthaloyl dichloride (0.201 g, 1.00 
mmol) was dissolved in dry dichloromethane (5.0 mL) and added slowly to the 
reaction mixture. The reaction mixture was stirred for 1 hour at -15 oC.  After this 
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period the reaction mixture was allowed to warm to room temperature and was stirred 
for sixteen hours. The reaction was quenched by adding distilled water (20.0 mL) and 
stirring for ten minutes. The reaction mixture was transferred to a separation funnel 
and the organic and aqueous layers were separated. The organic layer was washed with 
distilled water (50.0 mL X3), and saturated ammonium chloride solution (50.0 mL) 
and with saturated sodium chloride solution (50.0 mL). The organic layer was dried 
over magnesium sulphate and the solvent was removed in vacuo. The product was 
purified by column chromatography on a silica stationary phase with 2:1 
diethylether:dichloromethane followed by recrystallisation from chloroform:hexane to 
isolate the pure product (3.7 %, 21 mg, 0.037 mmol) as a colourless solid.  
1H NMR (CDCl3): δ(ppm) 7.74 (2H, dd, J = 5.7, 3.3 Hz, H2), 6.67 (4H, s, H15), 7.35 
(2H, dd, J = 8.0, 1.6 Hz, H6), 7.20-7.15 (4H, m, H’s 1 and 8),  6.99-6.95 (4H, m, H’s 7 
and  9), 4.59 (4H, v.br. s, H12), 4.32 (4H, v.br. s, H11). 
13C NMR (CDCl3): δ(ppm) 165.72 (C13), 164.63 (C4), 149.89 (C10), 140.24 (C5), 
133.09 (C14), 131.44 (C1), 131.24 (C3), 129.41 (C15), 129.36 (C2), 126.79 (C8), 
123.76 (C6), 121.70 (C7), 114.18 (C9), 66.60 (C11), 62.90 (C12). 
IR (KBr disc): σ(cm-1) 3446, 2952, 1721, 1605, 1501, 1456, 1410, 1370, 1276, 1256, 
1180, 1106, 1045. 
MP: 173-174oC 
Calculated exact mass for product: (C32H24O10) 568.1369 
Calculated exact mass for product + proton: (C32H24O10H+) 569.1442 
Found: HRMS (EI, 70 eV) 569.1464 
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Synthesis of 2,3,6,8,11,12,18,20-tetrabenzo-1,4,10,13,16,22-hexaoxacyclotetra-
icosa-2,6,11,18-tetraene-5,9,17,21-tetraone, 351:  
 
Bis(2-(2-Hydroxyethoxy)phenyl) isophthalate, 339, (0.438 g, 1.00 mmol) was 
dissolved in dry dichloromethane (25.0 mL) at room temperature and chilled to -15 oC. 
Dry triethylamine (0.7 mL, 5.0 mmol) was added. Isophthaloyl dichloride (0.201 g, 
1.00 mmol) was dissolved in dry dichloromethane (5.0 mL) and added slowly to the 
reaction mixture. The reaction mixture was stirred for 1 hour at -15 oC.  The reaction 
mixture was allowed to warm to room temperature and was stirred at room temperature 
for sixteen hours. After this time the reaction was quenched by adding distilled water 
(20.0 mL) and stirring for ten minutes. The reaction mixture was transferred to a 
separation funnel and the organic and aqueous layers were separated. The organic layer 
was washed with distilled water (50.0 mL X3), and saturated ammonium chloride 
solution (50.0 mL) and with saturated sodium chloride solution (50.0 mL). The organic 
layer was dried over magnesium sulphate and the solvent was removed in vacuo. The 
product was purified by column chromatography on a silica stationary phase with 1:1 
diethyl ether:chloroform followed by recrystallisation from toluene yielding the pure 
product (4.4 %, 0.025 g, 0.044 mmol) as a colourless solid. 
1H NMR (CDCl3): δ(ppm) 8.37 (1H, t, J = 1.6 Hz, H4), 8.15 (2H, dd, J = 7.6, 1.6 Hz, 
H2), 8.06 (1H, t, J = 1.6 Hz, H18), 8.02 (2H, dd, J = 7.6 , 1.6 Hz, H16), 7.35(2H, td, J 
= 7.2, 1.6 Hz, H7), 7.17-7.21 (2H, m, H’s 1 and 17), 7.05 (2H, dd, J = 7.6, 1.6 Hz, H9), 
6.97 (4H, td, J = 4.1, 1.2 Hz, H’s 8 and 10), 4.62 (4H, t, J = 4.2 Hz, H13), 4.30 (4H, t, J 
= 4.2 Hz, H12). 
13C NMR (CDCl3): δ(ppm) 165.36 (C14), 163.66 (C5), 150.08 (C11), 140.28 (C6), 
134.41 (C2), 133.82 (C16), 131.45 (C15), 130.66 (C4), 129.94 (C3), 129.66 (C18), 
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128.61 (C1), 128.34 (C17), 128.25 (C9), 127.11 (C8), 123.16 (C6), 121.67 (C7), 
113.74 (C10), 66.83 (C12), 60.65 (C13).  
IR (KBr disc): σ(cm-1) 3087, 2968, 2364, 1728, 1607, 1506, 1459, 1431, 1405, 1375, 
1308, 1293, 1263, 1231, 1187, 1163, 1114, 1058, 1001. 
MP: 176-178 oC 
Calculated exact mass for product: (C32H24O10) 568.1369 
Calculated exact mass for product + proton: (C32H24O10H+) 569.1442 
 Found: HRMS (EI, 70 eV) 569.1448 
 
Synthesis of 2,3,6,8,11,12,18,21-tetrabenzo-1,4,10,13,16,23-hexaoxacyclopenta-
icosa-2,6,11,18,20-pentaene-5,9,17,22-tetraone, 352:  
 
Bis(2-(2-Hydroxyethoxy)phenyl) isophthalate, 339, (0.438 g, 1.00 mmol) was 
dissolved in dry dichloromethane (25.0 mL) at room temperature and chilled to -15 oC. 
Dry triethylamine (0.7 mL, 5.0 mmol) was added. Terephthaloyl dichloride (0.201 g, 
1.00 mmol) was dissolved in dry dichloromethane (5.0 mL) and added slowly to the 
reaction mixture. The reaction mixture was stirred for 1 hour at -15 oC. The reaction 
mixture was allowed to warm to room temperature and was stirred for sixteen hours. 
After this time had elapsed the reaction was quenched by adding distilled water (20.0 
mL) and stirring for ten minutes. The reaction mixture was transferred to a separation 
funnel and the organic and aqueous layers were separated. The organic layer was 
washed with distilled water (50.0 mL X3), and saturated ammonium chloride solution 
(50.0 mL) and with saturated sodium chloride solution (50.0 mL). The organic layer 
was dried over magnesium sulphate and then the solvent was removed in vacuo. The 
product was purified by column chromatography on a silica stationary phase with 3:1 
diethylether:chloroform followed by recrystallisation from chloroform:hexane yielding 
the pure product (3.5 %, 0.020 g, 0.035 mmol) as a colourless solid. 
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1H NMR (CDCl3): δ(ppm) 8.72 (1H, t, J = 1.6 Hz, H4), 8.27 (2H, dd, J = 8.0, 1.6 Hz, 
H2), 7.64 (4H, s, H16), 7.41 (1H, t, J = 8.0 Hz, H1), 7.22 (2H, td, J = 7.6, 1.6 Hz, H9), 
7.06 (4H, td, J = 8.0, 1.2 Hz, H’s 7 and 8), 6.99 (2H, td, J = 7.6, 1.2 Hz, H10), 4.57 
(4H, t, J = 4.4 Hz, H13), 4.34 (4H, t, J = 4.4 Hz, H12). 
13C NMR (CDCl3): δ(ppm) 165.49 (C14), 163.74 (C5), 149.89 (C11), 140.63 (C6), 
134.49 (C2), 133.33 (C15), 131.88 (C4), 130.22 (C3), 129.24 (C16), 128.97 (C1), 
127.30 (C9), 123.44 (C7), 122.14 (C8), 114.86 (C10), 66.80 (C12), 62.85 (C13). 
IR (KBr disc): σ(cm-1) 3077, 2947, 2925, 2875, 1951, 1750, 1722, 1605, 1504, 1451, 
1413, 1381, 1253, 1221, 1184, 1126, 1081, 1046, 1018. 
MP: 197-199 oC 
Calculated exact mass for product: (C32H24O10) 568.1369 
Calculated exact mass for product + proton: (C32H24O10H+) 569.1442 
Found: HRMS (EI, 70 eV) 569.1448 
 
Synthesis of 2,3,6,9,11,12,13,19,22-tetrabenzo-1,4,11,14,17,24-hexaoxacyclohexa-
icosa-2,6,8,12,19,21-hexaene-5,10,18,23-tetraone, 353:  
 
Bis(2-(2-Hydroxyethoxy)phenyl) terephthalate, 340, (0.438 g, 1.00 mmol) was 
dissolved in dry dichloromethane (25.0 mL) at room temperature and chilled to -15 oC. 
Dry triethylamine (0.7 mL, 5.0 mmol) was added. Terephthaloyl dichloride (0.201 g, 
1.00 mmol) was dissolved in dry dichloromethane (5.0 mL) and added slowly to the 
reaction mixture. The reaction mixture was stirred for 1 hour at -15 oC.  The reaction 
mixture was then allowed to warm to room temperature and was stirred for sixteen 
hours. After this time had elapsed the reaction was quenched by adding distilled water 
(20.0 mL) and stirring for ten minutes. The reaction mixture was transferred to a 
separation funnel and the organic and aqueous layers were separated. The organic layer 
was washed with distilled water (50.0 mL X3), and saturated ammonium chloride 
solution (50.0 mL) and saturated sodium chloride solution (50.0 mL). The organic 
 121 
layer was then dried over magnesium sulphate and then the solvent was removed in 
vacuo. The product was purified by column chromatography on a silica stationary 
phase with 3:1 diethylether:chloroform followed by recrystallisation from toluene 
yielding the pure product (2.5 %, 0.014 g, 0.025 mmol) as a colourless solid. 
1H NMR (CDCl3): δ(ppm) 8.13 (4H, s, H1), 7.74 (4H, s, H14), 7.31 (2H, td, J = 5.3, 
1.2 Hz, H5), 7.19 (4H, qd, J = 8.0, 1.2 Hz, H6), 7.16 (2H, dd, J = 8.0, 1.2 Hz, H7), 7.09 
(2H, td, J = 5.3, 1.2 Hz, H8), 4.65 (4H, t, J = 4.2 Hz, H11), 4.45 (4H, t, J = 4.2 Hz, 
H10). 
13C NMR (CDCl3): δ(ppm) 165.81 (C12), 164.20 (C3), 150.17 (C9), 141.20 (C4), 
133.92 (C2), 133.74 (C13), 130.48 (C1), 129.69 (C14), 127.69 (C7), 123.75 (C6), 
122.68 (C5), 115.83 (C8), 67.59 (C11), 63.53 (C10).  
IR (KBr disc): σ(cm-1) 2963, 2364, 1944, 1736, 1607, 1578, 1501, 1457, 1407, 1376, 
1247, 1179, 1112, 1068, 1014. 
MP: 194-194 oC 
Calculated exact mass for product: (C32H24O10) 568.1369 
Calculated exact mass for product + proton: (C32H24O10H+) 569.1442 
Found: HRMS (EI, 70 eV) 569.1448 
 
Synthesis of 2,3,11,12,-dibenzo-6,8,18,20-difurano-1,4,7,10,13,16,19,22-
octaoxacyclohexaeicosa-2,11-diaene-5,9,17,21-tetraone, 354: 
 
Bis(2-(2-Hydroxyethoxy)phenyl) furan-2,5-dicarboxylate, 342,  (0.101 g, 0.236 mmol) 
was dissolved in dry dichloromethane (20.0 mL) at room temperature and chilled to -
15 oC. Dry triethylamine (0.25 mL, 1.8 mmol) was added. Furan-2,5-dicarbonyl 
dichloride (0.046 g, 0.236 mmol) was dissolved in dry dichloromethane (20.0 mL) and 
added slowly to the reaction mixture. The reaction mixture was stirred for 1 hour at -15 
oC.  The reaction mixture was allowed to warm to room temperature and was stirred at 
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room temperature for sixteen hours. After this time had elapsed the reaction was 
quenched by adding distilled water (20.0 mL) and stirring for ten minutes. The reaction 
mixture was transferred to a separation funnel and the organic and aqueous layers were 
separated. The organic layer was washed with  distilled water (50.0 mL X3), and 
saturated ammonium chloride solution (50.0 mL) and saturated sodium chloride 
solution (50.0 mL). The organic layer was then dried over magnesium sulphate and 
then the solvent was removed in vacuo. The product was purified by column 
chromatography on a silica stationary phase with dichloromethane followed by 
recrystallisation from chloroform:hexane isolating the pure product (12 %, 0.016 g, 
0.029 mmol) as a colourless solid.  
1H NMR (ACN-d3): δ(ppm) 7.34-7.29 (4H, m, H’s 5 and 7), 7.20-7.15 (6H, m, H’s 1, 6 
and 14), 7.05 (2H, td, J = 7.0, 1.4 Hz, H8), 4.56 (4H, t, J = 4.4 Hz, H11), 4.36 (4H, t, J 
= 4.4 Hz, H10) 
13C NMR (CDCl3): δ(ppm) 169.68 (C12), 157.91 (C3), 155.03 (C9), 149.54 (C2), 
146.14 (C13), 127.44 (C4), 124.43 (C7), 122.75 (C5), 121.42 (C6), 119.37 (C1), 
118.38 (C14), 114.31 (C8), 66.30 (C10), 62.40 (C11). 
IR (KBr disc): σ(cm-1) 3137, 2928, 1742, 1720, 1610, 1586, 1505, 1460, 1407, 1379, 
1289, 1226, 1188, 1158, 1126, 1024. 
MP: Turned from a colourless solid to a brown solid at 204 oC, did not melt below 300 
oC 
Calculated exact mass for product: (C28H20O12) 548.0955 
Calculated exact mass for product + sodium: (C28H20O12Na+) 571.0847 
Found: HRMS (EI, 70 eV) 571.0852 
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Methods for bis-phenols linked between the primary alcohols: 
2-(2-(Triethylsilyloxy)phenoxy)ethanol, 345:  
 
2-(2-Hydroxyethoxy)phenol (1.54 g, 10.0 mmol) was dissolved dry dichloromethane 
(30.0 mL) under nitrogen at room temperature. Triethylamine (1.4 mL, 10 mmol) was 
added. TES triflate (2.26 mL, 2.643 g, 10.0 mmol) was added to the reaction mixture. 
This was stirred for 48 hours. The reaction mixture was transferred to a separation 
funnel and was washed with distilled water (30.0 mL X4), saturated NH4Cl solution 
(40.0 mL X2). The organic layer was then dried over MgSO4 and the solvent was 
removed in vacuo. 
The product was purified by column chromatography on a silica stationary phase using 
dichloromethane isolating pure product (97 %, 1.301 g, 9.7 mmol) as a pale yellow 
liquid. As this product was an intermediate its infrared spectrum and exact mass were 
not recorded.  
1H NMR (CDCl3): δ(ppm) 7.03-6.95 (2H, m, H’s 5 and 7), 6.86-6.82 (2H, m, H’s 4 
and 6), 4.11 (2H, t, J = 4.7 Hz, H9), 3.85 (2H, t, J = 4.7 Hz, H10), 1.04 (9H, t, J = 8.0 
Hz, H1), 0.72 (6H, q, J = 8.0 Hz, H2). 
13C NMR (CDCl3): δ(ppm) 147.94 (C9), 146.21 (C3), 123.40 (C6), 119.87 (C4), 
116.61 (C5), 115.68 (C7), 72.90 (C9), 61.70 (C10), 6.67 (C2), 4.26 (C1). 
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Synthesis of bis-phenols from triethylsilyl protected 2-(2-hydroxyethoxy)phenol: 
Bis(2-(2-Hydroxyphenoxy)ethyl)-2,2-dimethylmalonate, 346:  
 
2-(2-(Triethylsilyloxy)phenoxy)ethanol, 345, (2.220 g, 8.27 mmol) was dissolved in 
dry dichloromethane (93.0 mL) at room temperature. Dry triethylamine
 
(3.73 mL, 27.8 
mmol) was added whilst stirring. Dimethylmalonyl chloride (0.55 mL, 4.14 mmol) was 
then added slowly to the reaction mixture. The reaction mixture was stirred for 48 
hours. The reaction was quenched by adding distilled water (20.0 mL) and stirring for 
ten minutes. The organic and aqueous layers were separated. The organic layer was 
washed with distilled water (20.0 mL X5), dried over magnesium sulphate and the 
solvent was removed in vacuo yielding the crude intermediate product. This was 
purified by column chromatography on a silica stationary phase using 3:1 diethyl 
ether:chloroform as the mobile phase to isolate the pure intermediate product.  
The intermediate was dissolved in 4:1 acetic acid:water mixture (16.0 mL).  This was 
stirred at 40 oC and monitored by TLC every 10 minutes with 3:1 diethyl 
ether:chloroform. When the reaction had gone to completion it was quenched by the 
addition of saturated sodium carbonate until the acid was neutralised and 
dichloromethane to keep the product in solution. The solution was transferred to a 
separating funnel. The organic layer was extracted and then washed with distilled 
water (50.0 mL X4), and saturated sodium bicarbonate solution (20.0 mL X4). The 
organic layer was dried over MgSO4 and then the solvent was removed in vacuo.   
The product was then recrystallised from chloroform:hexane to isolate the pure product 
(64 %, 1.074 g, 2.64 mmol) as a colourless solid.  
1H NMR (CDCl3): δ(ppm) 7.08 (2H, dt, J = 7.8, 1.0 Hz, H4), 6.98 (2H, dd, J = 7.8, 1.0 
Hz, H6), 6.86–6.82 (4H, m, H’s 3 and 5), 3.94 (4H, t, J = 4.4 Hz, H9), 3.64 (4H, broad 
s, H8), 1.67 (6H, s, H12). 
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13C NMR (CDCl3): δ(ppm) 169.91 (C10), 149.06 (C2), 138.54 (C7), 126.28 (C5), 
121.35 (C4), 120.07 (C3), 112.58 (C6), 69.14 (C8), 59.87 (C9), 49.36 (C11), 22.08 
(C12).  
IR (KBr disc): σ(cm-1) 3531, 3452, 3123, 3066, 2996, 2954, 2878, 2564, 2363, 1938, 
1753, 1607, 1504, 1459, 1412, 1391, 1371, 1255, 1144, 1100. 
MP: 100-101 oC 
Calculated exact mass for product: (C21H22O8) 404.1471 
Calculated exact mass for product + proton: (C21H22O8H+) 405.1544 
Found: HRMS (EI, 70 eV) 405.1549 
 
Bis(2-(2-Hydroxyphenoxy)ethyl)terephthalate, 347:  
 
2-(2-(Triethylsilyloxy)phenoxy)ethanol, 345, (2.276 g, 8.4 mmol) was dissolved in dry 
dichloromethane (60.0 mL) at room temperature. Dry triethylamine
 
(4.2 mL, 30 mmol) 
was added whilst stirring. Terephthaloyl dichloride (0.848 g, 4.2 mmol) was added 
slowly to the reaction mixture. The reaction mixture was stirred for 48 hours. The 
reaction was quenched by addition of distilled water (20.0 mL) and stirring for ten 
minutes. The organic and aqueous layers were separated. The organic layer was 
washed with distilled water (20.0 mL X5), dried over magnesium sulphate and the 
solvent was removed in vacuo yielding the crude intermediate product. This was 
purified by column chromatography on a silica stationary phase using 3:1 
diethylether:chloroform as the mobile phase to isolate the pure intermediate product.  
The crude intermediate was then dissolved in 4:1 acetic acid:water mixture (100 mL).  
This was stirred at 40 oC and monitored by TLC every 10 minutes with 3:1 diethyl 
ether:chloroform. When the reaction had gone to completion it was quenched by the 
addition of saturated sodium carbonate until the acid was neutralised and 
dichloromethane to keep the product in solution. The solution was transferred to a 
separating funnel. The organic layer was extracted and washed with distilled water 
(50.0 mL X4), and saturated sodium bicarbonate solution (20.0 mL X4). The organic 
layer was dried over MgSO4 and the solvent was removed in vacuo.  The product was 
 126 
recrystallised from chloroform:hexane to isolate the pure product (68 %, 1.282 g, 2.92 
mmol) as a colourless solid. 
1H NMR (CDCl3): δ(ppm) 8.08 (4H, s, H1), 6.89-6.75 (8H, m, H’s 7,8, 9 and 10 ), 
4.66 (4H, t, J = 4.6 Hz, H4), 4.33 (4H, t, J = 4.4 Hz, H5) 
13C NMR (CDCl3): δ(ppm) 165.77 (3), 146.15 (C11), 145.46 (C6), 133.70 (C2), 
129.79 (C1), 122.47 (C8), 120.18 (C9), 115.09 (C10), 112.49 (C7), 67.49 (C5), 63.67 
(C4). 
IR (KBr disc): σ(cm-1) 3436, 3288, 2953, 2926, 2362, 2340, 1732, 1605, 1507, 1458, 
1408, 1261, 1181, 1100, 1072, 1014. 
MP: 212-213 oC 
Calculated exact mass for product: (C24H22O8) 438.1315 
Calculated exact mass for product + proton: (C24H22O8H+) 439.1387 
Found: HRMS (EI, 70 eV) 439.1410 
  
Bis(2-(2-Hydroxyphenoxy)ethyl)isophthalate, 355:  
 
2-(2-(Triethylsilyloxy)phenoxy)ethanol, 345, (2.276 g, 8.4 mmol) was dissolved in dry 
dichloromethane (60.0 mL) at room temperature. Dry triethylamine
 
(4.2 mL, 30 mmol) 
was added whilst stirring. Isophthaloyl dichloride (0.848 g, 4.2 mmol) was added 
slowly to the reaction mixture. The reaction mixture was stirred for 48 hours. The 
reaction was quenched by adding distilled water (20.0 mL) and stirring for ten minutes. 
The organic and aqueous layers were separated. The organic layer was washed with 
distilled water (20.0 mL X5), then dried over magnesium sulphate and the solvent was 
removed in vacuo yielding the crude intermediate product. This was purified by 
column chromatography on a silica stationary phase using 3:1 diethylether:chloroform 
as the mobile phase to isolate the pure intermediate product.  
The intermediate was then dissolved in 4:1 acetic acid:water mixture (100 mL).  This 
was then stirred at 40 oC and monitored by TLC every 10 minutes with a 3:1 
diethylether:chloroform mobile phase. When the reaction had gone to completion it 
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was quenched by the addition of saturated sodium carbonate until the acid was 
neutralised and dichloromethane to keep the product in solution. The solution was 
transferred to a separating funnel. The organic layer was extracted and washed with 
distilled water (50.0 mL X4), and saturated sodium bicarbonate solution (20.0 mL X4). 
The organic layer was then dried over MgSO4 and the solvent removed in vacuo.  The 
product was recrystallised from chloroform:hexane to isolate the pure product (52 %, 
0.982 g, 2.18 mmol) as a colourless solid. 
1H NMR (CDCl3): δ(ppm) 8.63 (1H, t, J = 1.6 Hz, H4), 8.16 (2H, dd, J = 8.0, 1.6 Hz, 
H2), 7.46 (1H, t, J = 8.0 Hz, H1), 6.88-6.74 (8H, m, H’s 9, 10, 11 and 12), 4.66 (4H, t, 
J = 4.4 Hz, H6), 4.32 (4H, t, J = 4.4 Hz, H17). 
13C NMR (CDCl3): δ(ppm) 165.71 (C5), 146.15 (C13), 145.48 (C8), 134.29 (C2), 
130.94 (C4), 130.22 (C3), 128.89 (C1), 122.40 (C10), 120.18 (C11), 115.09 (C12), 
112.50 (C9), 67.51 (C6), 63.53 (C7). 
IR (KBr disc): σ(cm-1) 3452, 3074, 2942, 2882, 1737, 1605, 1501, 1452, 1304, 1268, 
1276, 1102, 1052. 
MP: 132-133 oC 
Calculated exact mass for product: (C24H22O8) 438.1315 
Calculated exact mass for product + proton: (C24H22O8H+) 439.1387 
Found: HRMS (EI, 70 eV) 439.1384 
 
Bis(2-(2-hydroxyphenoxy)ethyl)furan-2,5-dicarboxylate, 356: 
 
2-(2-(Triethylsilyloxy)phenoxy)ethanol, 345, (2.276 g, 8.4 mmol) was dissolved in dry 
dichloromethane (60.0 mL) at room temperature. Dry triethylamine
 
(4.2 mL, 30 mmol) 
was added whilst stirring. Furan-2,5-dicarbonyl dichloride (0.655 g, 4.2 mmol) was 
added slowly to the reaction mixture. The reaction mixture was stirred for 48 hours. 
The reaction was quenched by adding distilled water (20.0 mL) and stirring for ten 
minutes. The organic and aqueous layers were separated. The organic layer was 
washed with distilled water (20.0 mL X5), dried over magnesium sulphate and the 
solvent was removed in vacuo yielding the crude intermediate product. This was 
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purified by column chromatography on a silica stationary phase using 3:1 
diethylether:chloroform as the mobile phase to isolate the pure intermediate product.  
The intermediate was dissolved in 4:1 acetic acid:water mixture (100 mL).  This was 
stirred at 40 oC and monitored by TLC every 10 minutes with 3:1 
diethylether:chloroform. When the reaction had gone to completion it was quenched by 
the addition of saturated sodium carbonate until the acid was neutralised and 
dichloromethane to keep the product in solution. The solution was transferred to a 
separating funnel. The organic layer was extracted and washed with distilled water 
(50.0 mL X4), and saturated sodium bicarbonate solution (20.0 mL X4). The organic 
layer was dried over MgSO4 and the solvent was removed in vacuo.  The product was 
recrystallised from chloroform:hexane to isolate the pure product (61 %, 1.097 g, 2.56 
mmol) as a colourless solid. 
1H NMR (DMSO-d6): δ(ppm) 7.41 (2H, s, H1), 6.96 (2H, d, J = 7.6 Hz, H8), 6.79 (4H, 
dd, J = 4.3, 1.9 Hz, H’s 9 and 10), 6.71-6.74 (2H, m, H7), 4.61, (4H, t, J = 4.5 Hz, H4), 
4.29 (4H, t, J = 4.5 Hz, H5) 
13C NMR (DMSO-d6): δ(ppm) 157.34 (C3), 147.09 (C11), 146.34 (C2), 146.06 (C6), 
121.80 (C8), 119.29 (C9), 119.16 (C1), 115.89 (C10), 114.82 (C7), 66.67 (C5), 64.10 
(C4). 
IR (KBr disc): σ(cm-1) 3397, 2937, 2877, 2361, 1742, 1605, 1501, 1458, 1380, 1336, 
1309, 1291, 1264, 1221, 1169, 1131, 1111, 1069, 1045, 1035, 1004. 
MP: 113-115 oC 
Calculated exact mass for product: (C22H20O9) 428.1107 
Calculated exact mass for product + proton: (C22H20O9H+) 429.1180 
Found: HRMS (EI, 70 eV) 429.1172 
 
Synthesis of the 2-(2-hydroxyethoxy)phenol based macrocycles from the bis-phenols: 
Synthesis of 2,3,6,9,11,12,13,19,22-tetrabenzo-1,4,11,14,17,24-hexaoxacyclohexa-
icosa-2,6,8,12,19,21-hexaene-5,10,18,23-tetraone, 353: 
Bis(2-(2-Hydroxyphenoxy)ethyl) terephthalate, 347, (0.250 g, 0.571 mmol) was 
dissolved in dichloromethane (10.0 mL) under nitrogen at room temperature. 
Triethylamine (0.4 mL, 2.8 mmol) was added. Terephthaloyl dichloride (0.115 g, 0.571 
mmol) was dissolved in dichloromethane (10.0 mL) and added slowly to the reaction 
mixture. This was stirred for sixteen hours. After this time had elapsed the reaction was 
quenched by adding distilled water (20.0 mL) and stirring for ten minutes. The reaction 
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mixture was transferred to a separation funnel and the organic and aqueous layers were 
separated. The organic layer was washed with distilled water (50.0 mL X3), dried over 
magnesium sulphate and then the solvent was removed in vacuo. Recrystallisation 
from chloroform:hexane gave the pure product (7 %, 0.022 g, 0.040 mmol) as a 
colourless solid. 1H NMR, 13C NMR, MP and IR data matches that which is stated on 
page 120. 
 
Synthesis of 2,3,6,7,10,11,17,20-tetrabenzo-1,4,9,12,15,22-hexaoxacyclotetraeicosa-
2,6,10,17,19-pentaene-5,8,16,21-tetraone, 350: 
Bis(2-(2-Hydroxyphenoxy)ethyl) terephthalate, 347,  (0.250 g, 0.571 mmol) was 
dissolved in dichloromethane (10.0 mL) under nitrogen at room temperature. 
Triethylamine (0.4 mL, 2.8 mmol) was added. Phthaloyl dichloride (0.0814 mL, 0.571 
mmol) was dissolved in dichloromethane (10.0 mL) and added slowly to the reaction 
mixture. This was stirred for sixteen hours. After this time had elapsed the reaction was 
quenched by adding distilled water (20.0 mL) and stirring for ten minutes. The reaction 
mixture was transferred to a separation funnel and the organic and aqueous layers were 
separated. The organic layer was washed with distilled water (50.0 mL X3), dried over 
magnesium sulphate and the solvent was removed in vacuo. Recrystallisation from 
chloroform:hexane gave the pure product (6 %, 19 mg, 0.034 mmol) as a colourless 
solid. 1H NMR, 13C NMR, MP and IR data matches that which is stated on page 116. 
 
 
Synthesis of 2,3,6,8,11,12,18,21-tetrabenzo-1,4,10,13,16,23-hexaoxacyclopenta-
icosa-2,6,11,18,20-pentaene-5,9,17,22-tetraone, 352:  
Bis(2-(2-Hydroxyphenoxy)ethyl) terephthalate, 347,  (0.250 g, 0.571 mmol) was 
dissolved in dichloromethane (10.0 mL) under nitrogen at room temperature. 
Triethylamine (0.4 mL, 2.8 mmol) was added. Isophthaloyl dichloride (0.116 mg, 
0.571 mmol) was dissolved in dichloromethane (10.0 mL) and added slowly to the 
reaction mixture. This was stirred for sixteen hours. After this time had elapsed the 
reaction was quenched by adding distilled water (20.0 mL) and stirring for ten minutes. 
The reaction mixture was transferred to a separation funnel and the organic and 
aqueous layers were separated. The organic layer was washed with distilled water 
(50.0 mL X3), dried over magnesium sulphate and the solvent was removed in vacuo. 
Recrystallisation from chloroform:hexane gave the pure product (3.1 %, 10 mg, 0.018 
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mmol) as a colourless solid. 1H NMR, 13C NMR, MP and IR data matches that which 
is stated on page 119. 
 
Synthesis of 2,3,9,10-dibenzo-6,16-tetramethyl-1,4,8,11,14,18-hexaoxacyclohexa-
icosa-2,9-diene-5,7,15,17-tetraone, 357:  
 
Bis(2-(2-Hydroxyphenoxy)ethyl)-2,2-dimethylmalonate, 346, (0.222 g, 0.54 mmol) 
was dissolved in dichloromethane (10.0 mL) under nitrogen at room temperature. To 
this triethylamine (0.4 mL, 2.8 mmol) was added. Dimethylmalonyl chloride (0.073 
mL, 0.54 mmol) was dissolved in dichloromethane (10.0 mL) and added slowly to the 
reaction mixture. This was stirred for sixteen hours. After this time had elapsed the 
reaction was quenched by adding distilled water (20.0 mL) and stirring for ten minutes. 
The reaction mixture was transferred to a separation funnel and the organic and 
aqueous layers were separated. The organic layer was washed with distilled water 
(50.0 mL X3), dried over magnesium sulphate and the solvent was removed in vacuo. 
Recrystallisation from chloroform:hexane gave the pure product (25 %, 0.070 g, 0.14 
mmol) as a colourless solid.  
1H NMR (CDCl3): δ(ppm) 7.14-7.02 (8H, m, H’s 5 to 8), 4.48 (4H, t, J = 4.4 Hz, H11), 
4.05 (4H, t, J = 4.4 Hz, H10), 1.53 (12H, s, H’s 1 and 14). 
13C NMR (CDCl3): δ(ppm) 172.70 (C12), 170.81 (C3), 150.77 (C9), 142.82 (C4), 
127.33 (C7), 124.69 (C6), 124.45 (C5), 123.25 (C8), 72.54 (C11), 64.03 (C10), 50.95 
(C’s 2 and 13), 20.96 (C’s 1 and 14).  
IR (KBr disc): σ(cm-1) 3102, 3067, 3041, 2999, 2966, 2885, 2361, 1784, 1742, 1600, 
1491, 1455, 1390, 1366, 1276, 1237, 1177, 1149, 1095, 1044, 1019. 
MP: 126-128 oC 
Calculated exact mass for product: (C26H28O10) 500.1682 
Calculated exact mass for product + proton: (C26H28O10H+) 501.1755 
Found: HRMS (EI, 70 eV) 501.1761 
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One pot synthesis of the 2-(2-hydroxyethoxy)phenol based macrocycles: 
Synthesis of 2,3,6,9,11,12,13,19,21-tetrabenzo-1,4,11,14,17,23-hexaoxacyclopenta-
icosa-2,6,8,12,19-pentaene-5,10,18,22-tetraone, 358:  
 
2-(2-Hydroxyethoxy)phenol (1.54 g, 10.0 mmol) was dissolved in dry 
dichloromethane (100 mL) at room temperature under nitrogen and chilled to -15oC. 
At -15oC dry triethylamine (5.0 mL, 36 mmol) was added with stirring. Terephthaloyl 
dichloride (1.005 g, 5.0 mmol) was dissolved in dry dichloromethane (25.0 mL) and 
added slowly to the reaction mixture. The reaction mixture was stirred for one hour at -
15 oC.  After this period had elapsed the reaction mixture was allowed to warm to 
room temperature and was stirred at room temperature for sixteen hours. Dry 
triethylamine (5.0 mL, 36 mmol) was added to the reaction flask. Isophthaloyl 
dichloride (1.005 g, 5.00 mmol) was dissolved in dry dichloromethane (300 mL) and 
added slowly to the reaction mixture. This reaction mixture was stirred for sixteen 
hours and then quenched by adding distilled water (50.0 mL) and stirring for ten 
minutes. The reaction mixture was transferred to a separation funnel and the organic 
and aqueous layers were separated. The organic layer was washed with distilled water 
(50.0 mL X6), dried over magnesium sulphate and the solvent was removed in vacuo. 
Column chromatography on a silica stationary phase with mobile phase of 3:1 
ether:chloroform followed by recrystallisation from toluene gave the pure product (6 
%, 0.170 g, 0.3 mmol) as a colourless solid. 
1H NMR (CDCl3): δ(ppm) 8.14 (1H, br. s, H16), 8.13 (2H, dd, J = 8.7, 1.2 Hz, H14), 
7.73 (4H, s, H1), 7.46 (1H, t, J = 8.2 Hz, H5), 7.21 (2H, td, J = 8.7, 1.2 Hz, H15), 7.12 
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(4H, dd, J = 6.9, 1.2 Hz, H7), 7.07 (4H, dd, J = 6.9, 1.2 Hz, H6),  6.99 (2H, td, J = 7.6, 
1.2 Hz, H8), 4.53 (4H, t, J = 4.0 Hz, H11), 4.37 (4H, t, J = 4.0 Hz, H10). 
13C NMR (CDCl3): δ(ppm) 165.31 (C12), 163.83 (C3), 149.65 (C9), 140.90 (C4), 
133.91 (C2), 132.85 (C14), 130.43 (C13), 130.13 (C1), 129.67 (C16), 128.53 (C15), 
127.16 (C7), 123.09 (C6), 122.08 (C5), 114.67 (C8), 66.91 (C10), 62.95 (C11). 
 IR (KBr disc): σ(cm-1) 3069, 2967, 2878, 2364, 1728, 1607, 1589, 1501, 1457, 1435, 
1407, 1375, 1310, 1262, 1229, 1186, 1114, 1088, 1058, 1015. 
MP: 126-128 oC 
Calculated exact mass for product: (C32H24O10) 568.1369 
Calculated exact mass for product + proton: (C32H24O10H+) 569.1442 
Found: HRMS (EI, 70 eV) 569.1448 
 
Synthesis of 2,3,11,12-dibenzo-1,4,7,10,13,16,19,22-octaoxacyclotetraeicosa-2,11-
diene-5,9,17,21-tetraone, 359:  
  
2-(2-Hydroxyethoxy)phenol (1.54 g, 10.0 mmol) was dissolved in dry dichloromethane 
(100 mL) at room temperature under nitrogen and chilled to -15oC. At -15oC dry 
triethylamine (5.0 mL, 36 mmol) was added with stirring. Diglycolyl chloride (0.855 g, 
5.0 mmol) was dissolved in dry dichloromethane (25.0 mL) and added slowly to the 
reaction mixture. The reaction mixture was stirred for one hour at -15 oC.  After this 
period had elapsed the reaction mixture was allowed to warm to room temperature and 
was stirred at room temperature for sixteen hours. Dry triethylamine (5.0 mL, 36 
mmol) was added to the reaction flask. Diglycolyl chloride (0.855 g, 5.0 mmol) was 
dissolved in dry dichloromethane (300 mL) and added slowly to the reaction mixture. 
This reaction mixture was stirred for 24 hours and quenched by adding distilled water 
(50.0 mL) and stirring for ten minutes. The reaction mixture was transferred to a 
separation funnel and the organic and aqueous layers were separated. The organic layer 
was washed with distilled water (50.0 mL X6), dried over magnesium sulphate and the 
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solvent was removed in vacuo. Column chromatography on a silica stationary phase 
with mobile phase of 1:1 ethylacetate:chloroform yielded the pure product (7 %, 0.185 
g, 0.35 mmol) as a colourless solid.  
1H NMR (CDCl3): δ(ppm) 7.14 (2H, dt, J = 7.8, 1.7 Hz, H4), 7.01 (2H, dd, J = 7.9, 1.7 
Hz, H6), 6.98 (2H, dt, J = 7.8, 1.3 Hz, H5), 6.86 (2H, dd, J = 7.9, 1.3 Hz, H7), 4.54 
(4H, s, H12), 4.46 (4H, t, J = 4.1 Hz, H10), 4.30 (4H, s, H1), 4.12 (4H, t, J = 4.1 Hz, 
H9) 
13C NMR (CDCl3): δ(ppm) 169.00 (C11), 166.58 (C2), 148.56 (C8), 138.30 (C3), 
126.20 (C6), 121.69 (C4), 120.46 (C5), 111.97 (C7), 67.15 (C12), 67.08 (C1), 65.44 
(C10), 61.29 (C9). 
IR (KBr disc): σ(cm-1) 3065, 3039, 2968, 2931, 2364, 1741, 1607, 1503, 1452, 1410, 
1378, 1285, 1261, 1178, 1145, 1041, 984, 953, 911, 820, 779, 742, 602. 
MP: 97-99 oC 
Calculated exact mass for product: (C22H24O12) 504.1268  
Calculated exact mass for product + sodium: (C24H24O12Na+) 527.1160 
Found: HRMS (EI, 70 eV) 527.1165 
 
Synthesis of 2,3,6,9,12,13,19,21-tetrabenzo-20-aza-1,4,11,14,17,23-hexaoxacyclo-
pentaicosa-2,6,8,12,19-pentaene-5,10,18,22-tetraone, 360:  
 
2-(2-Hydroxyethoxy)phenol (0.308 g, 2.00 mmol) was dissolved in dry 
dichloromethane (20 mL) at room temperature under nitrogen and chilled to -15 oC. 
Once the temperature had reached -15 oC dry triethylamine (0.7 mL, 5.0 mmol) was 
added with stirring. Terephthaloyl dichloride (203 mg, 1.00 mmol) was dissolved in 
dry dichloromethane (20.0 mL) and added slowly to the reaction mixture. The reaction 
mixture was stirred for one hour at -15 oC.  After this period had elapsed the reaction 
mixture was allowed to warm to room temperature and was stirred at room temperature 
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for sixteen hours. Dry triethylamine (0.7 mL, 5.0 mmol) was added to the reaction 
flask. Pyridine-2,6-dicarbonyl dichloride (204 mg, 1.00 mmol) was dissolved in dry 
dichloromethane (260 mL) and added slowly to the reaction mixture. This reaction 
mixture was stirred for 24 hours and then quenched by adding distilled water (50.0 
mL) and stirring for ten minutes. The reaction mixture was transferred to a separation 
funnel and the organic and aqueous layers were separated. The organic layer was 
washed with distilled water (50.0 mL X6), dried over magnesium sulphate and the 
solvent was removed in vacuo. Column chromatography on a silica stationary phase 
with mobile phase of 4:1 diethyl ether:dichloromethane yielded the pure product (6 %, 
0.034 g, 0.06 mmol) as a colourless solid.  
1H NMR (CDCl3): δ(ppm) 8.14 (2H, d, J = 7.8 Hz, H14), 7.91 (1H, t, J = 7.8 Hz, H15), 
7.70 (4H, s, H1), 7.21 (2H, td, J = 8.2 Hz, 1.7 Hz, H5), 7.08 (2H, dd, J = 7.8, 1.7 Hz, 
H7), 7.04 (4H, dd, J = 8.2, 1.2 Hz, H6), 6.99 (2H, td, J = 7.8 Hz, 1.2 Hz, H8), 4.58 (4H, 
t, J = 4.2 Hz, H11), 4.39 (4H, t, J = 4.2 Hz, H10). 
13C NMR (CDCl3): δ(ppm) 163.90 (C’s 3 and 12), 149.60 (C9), 148.04 (C13), 140.90 
(C2), 137.95 (C15), 132.91 (C4), 129.63 (C1), 127.84 (C14), 127.18 (C7), 123.06 
(C6), 122.12 (C5), 114.76 (C8), 66.60 (C10), 63.71 (C11).  
IR (KBr disc): σ(cm-1) 2961, 2365, 2345, 1746, 1722, 1606, 1498, 1317, 1284, 1263, 
1247, 1181, 1146, 1110, 1063, 1016. 
MP: 226-227 oC 
Calculated exact mass for product: (C31H23NO10) 569.1322.  
Calculated exact mass for product + proton: (C31H23NO10H+) 570.1395 
Found: HRMS (EI, 70 eV) 570.1400 
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Synthesis of 2,3,6,8,11,12,18,21-tetrabenzo-7-aza-1,4,10,13,16,23-hexaoxacyclo-
pentaicosa-2,6,11,18,20-pentaene-5,9,17,21-tetraone, 361:  
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2-(2-Hydroxyethoxy)phenol (0.308 g, 2.00 mmol) was dissolved in dry 
dichloromethane (20 mL) at room temperature under nitrogen and chilled to -15 oC. 
Dry triethylamine (0.7 mL, 5.0 mmol) was added with stirring. Pyridine-2,6-dicarbonyl 
dichloride (204 mg, 1.00 mmol) was dissolved in dry dichloromethane (20.0 mL) and 
added slowly to the reaction mixture. The reaction mixture was stirred for one hour at -
15 oC.  After this period had elapsed the reaction mixture was allowed to warm to room 
temperature and was stirred at room temperature for sixteen hours. Dry triethylamine 
(0.7 mL, 5.0 mmol) was added to the reaction flask. Terephthaloyl dichloride (203 mg, 
1.00 mmol) was dissolved in dry dichloromethane (260 mL) and added slowly to the 
reaction mixture. This reaction mixture was stirred for 24 hours and quenched by 
adding distilled water (50.0 mL) and stirring for ten minutes. The reaction mixture was 
transferred to a separation funnel and the organic and aqueous layers were separated. 
The organic layer was washed with distilled water (50.0 mL X6), dried over 
magnesium sulphate and then the solvent was removed in vacuo. Column 
chromatography on a silica stationary phase with mobile phase of 4:1 diethyl 
ether:dichloromethane yielded the pure product (3.5 %, 0.020 g, 0.035 mmol) as a 
colourless solid. Due to the low solubility of this product in all available solvents a 13C 
NMR could not be recorded. There was not enough isolated product to record the 
melting point. 
1H NMR (ACN-d3): δ(ppm) 8.28 (2H, dd, J = 7.2, 1.8 Hz, H2), 8.03-7.97 (5H, m, H’s 
15 and 1), 7.34 (2H, td, J = 7.9, 1.6 Hz, H7), 7.20 (4H, dd, J = 7.8, 1.5 Hz, H’s 6 and 
8), 7.08 (2H, td, J = 7.7, 1.4 Hz, H9), 4.60 (4H, t, J = 4.3 Hz, H12), 4.40 (4H, t, J = 4.3 
Hz, H11). 
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IR (KBr disc): σ(cm-1) 3449, 2366, 2346, 1754, 1718, 1686, 1500, 1458, 1315, 1287, 
1236, 1185, 1138, 1162, 1111. 
Calculated exact mass for product: (C31H23NO10) 569.1322.  
Calculated exact mass for product + proton: (C31H23NO10H+) 570.1395 
Found: HRMS (EI, 70 eV) 570.1400 
 
Synthesis of 2,3,6,8,11,12,18,20-tetrabenzo-7,19-diaza-1,4,10,13,16,22-hexaoxa-
cyclotetraicosa-2,6,11,18-tetraene-5,9,17,21-tetraone, 362:  
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2-(2-Hydroxyethoxy)phenol (0.308 g, 2.00 mmol) was dissolved in dry 
dichloromethane (20 mL) at room temperature under nitrogen and chilled to -15 oC. 
Dry potassium carbonate (1.2 g) was added with stirring. Pyridine-2,6-dicarbonyl 
dichloride (204 mg, 1.00 mmol) was dissolved in dry dichloromethane (20.0 mL) and 
added slowly to the reaction mixture. The reaction mixture was stirred for one hour at -
15 oC.  After this period had elapsed the reaction mixture was allowed to warm to room 
temperature and was stirred at room temperature for sixteen hours. Dry potassium 
carbonate (1.2 g) was added to the reaction flask. Pyridine-2,6-dicarbonyl dichloride 
(204 mg, 1.00 mmol) was dissolved in dry dichloromethane (260 mL) and added 
slowly to the reaction mixture. This reaction mixture was stirred for 24 hours and then 
quenched by adding distilled water (50.0 mL) and stirring for ten minutes. The reaction 
mixture was transferred to a separation funnel and the organic and aqueous layers were 
separated. The organic layer was washed with distilled water (50.0 mL X6), dried over 
magnesium sulphate and the solvent was removed in vacuo. Recrystallisation from 
CHCl3 gave the pure product (14 %, 80 mg, 0.14 mmol) as a colourless solid. 
1H NMR (ACN-d3): δ(ppm) 8.25 (2H, d, J = 7.6 Hz, H2), 8.18 (2H, d, J = 8.0 Hz, 
H15), 8.02 (1H, t, J = 7.6 Hz, H1), 7.97 (1H, t, J = 8.0 Hz, H16),  7.34 (2H, dt, J = 7.7, 
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1.6 Hz, H6), 7.23 (4H, dt, J = 7.9, 1.4 Hz, H8), 7.22 (4H, dt, J = 7.9, 1.6 Hz, H7), 7.08 
(2H, dt, J = 7.7, 1.4 Hz, H9), 4.69 (4H, t, J = 4.2 Hz, H12), 4.42 (4H, t, J = 4.2 Hz, 
H11).  
13C NMR (ACN-d3): δ(ppm) 163.83 (C13), 162.17 (C4), 149.73 (C10), 147.38 (C14), 
146.83 (C3), 139.98 (C16), 138.61 (C1), 138.30 (C5), 128.48 (C15), 127.91 (C2), 
127.18 (C8), 122.54 (C7), 121.29 (C6), 114.09 (C9), 66.70 (C11), 63.48 (C12).  
IR (KBr disc): σ(cm-1) 3407, 3105, 2966, 2885, 2366, 1755, 1734, 1717, 1630, 1608, 
1584, 1504, 1458, 1403, 1378, 1316, 1285, 1235, 1186, 1164, 1113, 1077, 1063. 
MP: 257-258 oC (at 245 oC turned from colourless solid to brown solid) 
Calculated exact mass for product: (C30H22N2O10) 570.1274 
Calculated exact mass for product + proton: (C31H23NO10H+) 571.1347 
Found: HRMS (EI, 70 eV) 571.1334 
 
Synthesis of 2,3,6,8,11,12,18,20-tetrabenzo-1,4,10,13,16,22-hexaoxacyclotetra-
icosa-2,6,11,18-tetraene-5,9,17,21-tetraone, 351:  
2-(2-Hydroxyethoxy)phenol (0.462 g, 3.0 mmol) was dissolved in dry dichloromethane 
(20 mL) at room temperature under nitrogen and chilled to -15 oC. Dry triethylamine 
(1.5 mL, 11 mmol) was added with stirring. Isophthaloyl dichloride (304 mg, 1.5 
mmol) was dissolved in dry dichloromethane (20.0 mL) and added slowly to the 
reaction mixture. The reaction mixture was then stirred for one hour at -15 oC.  After 
this period had elapsed the reaction mixture was allowed to warm to room temperature 
and was stirred at room temperature for sixteen hours. Dry triethylamine (1.5 mL, 11 
mmol) was added to the reaction flask. Isophthaloyl dichloride (304 mg, 1.5 mmol) 
was dissolved in dry dichloromethane (340 mL) and added slowly to the reaction 
mixture. This reaction mixture was stirred for 24 hours and then quenched by adding 
distilled water (50.0 mL) and stirring for ten minutes. The reaction mixture was 
transferred to a separation funnel and the organic and aqueous layers were separated. 
The organic layer was washed with distilled water (50.0 mL X6), dried over 
magnesium sulphate and the solvent was removed in vacuo. Column chromatography 
on a silica stationary phase with mobile phase of 3:1 diethyl ether:chloroform yielded 
the pure product (23 %, 0.199 g, 0.234 mmol) as a colourless solid. 1H NMR, 13C 
NMR, MP and IR data matches that which is stated on page 118. 
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Synthesis of 2,3,6,8,11,12,18,21-tetrabenzo-1,4,10,13,16,23-hexaoxacyclopenta-
icosa-2,6,11,18,20-pentaene-5,9,17,22-tetraone, 352:  
2-(2-Hydroxyethoxy)phenol (1.54 g, 10.0 mmol) was dissolved in dry dichloromethane 
(100 mL) at room temperature under nitrogen and chilled to -15 oC. Dry triethylamine 
(5.0 mL, 36 mmol) was added with stirring. Isophthaloyl dichloride (1.005 g, 5.0 
mmol) was dissolved in dry dichloromethane (25.0 mL) and added slowly to the 
reaction mixture. The reaction mixture was then stirred for one hour at -15 oC.  After 
this period had elapsed the reaction mixture was allowed to warm to room temperature 
and was stirred at room temperature for sixteen hours. Dry triethylamine (5.0 mL, 36 
mmol) was added to the reaction flask. Terephthaloyl dichloride (1.005 g, 5.0 mmol) 
was dissolved in dry dichloromethane (340 mL) and added slowly to the reaction 
mixture. This reaction mixture was stirred for 24 hours and then quenched by adding 
distilled water (50.0 mL) and stirring for ten minutes. The reaction mixture was 
transferred to a separation funnel and the organic and aqueous layers were separated. 
The organic layer was washed with distilled water (50.0 mL X6), dried over 
magnesium sulphate and the solvent was removed in vacuo. Column chromatography 
on a silica stationary phase 3:1 diethylether:chloroform followed by recrystallisation 
from diethylether:chloroform gave the pure product (14 %, 0.078 g, 0.7 mmol) as a 
colourless solid. 1H NMR, 13C NMR, MP and IR data matches that which is stated on 
page 119. 
 
Synthesis of 2,3,6,9,11,12,13,19,22-tetrabenzo-1,4,11,14,17,24-hexaoxacyclohexa-
icosa-2,6,8,12,19,21-hexaene-5,10,18,23-tetraone, 353:  
2-(2-Hydroxyethoxy)phenol (1.54 g, 10.0 mmol) was dissolved in dry dichloromethane 
(100 mL) at room temperature under nitrogen and chilled to -15 oC. Dry triethylamine 
(5.0 mL, 36 mmol) was added with stirring. Terephthaloyl dichloride (1.005 g, 5 
mmol) was dissolved in dry dichloromethane (25.0 mL) and added slowly to the 
reaction mixture. The reaction mixture was stirred for one hour at -15 oC.  After this 
period had elapsed the reaction mixture was allowed to warm to room temperature and 
was stirred at room temperature for sixteen hours. Dry triethylamine (5.0 mL, 36 
mmol) was added to the reaction flask. Terephthaloyl dichloride (1.005 g, 5.0 mmol) 
was dissolved in dry dichloromethane (340 mL) and added slowly to the reaction 
mixture. This reaction mixture was stirred for 24 hours and then quenched by adding 
distilled water (50.0 mL) and stirring for ten minutes. The reaction mixture was 
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transferred to a separation funnel and the organic and aqueous layers were separated. 
The organic layer was washed with distilled water (50.0 mL X6), dried over 
magnesium sulphate and then the solvent was removed in vacuo. Column 
chromatography on a silica stationary phase 3:1 ether:chloroform followed by 
recrystallisation from toluene gave the pure product (2.5 %, 14 mg, 0.12 mmol) as a 
colourless solid. 1H NMR, 13C NMR, MP and IR data matches that which is stated on 
page 120. 
 
Synthesis of 2,3,11,12,-dibenzo-6,8,18,20-difurano-1,4,7,10,13,16,19,22-octaoxa-
cyclohexaicosa-2,11-diaene-5,9,17,21-tetraone, 354: 
2-(2-Hydroxyethoxy)phenol (0.308 g, 2.00 mmol) was dissolved in dry 
dichloromethane (10.0 mL) at room temperature under nitrogen and chilled to -15 oC. 
Dry triethylamine (1.0 mL, 7.2 mmol) was added with stirring. Furan-2,5-dicarbonyl 
dichloride (0.193 g, 1.00 mmol)  was dissolved in dry dichloromethane (25.0 mL) and 
added slowly to the reaction mixture. The reaction mixture was stirred for one hour at -
15 oC.  After this period had elapsed the reaction mixture was allowed to warm to room 
temperature and was stirred at room temperature for sixteen hours. Dry triethylamine 
(1.0 mL, 7.2 mmol) was added to the reaction flask. Furan-2,5-dicarbonyl dichloride 
(0.193 g, 1.00 mmol) was dissolved in dry dichloromethane (120 mL) and added 
slowly to the reaction mixture. This reaction mixture was stirred for 24 hours and 
quenched by adding distilled water (50.0 mL) and stirring for ten minutes. The reaction 
mixture was transferred to a separation funnel and the organic and aqueous layers were 
separated. The organic layer was washed with distilled water (50.0 mL X6), dried over 
magnesium sulphate and the solvent was removed in vacuo. Column chromatography 
on a silica stationary phase dichloromethane followed by recrystallisation from 
chloroform:hexane gave the pure product (9 %, 0.049 g, 0.09 mmol)  as a colourless 
solid. 1H NMR, 13C NMR, MP and IR data matches that which is stated on page 121. 
 
Synthesis of 2,3,9,10-dibenzo-6,16-tetramethyl-1,4,8,11,14,18-hexaoxacyclo-
hexaicosa-2,9-diene-5,7,15,17-tetraone, 357:  
2-(2-Hydroxyethoxy)phenol (1.54 g, 10.0 mmol) was dissolved in dry 
dichloromethane (100 mL) at room temperature under nitrogen and chilled to -15 oC. 
Dry triethylamine (5.0 mL, 36 mmol) was added with stirring. Dimethylmalonyl 
chloride (0.845 g, 5 mmol) was dissolved in dry dichloromethane (25.0 mL) and added 
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slowly to the reaction mixture. The reaction mixture was stirred for one hour at -15 oC.  
After this period had elapsed the reaction mixture was allowed to warm to room 
temperature and was stirred at room temperature for sixteen hours. Dry triethylamine 
(5.0 mL, 36 mmol) was added to the reaction flask. Dimethylmalonyl chloride (0.845 
g, 5.0 mmol) was dissolved in dry dichloromethane (300 mL) and added slowly to the 
reaction mixture. This reaction mixture was stirred for sixteen hours and then 
quenched by adding distilled water (50.0 mL) and stirring for ten minutes. The 
reaction mixture was transferred to a separation funnel and the organic and aqueous 
layers were separated. The organic layer was washed with distilled water (50.0 mL 
X6), dried over magnesium sulphate and the solvent was removed in vacuo. The crude 
product was a viscous liquid and with the addition of 3:1 ether:chloroform (20.0 mL) 
the product was isolated (2.5 %, 0.057 g, 0.12 mmol) as a colourless solid. 1H NMR, 
13C NMR, MP and IR data matches that which is stated on page 130. 
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Chapter 3:  
Attempted Synthesis of the Macrocyclic Compounds Containing 
Morphine and the synthesis of precursors to these macrocycles 
 
3.1 Introduction: 
This chapter details the synthesis of five phenol linked morphine open structures and 
the attempted synthesis of two more phenol linked morphine open structures. The 
details of the attempted synthesis of twenty one macrocycles containing morphine are 
also discussed.  
The main reasons for the study of synthetic methods of macrocycles containing 
morphine was to assist the long term goals of the Gathergood group; the development 
of chiral ligands for asymmetric synthesis, ion sensors and development of novel 
therapeutics.  
The concept is to bind a chiral ligand to metals that had proven ability to act as 
catalysts, e.g. copper(II)69, then use this metal bound species as a catalyst and as the 
ligand is chiral it may direct the reaction towards one enantiomer over the other. The 
chiral macrocycles being investigated in this chapter are under investigation for use as 
potential chiral ligands which can then be used in asymmetric synthesis. Although 
morphine has well known biological activity,70 the reason it was chosen as a scaffold 
for chiral catalyst design and host guest studies was its rigid three dimensional 
structure. The rigid structure would then increase the likelihood of preferential binding 
of chiral guests. Also the rigid chiral structure may induce enantioselectivity to the 
products in any potential catalysed reactions. This would be done by carrying out 
binding studies, with various metals of interest from a catalytic perspective, to the 
macrocycles. Each of the macrocycles that bind effectively to the metals could then be 
tested in an established reaction making a chiral product to see if the macrocycle has an 
effect on the outcome of the reaction, i.e. increases the enantiomeric excess of either 
the R or S enantiomer.  
The study of novel opiate products, including examples synthesised in this project, as 
potential analgesic therapeutics is also being carried out within the research group. 
This work is being undertaken as part of another project and will not be reported on in 
this thesis.  
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Each of the phenol linked morphine open structures were synthesised for use in the 
synthesis of morphine macrocycles. Metal binding studies were carried out on each of 
the successfully synthesised and isolated phenol linked morphine open structures with 
a variety of metal ions, the results of which will be discussed in chapter four.  
The optimised method developed in chapter two for the synthesis of compound 353 is 
used in the study of the synthesis of the analogous macrocycle containing morphine 
and then other methods were tried to isolate this macrocycle.  
The methods used for the investigation into another twenty macrocycles are also 
detailed.  
The rigidity of the morphine molecule compared to the diol model was thought to be a 
limitation in the macrocyclisation reactions. As one of the aims of this project was to 
prepare the morphine macrocycles the size of the ring was varied in attempts to 
establish if any ring size was especially favourable to the cyclisation. Also the linker 
was varied to include both rigid and flexible linkers to test the effect of these on the 
macrocyclisation reactions. This approach meant the attempted synthesis of many 
different morphine macrocycle targets to try to establish if one macrocycle was more 
favourable. 
 
3.2: Synthesis of phenol linked Morphine open structures 
Five open structures (368-372) were successfully isolated and characterised. Attempts 
were made to synthesise and isolate two more open structures (373 and 374) but all 
these attempts were unsuccessful. The structures of these seven compounds are given 
in figure 80. 
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Figure 80: Compounds 368 to 374 
368-372 were successfully synthesised by the same methodology, with the exception 
of the synthesis of 371 in which potassium carbonate was used instead of 
triethylamine. This method was the same as used for the synthesis of the analogous 
structures with 2-(2-hydroxyethoxy)phenol and an example of this, the synthesis of 
368 and 346, is shown in scheme 31.   
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Scheme 31: Synthesis of 346 and 368  
The methodology successfully produced 368-372. In this method, in chapter 2, it has 
been shown that the acid chloride preferentially reacts with the phenol over the 
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aliphatic alcohol creating the target product. The bis-alcohol products in chapter 2 
(338-344) did not undergo transesterification to create isomers. Although the reactivity 
of the alcohol groups will be different in morphine compared to the model (2-(2-
hydroxyethoxy)phenol) the two alcohol groups should react in the same preferential 
order. This should lead to the selective synthesis of the target products over their 
isomers, e.g. 368 over 397. Also if 368 is successfully synthesised then the likelihood 
of intermolecular transesterification is reduced because of the bulkiness and rigidity of 
the morphine moiety.  
Also Mignat et al.71 have synthesised ten morphine derivatives, all of which have been 
modified by esterification at the phenol. Each of these modified opiates have 
remarkably similar 1H-NMR spectra and each of these are also similar to the recorded 
NMR data for the compounds 368-372. The NMR data was similar for both the 
aromatic hydrogens (hydrogens on the A-ring) and also the hydrogens on the C-ring, 
ring labels shown in figure 81 below.  
 
Figure 81: Ring labels of morphine 
Although a lot of the other hydrogens also appear very similar the hydrogens of the A 
and C rings are the pivotal hydrogens for the differentiation of the possible isomers, 
those linked between the phenol groups and those linked between the aliphatic 
alcohols. If there is an ester formed on the aliphatic alcohols the hydrogens on rings A 
and C will be significantly different to the hydrogens in the same positions if the ester 
is on the phenol groups. This can be seen by the comparison of the recorded NMR data 
to that of 6-O-acetylmorphine reported by Schwarzinger et al.72 For each of the 
products isolated in this section of the project H1 (as shown in figure 81) appears at 4.8 
ppm with variation of approximately 0.1 ppm depending on the ester in the product, 
H2 at about 4.1 ppm, H3 at 5.7 ppm and H4 at 5.1 ppm, each with similar variation. 
This closely matches that which was by Mignat et al. whereas the reported NMR for 6-
O-acetylmorphine by Schwarzinger et al. is significantly different showing the same 
hydrogens at 5.1 ppm for both H1 and H2, 5.4 ppm for H3 and 5.7 ppm for H4.  
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368, 369 and 371 were each isolated directly from the reaction in yields of 85 %, 63 % 
and 50 % respectively. 370 needed recrystallisation for purification and was isolated in 
16 %. 372 required purification by column chromatography, and was isolated in a 
lower yield (4.2 %) than those successfully isolated with the aromatic diacid 
dichlorides.  
373 and 374 (figure 80) were not successfully isolated. On the first attempt 373 was 
obtained with sufficient purity to record proton and carbon NMR spectra, this data is 
consistent with the structure of 373.  This suggests that with some further work this 
compound can be isolated. There were five further attempts to prepare and isolate 
compound 373. The synthesis appeared to work on the first of these attempts with 
isolation failing, so the synthesis was repeated twice using the same method and 
different methods were attempted for isolation of the product. On the second attempt 
the aqueous layer was basified by the addition of saturated sodium hydroxide solution 
(2.0 mL). This was done in an attempt to force the product out of solution by ensuring 
that the nitrogen atoms in the opiate subunits were not protonated. The solution was 
then extracted with chloroform and both aqueous and organic layers were tested by 
NMR. It was found that the target product remained in the aqueous layer. Additional 
portions of saturated sodium hydroxide solution (2.0 mL) were added and after each 
addition the aqueous extracted with chloroform and both fractions were tested by NMR 
again. This was done until the product in the aqueous layer was seen to have degraded 
back to the starting material. On the final attempt using this method no water was 
added to quench or wash the reaction. The reaction was dried on the rotary evaporator 
without work up. Attempts were then made to purify this by recrystallisation, 
development of mobile phase for column chromatography, solid-liquid extractions and 
liquid-liquid extractions. All attempts were unsuccessful. The next attempt at the 
synthesis and isolation was carried out by refluxing in dichloromethane overnight, with 
the idea that as increased would lead to an easier isolation. This did not work, with a 
decreased yield being recorded by 1H-NMR and attempts to isolate the product pure 
failed. The final attempt to synthesise and isolate compound 373 was done with 
dimethylaminopyridine instead of triethylamine. The reason for this was that in the 
reaction which had no water added the main impurity which could not be separated 
from the target product was the hydrochloride salt of triethylamine. With the change in 
base it was intended that this would be avoided. In the 1H-NMR spectrum of the crude 
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product of this reaction it was found that the reaction did not work and therefore 
purification was not attempted.  
The last open structure of this group at which attempts were made at the synthesis of 
was compound 374. There were four attempts at the synthesis of compound 374. All 
attempts at the synthesis of 374 were unsuccessful. The first two attempts were the 
same as the method that was used for each compound 368-372 with varying attempts at 
purification, including recrystallisation, using single solvents and solvent mixes, solid-
liquid extraction, column chromatography and attempts at vacuum distillation. Then 
two attempts by the same method but varying the base were made, one with 
dimethylaminopyridine as base and one with potassium carbonate as base. No reaction 
took place in these two attempts at the synthesis and the starting material was 
recovered.  
 
3.3: Attempted synthesis of the morphine containing macrocycles. 
There were twenty one macrocycles containing morphine at which attempts were made 
at the synthesis and isolation. These are comprised of thirteen macrocycles analogous 
to the macrocycles in chapter 2 with morphine in place of 2-(2-hydroxyethoxy)phenol, 
shown in figure 82, and eight others which combined the aromatic linkers with 
aliphatic linkers, shown in figure 83 (page 156).  
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Figure 82: Compounds 375-387, the analogous macrocycles to those in chapter 2 
which were not successfully isolated 
380 had the most attempts made at its synthesis as this was the macrocycle for which 
the analogous synthesis using the 2-(2-hydroxyethoxy)phenol was optimised. There 
were nineteen different methods used in the attempted synthesis and isolation of 
compound 380. On the first attempt using the method directly from the optimisation of 
the synthesis of 290 from chapter two there appeared to be product present by NMR 
(NMR spectra are shown in figure 84 and 85).  
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Figure 84: 1H-NMR of compound 380 
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Figure 85: 13C-NMR of compound 380 
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In the proton NMR there can be clearly seen two singlets at 7.75 and 8.06 which have 
equal integral values. These peaks have a series of peaks throughout the spectrum 
which are in the correct regions for the morphine units expected in the macrocycle and 
these each have integral values matching the expected values. The product appears to 
be approximately 66 % pure by 1H-NMR, with the peaks thought to be from the 
product having an integration of 2 and the impurity having an integration of 1.  
The correct amount of peaks exist in the 13C-NMR for the macrocycle and these peaks 
appear in the correct regions of the spectrum. There are two very similar peaks, at 
128.79 and 128.81 at a stronger intensity than those around them, suggesting there are 
more carbon atoms for each of these peaks than for the surrounding peaks. This would 
be an expected if there are two terephthaloyl groups as in the proposed structure 380. 
The mass spectrum, IR spectrum, melting point and optical rotation were not recorded 
as it was intended to do this on the product once isolated pure and the attempted 
purification was not successful resulting in the loss of the target product.  
380 was not isolated pure and it cannot be determined absolutely if the target product 
was successfully synthesised. This synthesis and purification is outlined in detail in the 
experimental section. The synthesis was repeated twice by the same method and no 
target product was seen in the crude products of the two subsequent attempts at the 
synthesis. The crude products were purified by column chromatography but no target 
product was seen. The main details for the other methods used in the attempted 
synthesis of compound 380 are given in table 17. Attempts one to four give the 
conditions tried for the one pot method. Attempts five to eighteen give the conditions 
tried for the attempts at the synthesis of compound 380 using the bis-alcohol precursor 
368 as the starting material. Using this method 0.5 mmol of 368 was dissolved in the 
designated solvent, under nitrogen, and followed by addition of the base. The reaction 
mixture was brought to the designated temperature and terephthaloyl dichloride was 
added. The reaction was stirred at the designated temperature for the allotted time and 
then quenched by addition of water and worked up as done in the one pot method. All 
volumes of solvent are normalised for 1.00 mmol of morphine as starting material.  
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Attempt 
Starting 
material 
Base (eq.)  Solvent (vol.) Temp. Time (h) 
1 
Morphine. 
335 
5.0 eq. NEt3 125 mL DCM RT 4  
2 
Morphine 
335 
5.0 eq. NEt3 125 mL DCM RT 72  
3 
Morphine 
335 
5.0 eq.  NEt3 125 mL DCM 40 oC 48  
4 
Morphine 
335 
6.4 eq. NEt3 125 mL DCM 40 oC 48  
      
5 368 5.0 eq. NEt3 32 mL DCM RT 48  
6 368 1.1 eq. DMAP 200 mL DCM RT 48  
7 368 5.0 eq. NEt3 200 mL DCM RT 48  
8 368 108 eq. NEt3 15 mL DCM 
-78 oC for 4 hours, 
then RT 
24  
9 368 64 eq. NEt3 260 mL DCM 
-78 oC for 4 hours, 
then RT 
24  
10 368 12 eq. NEt3 250 mL DCM 40 oC 72  
11 368 1.1 eq. DMAP 125 mL DCM RT 72  
12 368 13 eq.K2CO3 170 mL DCM RT 72  
13 368 6 eq. K2CO3 125 mL DCM RT 24  
14 368 6 eq. Na2CO3 250 mL DCM 40 oC 24  
15 368 6 eq. Na2CO3 250 mL chloroform 70 oC 24  
16 368 5.0 eq. NEt3 125 mL chloroform 70 oC 24  
17 368 7.2 eq. NEt3 300 mL DCM 40 oC 72  
18 368 7.2 eq. NEt3 300 mL DCM RT 72  
Table 17: Conditions used in the attempted synthesis of compound 380. 
After each attempted synthesis attempts were made at the isolations of the target 
product, by column chromatography, recrystallisations (from single solvent and solvent 
mixes), solid-liquid extraction, liquid-liquid extraction and some attempts by short-
path vacuum distillation on a Buchi glass oven B-585 Kugelrohr. The target product, 
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macrocycle 380, was not seen in the products (crude or purified) of any of these 
reactions. The following set of NMR spectra are a typical example of the results from 
the column chromatography of one of the synthesis attempts, each NMR represents a 
fraction obtained from the column.  
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Figure 86: NMR of 1st fraction.  
In the first fraction there is clearly no opiate material and hence clearly no target 
product. The diacid of the diacid chloride starting material, terephthalic acid, is seen at 
8.036 ppm. 
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Figure 87: NMR of 2nd fraction.  
In the second fraction there is opiate present but it appears to be 3-O-morphinyl 
terephthalate, the single adduct of morphine and terephthaloyl dichloride. There are 
two aromatic peaks in the region of 8.0 to 8.3, but these peaks are not singlets as 
expected for the target product but instead are doublets with bias towards each other 
signifying that they couple each other. This would suggest it is from the terephthaloyl 
moiety with one side as the acid and the other as the ester.  
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Figure 88: NMR of 3rd fraction.  
The third fraction contains opiate product but it appears to be bis(3-morphinyl) 
terephthalate, compound 368. There is one singlet at 8.24 and this integrates correctly 
to the opiate peaks thus suggesting that this is compound 368. 
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Figure 89: NMR of 4th fraction .  
 154 
The fourth fraction contains opiate product but it appears to be impure. It appears as 
mixture of bis(3-morphinyl) terephthalate and O-morphinyl terephthalate. Although 
this is a postulated mixture, we are confident that the isolated material is not the target 
product nor is it pure.  
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Figure 90: NMR of Last fraction (methanol flush) 
When all the fractions seen by TLC had eluted, the column was flushed with methanol. 
After removal of the solvent in vacuo this fraction gave the NMR spectrum shown in 
figure 90 above. Again this fraction seems impure, although again the exact product is 
unsure it can be clearly seen that the target product is not present.  
After the synthesis of compound 385 was tried, unsuccessfully, by the nineteen 
methods it was decided to prepare some macrocycles using the aliphatic diacid 
chlorides. The diacid dichlorides, diglycolyl dichloride and dimethylmalonyl chloride, 
were next to be attempted. They are more flexible and it was thought that one of the 
problems for the synthesis of compound 385 may have been that each of the units 
being brought together were inflexible and therefore this could hinder the cyclisation 
reaction. Attempts were then made to synthesise compounds 386 and 387. Synthesis 
and isolation of each of these were attempted three times, all of which were from 
morphine carried out from the morphine starting material (rather than from the bis-
morphine open structures) using the one pot general method. Table 18 shows the 
details of the solvent, base, temperature and time used in the attempted synthesis of 
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compounds 386 and 387. As with table 17 all volumes used are normalised for 1.00 
mmol of morphine starting material.  
Product, Attempt 
Base (type and 
equivalents) 
Solvent (type and 
volume) 
Temperature Time (h) 
 386, A 
5.0 equivalents 
NEt3 
125 mL 
DCM 
RT 4 
386, B 
5.0 equivalents 
NEt3 
125 mL 
DCM 
RT 72 
386, C 
10 equivalents 
NEt3 
125 mL 
DCM 
40 oC 48 
387, A 
5.0 equivalents 
NEt3 
125 mL 
DCM 
40 oC 48 
387, B 
7.2 equivalents 
NEt3 
125 mL 
DCM 
RT 48 
387, C 
5.0 equivalents 
NEt3 
20 mL DCM 40 oC 48 
Table 18: Details of attempted synthesis of 386 and 387. 
After each synthesis attempts were made to purify the crude product and to isolate the 
target products. The target product was not isolated from these reactions, but the 
starting material (morphine) was recovered, typically in 70 % mass recovery.  
The next macrocycles to be attempted were compounds 388-395. The structures are 
shown in figure 83.  
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Figure 83: 388-395, macrocycles with aromatic and aliphatic linkers combined which 
were not successfully isolated 
A mix of aliphatic and aromatic diacid chlorides were used in the attempted synthesis 
of these compounds. Each synthesis was attempted only once and each was carried out 
by the same method. This was the same method first used for the synthesis of 380 
except the second step was left refluxing for seventy two hours. Again there were 
attempts made at the isolation of each product and again each attempt failed. In each 
case the crude product contained a mixture of unreacted morphine, typically 40-50 % 
mass recovery of the starting material, the left over diacid and also some phenol linked 
bis-morphine open structures, although these were not typically purified.  
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After each of the attempted synthesis above failed it was decided to try to synthesise 
compounds 375-379 and 381-385, the analogues of each of the compounds which were 
synthesised in chapter two that have not already been attempted. These attempts were 
made in the final stages of the project in an effort to isolate a macrocycle containing 
morphine. Each of the synthesis attempts at these macrocycles were carried out using 
the one pot method and also from the phenol linked bis-morphine open structures, 
where they were available. The method for the one pot synthesis was the same as the 
general method from chapter two: the morphine was dissolved in dichloromethane with 
triethylamine under nitrogen at -15 oC and then half an equivalent of diacid dichloride 
was added. This was stirred at -15 oC then at room temperature for another hour. 
Another aliquot of triethylamine and dichloromethane were added. Another half 
equivalent of diacid dichloride was then dissolved in dichloromethane and added 
dropwise to the reaction. After the allotted time this was quenched with water, washed 
and the organic removed in vacuo. The synthesis of each of these products was 
attempted from the appropriate phenol linked bis-morphine structure. For this method 
the bis-morphine structure was dissolved in dichloromethane and triethylamine was 
added. Then the diacid dichloride was dissolved in dichloromethane and added 
dropwise to the reaction and left to stir overnight. The reaction was then quenched by 
addition of water and washed and evaporated to dryness. After each of these reactions, 
attempts were made to isolate the target products, however unsuccessfully. 
The crude products from all of the attempts to produce macrocycles 375-387 were 
purified by column chromatography and in each case no target product was 
successfully isolated pure. In each case the results were similar to those reported for 
attempts 1-18 of the synthesis of 380 above. The first fraction was the diacid formed 
from the reaction of the acid chloride and water on quenching of the reaction. Each of 
the other fractions contained opiate compounds but no detectable target product.  
Below in figures 91-99 are shown the NMR spectra of the fractions from the column 
chromatography of the crude product from the attempted synthesis of 378 and 383 as 
typical examples of the results obtained from each of the attempted synthesis of the 
macrocycles. Figures 91-95 are the spectra of the fractions isolated of the crude 
product obtained from the attempted synthesis of 378. 
 
 158 
-3-2-116 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm
-
0.
00
0
1.
31
8
1.
33
6
1.
35
4
3.
86
9
4.
32
1
4.
33
9
7.
20
1
7.
43
2
7.
43
3
7.
45
2
7.
46
8
7.
47
1
7.
47
1
8.
12
9
8.
13
3
8.
13
7
8.
14
3
8.
14
7
8.
14
8
8.
15
2
8.
15
7
8.
16
2
8.
59
9
8.
60
0
8.
60
3
8.
60
4
8.
60
8
0.
31
14
.
85
12
.
42
0.
63
0.
69
38
.
36
3.
58
0.
97
7.
29
14
.
07
6.
85
Meta opiate macrocycle attempt
1st spot off column
 
Figure 91: NMR of 1st fraction from the attempted synthesis of 378 
The 1H-NMR spectrum of the 1st fraction shows there is clearly no opiate material and 
hence clearly no target product. The diacid of the diacid chloride starting material, 
isophthalic acid, is seen at 7.4, 8.1 and 8.6 ppm. 
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Figure 92: NMR of 2nd fraction from the attempted synthesis of 378 
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In the 1H-NMR spectrum of the 2nd fraction there is opiate product but it appears to be 
3-O-morphinyl isophthalate, the single adduct of morphine and isophthaloyl dichloride.  
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Figure 93: NMR of 3rd fraction from the attempted synthesis of 378 
In the 1H-NMR spectrum of the third fraction (figure 93) there appears to be a mix of 
products, but most notably there is no sign of the target product (378).  
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Figure 94: NMR of 4th fraction from the attempted synthesis of 378 
In the 4th fraction there is one pure isolated material, it is clearly bis(3-morphinyl) 
isophthalate (369) as seen in 1H-NMR spectrum in figure 94 above.  
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Figure 95: NMR of last fraction (methanol flush) from the attempted synthesis of 378 
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Again this fraction seems impure, as seen in the 1H-NMR spectra (figure 95). Although 
the exact product is unsure it can be clearly seen that the target product is not in the 
present. 
The next set of 1H-NMR spectra (figures 96-99) are of the fractions isolated after 
passing the crude product obtained from the attempted synthesis of 383 down a silica 
column. 
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Figure 96: NMR of 1st fraction from the attempted synthesis of 383 
The 1H-spectrum of the 1st fraction shows clearly that no opiate material is present in 
this fraction and hence clearly no target product. The diacid of the diacid chloride 
starting material, pyridine-2,6-dicarboxylic acid, is seen at 7.9 and 8.2 ppm. 
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Figure 97: NMR of 2nd fraction from the attempted synthesis of 383 
In figure 97 there is no sign of the target product, although this fraction is impure, and 
there is a clear abundance of pyridine-2,6-dicarboxylic acid.  
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Figure 98: NMR of 3rd fraction from the attempted synthesis of 383 
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In the third fraction it can be clearly seen again that there is no target product with 
there still being an abundance of the pyridine-2,6-dicarboxylic acid, alongside an 
impure opiate product.  
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5 ppm
1.
13
0.
95
1.
32
2.
89
1.
05
1.
11
0.
92
1.
08
0.
96
1.
00
1.
11
Pyri Opiate macrocycle attempt
last Spot off column (meoh Flush)
5.56.06.57.07.58.0 ppm
4.
72
2
4.
86
7
4.
87
0
4.
88
3
4.
88
6
4.
91
8
5.
26
1
5.
26
8
5.
27
4
5.
28
6
5.
29
2
5.
29
9
5.
68
6
5.
71
0
6.
50
3
6.
52
4
6.
58
1
6.
60
1
7.
98
3
8.
00
2
8.
03
2
8.
05
1
8.
09
4
8.
10
4
8.
10
6
8.
14
5
8.
17
2
8.
17
5
2.02.53.03.54.0 ppm
2.
7
81
2.
82
7
2.
84
4
3.
01
3
3.
02
3
3.
03
0
3.
03
6
3.
04
3
3.
14
4
3.
16
2
3.
17
0
3.
18
0
3.
19
9
3.
21
9
3.
24
1
3.
26
3
3.
26
7
3.
27
1
3.
27
5
3.
27
9
3.
31
0
3.
42
7
3.
95
5
4.
07
1
4.
07
8
4.
08
7
4.
21
6
4.
22
4
4.
23
1
4.
23
8
 
Figure 99: NMR of last fraction (methanol flush) from the attempted synthesis of 383 
The 1H-NMR spectrum shown in figure 99 shows that the methanol flush is impure, 
although again the exact product is unsure it can be clearly seen that the target product 
is not present. Also there appears to be morphine starting material left over.  
 
3.4: Attempts to synthesise the secondary alcohol linked morphine open 
structures.  
After the attempted synthesis of the macrocycles detailed in section 3.3 proved fruitless 
it was decided to synthesise the 2o alcohol linked bis-morphine open structures. Then 
to attempt the synthesis of the macrocycles from the 2o alcohol linked morphine open 
structures. It was postulated that the increased reactivity of the phenols would lead to a 
higher conversion for the reactions with the diacid chloride on attempts to synthesise 
the macrocycles. Also preparing the more labile ester bonds last may lead to less 
decomposition products, as the ester bonds can be broken in the presence of base or 
acid and there is base used in the reaction. Hydrogen chloride is also a side product of 
the reaction and this could react with the ester to break the bond. If the more stable 
 164 
bond is formed first then this is less likely to decompose under the reaction conditions 
and therefore it is more likely that the target product will be synthesised. The first step 
was the synthesis of TES protected morphine, 396, and then using compound 396 as a 
starting material attempts were made at the synthesis of compounds 397 and 398. 
Scheme 32 shows the synthetic pathway for the synthesis of compounds 396, 397 and 
398. 
 
Scheme 32: Failed Synthetic pathway for 397 and 398. 
The TES protected morphine (396) was successfully synthesised and isolated. Using 
396 attempts were made at the synthesis and isolation of compounds 397 and 398. The 
same reaction conditions were used for both compounds. The first attempt was using 
the same method for the synthesis of the phenol linked morphine open structures. The 
reactions were also carried out using dimethylaminopyridine instead of triethylamine. 
No reaction occurred with dimethylaminopyridine and only the starting material, 
compound 396, was recovered from the reactions. From the reaction using 
triethylamine the TES protected intermediates were synthesised, although not isolated 
pure. Multiple attempts at the purification failed and instead it was decided to proceed 
to the deprotection step and to isolate pure after deprotection. This decision was made 
with the experiences of the synthesis of the analogous 2-(2-hydroxyethoxy)phenol 
compounds (346 and 347). With 346 and 347 if the protected intermediate was not 
pure it was easier to isolate the final product than it was to isolate the intermediate. For 
this reason the impure intermediate compounds were deprotected. The deprotection 
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was to be carried out in the same way as done previously, in 4:1 acetic acid: water at 
40 oC monitored every 10 minutes by thin layer chromatography. The target product 
decomposed during the deprotection within 20 minutes. This may have happened for a 
number of reasons including: the products may be more soluble in the acid solution 
than the analogous 2-(2-hydroxyethoxy)phenol compounds were; and the ester bond of 
the target product may be more sensitive to acidic hydrolysis than that of the analogous 
2-(2-hydroxyethoxy)phenol compounds. This could happen because the pKa of the 
hydroxy group on 3-O-triethylsilyl morphine is calculated to be 13.5 ±0.2 compared to 
that of the hydroxy group in 2-{2-[(triethylsilyl)oxy]phenoxy}ethanol calculated to be 
14.3 ±0.1. The pKa’s were calculated using Advanced Chemistry Development 
(ACD/Labs) Software V8.14 for Solaris (© 1994-2009 ACD/Labs). Work is ongoing 
within the research group to attempt the isolation compounds 397 and 398 and other 
related analogues, and then, if successfully isolated, to use these as starting materials in 
attempts to make the macrocycles discussed in this chapter.  
 
Conclusion: 
In conclusion five new open structures containing morphine, 368-372, were 
successfully synthesised and isolated.  
Although there were attempts at the synthesis and isolation of twenty one new 
macrocycles none of the macrocycles were isolated. The synthesis of compound 380 
was attempted nineteen times, starting with the optimised method developed for 353. 
Although this product was not isolated pure it seems to have been synthesised by the 
first attempt, but this can only be confirmed by 1H and 13C NMR at this stage.  
The other macrocycles attempted (375-379 and 381-395) were not isolated and it is 
unsure if these macrocycles were successfully synthesised and not isolated or if the 
synthesis was unsuccessful.  
The macrocycles discussed in this chapter were the primary synthetic target at the 
beginning of the research, but as with all research the focus changes. This impacted on 
the volume of work done in an effort to synthesise and isolate these macrocycles. For 
this project the focus changed from the isolation of these macrocycles to the 
optimisation of the synthesis of bis(2-(2-hydroxyphenoxy)ethyl) 2,2-dimethylmalonate 
and other work related to the possible biological activity of this compound. The 
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optimisation part of this work was already discussed in chapter two and the biological 
activity and the work related to the will be discussed in chapter five.  
The synthesis of these macrocycles is still seen as an important goal of the research this 
project has started. For this reason the synthesis and isolation of the triethylsilyl 
protected morphine (396) and the attempted isolation of the secondary alcohol linked 
open structures (397 and 398) was carried out. With some further work it is intended to 
synthesise and isolate these open structures, with less acid being used or maybe a lower 
temperature. Then if successfully isolated compounds 397 and 398 could be used in the 
synthesis of the macrocycles.  
Another method for the synthesis and isolation of 380 may be to return to the 
optimisation of 353. As the method from reaction AD (tables 2 and 3, pages 67) was 
the only method used in the attempted synthesis of compound 380 which appeared to 
yield the target product it is likely that a new method with higher yield of 353 would 
give compound 380 in sufficient yield that it could be isolated.  
A factor that may be hindering the synthesis of the morphine macrocycles is the rigid 
structure of morphine in comparison to the 2-(2-hydroxyethoxy)phenol used to develop 
the synthesis. This rigidity decreases the chances of the linear open structures, e.g.  
bis(3-morphinyl) phthalate, 370, flexing into a position in which the macrocyclisation 
can occur. To overcome this there are two options, one is to obtain a more rigid diol 
and to use this for the method development and the other is to do the method 
development using morphine. The use of a more rigid diol in place of the 2-(2-
hydroxyethoxy)phenol comes with the risk of the developed method being non-
transferable to the morphine. The first step in this second method utilised to overcome 
the rigidity was to switch the order of linking and closing the macrocycles. The 
synthesis was attempted by first linking across the aliphatic alcohols and then closing 
the macrocycles between the phenols. By carrying out the synthesis by this method the 
cyclisation step of the models more closely matches that of the morphine so the same 
method could work to close the opiate macrocycle as was used to close the model. 
Also if the reaction between the acid chloride and the alcohol is more likely to occur 
then each time the alcohol and acid chloride come close enough to react then they are 
more likely to react. Thus, although there is less chance of them coming close, because 
of the rigid structure, each time they are close they are more likely to react to form the 
target product. This method of synthesis was shown to have worked with the model 
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systems but compounds 397 and 398 were not successfully isolated to test the method 
for the synthesis of the envisaged opiate macrocycles.  
Although it is envisaged that future work preparing models may aide the development 
of the opiate macrocycles but will most likely be due to observed trends rather than 
direct method transfer. Carrying out the method development using morphine as the 
starting material may be expensive, due to the cost of morphine, its storage, disposal 
and licensing, but the method development should be done using morphine in future.  
 
Experimental: 
All chemicals were purchased from Sigma/Aldrich and used as received, with the 
exception of the morphine hydrochloride trihydrate which was purchased from 
Johnson Matthey Macfarlan Smith, Edinburgh, and dried for one week under vacuum 
before being used. When necessary solvents were purified prior to use and stored under 
nitrogen. Dichloromethane was distilled from CaH2 and triethylamine was distilled and 
stored over potassium hydroxide pellets. Commercial grade reagents were used without 
further purification. Davisil 60A silica gel was used for thin layer and column flash 
chromatography. Melting points were determined using a Stuart melting point, SMP3, 
apparatus and are uncorrected. Infrared spectra were recorded on an IR is Perkin Elmer 
FT-IR system, spectrum GX spectrometer. Optical rotations were measure on a Perkin 
Elmer 343 Polarimeter in HPLC grade chloroform. Liquid chromatography time-of-
flight mass spectrometry was recorded on a Waters Corp. Liquid Chromatography-
Time of flight mass spectrometer from Micromass MS Technologies Centre. NMR 
spectra were obtained on a Bruker AC 400 NMR spectrometer operating at 400 MHz 
for 1H NMR and 100 MHz for 13C NMR. The 1H and 13C NMR chemical shifts (ppm) 
are relative to tetramethylsilane. All coupling constants (J) are in Hertz.  
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Synthesis of the phenol linked open structures: 
Synthesis of bis(3-morphinyl) terephthalate, compound 368:  
 
Morphine hydrochloride (0.339 g, 1.06 mmol) was dissolved in dry dichloromethane 
(10.0 mL) at room temperature under nitrogen and then chilled to -15 oC. Dry 
triethylamine (0.5 mL, 3.6 mmol) was added while stirring and maintaining the 
temperature at -15 oC. Terephthaloyl dichloride (107 mg, 0.53 mmol) was dissolved in 
dry dichloromethane (10.0 mL) and added to the reaction mixture. The reaction 
mixture was stirred for 1 hour, allowed to warm to room temperature and stirred for 
another hour. The reaction was quenched by adding distilled water (10.0 mL), and 
stirring for twenty minutes. The reaction mixture was transferred to a separation funnel 
and the organic and aqueous layers were separated. The organic layer was washed with 
distilled water (10.0 mL X10), dried over MgSO4 and the solvent was removed in 
vacuo. Drying in vacuo for 1 week yielded the pure product (85 %, 0.316 g, 0.45 
mmol) as a colourless powder. 
1H NMR (CDCl3): δ(ppm) 8.22 (4H, s, H1), 6.81 (2H, d, J = 8.0 Hz, H5), 6.60 (2H, d, 
J = 8.0 Hz, H6), 5.73 (2H, dt J = 9.6, 3.0 Hz, H13), 5.25 (2H, dt, J = 9.6, 2.8 Hz, H14), 
4.88 (2H, d, J = 2.8 Hz, H10), 4.12 (2H, Broad s, H15), 3.42 (2H, Broad s, H16), 3.31 
(2H, dd, J = 6.0, 3.0 Hz, H17), 3.01 (2H, d, J = 19.0 Hz, H20),  2.64 (2H, t, J = 3.0 Hz, 
H18), 2.54 (2H, dd, J = 12.2, 3.0 Hz, H12), 2.36 (6H, s, H19), 2.29 (4H, td, J = 19.0, 
5.9 Hz, H’s 17 and 20 ), 2.01 (2H, td, J = 12.0, 5.9 Hz, H21), 1.85 (2H, d(broad), J = 
12.0 Hz, H21). 
13C NMR (CDCl3): δ(ppm) 163.22 (C3), 148.73 (C9), 134.20 (C2), 133.39 (C4), 
133.29 (C14), 132.56 (C8), 131.68 (C7), 130.50 (C1), 127.87 (C13), 121.07 (C6), 
120.09 (C5), 92.53 (C15), 65.86 (C18), 58.87 (C10), 46.39 (C20), 43.13 (C19), 42.69 
(C11), 40.45 (C12), 35.24 (C21), 20.77 (C17).  
IR (KBr disc): σ(cm-1) 3511, 3031, 2911, 2847, 2801, 2362, 2345, 1735, 1617, 1560, 
1491, 1451, 1375, 1350, 1243, 1199, 1173, 1155, 1118, 1099, 1072, 1034, 1015. 
MP: 165-167 oC 
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Optical Rotation (0.3 c, CHCl3, 589nm, 20 oC): -152 o 
Calculated exact mass for product: (C42H40N2O8) 700.2785 
Calculated exact mass for product: (C42H40N2O8H+) 701.2857 
Found, HRMS (EI, 70 eV): 701.2890 
 
Synthesis of bis(3-morphinyl) isophthalate, compound 369:  
 
Morphine hydrochloride (0.339 g, 1.06 mmol) was dissolved in dry dichloromethane 
(10.0 mL) at room temperature under nitrogen and chilled to -15 oC. Dry triethylamine 
(0.5 mL, 3.6 mmol) was added while stirring and maintaining the temperature at -15 
oC. Isophthaloyl dichloride (107 mg, 0.53 mmol) was dissolved in dry dichloromethane 
(10.0 mL) and added to the reaction mixture. The reaction mixture was stirred for 1 
hour, allowed to warm to room temperature and was stirred for another hour. The 
reaction was quenched by adding distilled water (10.0 mL), and stirring for twenty 
minutes and then transferred to a separation funnel and the organic and aqueous layers 
were separated. The organic layer was then washed with distilled water (10.0 mL X10) 
and dried over MgSO4 and the solvent was removed in vacuo. Drying in vacuo for 1 
week yielded the pure product (63 %, 0.213 g, .033 mmol) as a colourless powder. 
1H NMR (CDCl3): δ(ppm) 8.93 (1H, t, J = 1.6 Hz, H1), 8.38 (2H, dd, J = 7.5, 1.6 Hz, 
H3), 7.59 (1H, t, J = 7.5 Hz, H2), 6.83 (2H, d, J = 8.0 Hz, H7), 6.61 (2H, d, J = 8.0 Hz, 
H8), 5.76 (2H, d, J = 10.0 Hz, H15), 5.25 (2H, dt, J = 10.0, 2.4 Hz, H16), 4.88 (2H, d, 
J = 3.6 Hz, H12), 4.13 (2H, q, J = 2.0 Hz, H17), 3.43 (2H, q, J = 3.6 Hz, H19), 3.04 
(2H, d, J = 17.2 Hz, H22), 2.79 (2H, t, Broad s, H20),  2.68 (2H, dd, J = 17.0, 4.3 Hz, 
H14), 2.46 (6H, s, H21), 2.43-2.34 (4H, m, H’s 19 and 22), 2.12 (2H, td, J = 11.7, 4.3 
Hz, H23), 1.89 (2H, d(broad), J = 11.7 Hz, H23). 
13C NMR (CDCl3): δ(ppm) 163.20 (C5), 148.73 (C11), 135.39 (C3), 134.24 (C16), 
133.18 (C6), 132.50 (C1), 132.21 (C10), 131.71 (C4), 129.67 (C2), 129.13 (C9), 
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127.84 (C15), 121.12 (C8), 1120.08 (C7), 92.50 (C12), 65.87 (C20), 58.90 (17), 46.40 
(C22), 43.12 (C21), 42.69 (C13), 40.46 (C14), 35.24 (C23), 20.78 (C19).  
IR (KBr disc): σ(cm-1) 3504, 2927, 2361, 2341, 1868, 1847, 1830, 1772, 1734, 1700  
1684, 1653, 1616, 1559, 1540, 1490, 1473, 1456, 1397, 1300, 1197, 1065. 
MP: 216-218 oC 
Optical Rotation (0.32 c, CHCl3, 589 nm, 20 oC): -173.5 o 
Calculated exact mass for product: (C42H40N2O8) 700.2785 
Calculated exact mass for product: (C42H40N2O8H+) 701.2857 
Found, HRMS (EI, 70 eV):  701.2890 
 
Synthesis of bis(3-morphinyl) phthalate, compound 370:  
 
Morphine hydrochloride (0.339 g, 1.06 mmol) was dissolved in dry dichloromethane 
(10.0 mL) at room temperature under nitrogen and then chilled to -15 oC. Dry 
triethylamine (0.5 mL, 3.6 mmol) was added while stirring and maintaining the 
temperature at -15 oC. Phthaloyl dicarbonyl dichloride (0.147 mL, 0.53 mmol) was 
dissolved in dry dichloromethane (10.0 mL) and added to the reaction mixture. The 
reaction mixture was stirred for 1 hour, then allowed to warm to room temperature and 
was stirred for another hour. The reaction was quenched by adding distilled water (10.0 
mL), and stirring for twenty minutes. The reaction mixture was transferred to a 
separation funnel and the organic and aqueous layers were separated. The organic layer 
was washed with distilled water (10.0 mL X10), dried over MgSO4 and the solvent was 
removed in vacuo. Recrystallisation from chloroform:hexane yielded the pure product 
(16 %, 0.060 g, 0.08 mmol) as a colourless powder. 
1H NMR (CDCl3): δ(ppm) 7.89 (2H, dd, J = 5.7, 3.3 Hz, H2), 7.60 (2H, dd, J = 5.7, 3.3 
Hz, H1), 6.81 (2H, d, J = 8.0 Hz, H6), 6.53 (2H, d, J = 8.0 Hz, H7), 5.67 (2H, dt J = 
10.0, 1.2 Hz, H14), 5.20 (2H, dt, J = 8.6, 1.5 Hz, H15), 4.76 (2H, d, J = 3.8 Hz, H11), 
4.07 (2H, Broad s, H16), 3.32 (2H, dd, J = 8.6, 3.8 Hz, H18), 3.00 (2H, d, J = 18.8 Hz, 
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H21),  2.65 (2H, Broad s, H19), 2.54 (2H, dd, J = 17.5, 4.3 Hz, H13), 2.39 (6H, s, 
H20), 2.32 (2H, dd, J = 12.3, 3.3 Hz, H18), 2.26 (2H, dd, J = 17.5, 1.2 Hz, H21), 1.98 
(2H, td, J = 11.2, 4.3 Hz, H22), 1.71 (2H, d(broad), J = 11.2 Hz, H22). 
13C NMR (CDCl3): δ(ppm) 163.78 (C4), 147.75 (C10), 133.27 (C5), 131.57 (C1), 
131.08 (C9), 130.87 (C’s 3 and 15), 130.15 (C8), 128.92 (C14), 126.53 (C2), 120.48 
(C7), 118.69 (C6), 91.17 (C11), 64.97 (C16), 57.91 (C19), 45.37 (C21), 41.98 (C20), 
41.54 (C12), 39.24 (C13), 34.04 (C22), 19.81 (C18).  
IR (KBr disc): σ(cm-1) 2926, 2361, 2341, 1868, 1772, 1734, 1717, 1700, 1684, 1653, 
1617, 1559, 1540, 1507, 1490, 1457, 1419, 1261, 1050. 
MP: 139-141 oC 
Optical Rotation (0.22 c, CHCl3, 589 nm, 20 oC): -136 o 
Calculated exact mass for product: (C42H40N2O8) 700.2785 
Calculated exact mass for product: (C42H40N2O8H+) 701.2857 
Found, HRMS (EI, 70 eV):  701.2890 
 
Synthesis of bis(3-morphinyl) pyridine-2,6-dicarboxylate, compound 371:  
 
Morphine hydrochloride (0.339 g, 1.06 mmol) was dissolved in dry dichloromethane 
(10.0 mL) at room temperature under nitrogen and then chilled to -15 oC. Dry 
potassium carbonate (0.9 g, 6.5 mmol) was added while stirring and maintaining the 
temperature at -15 oC. Pyridine dicarbonyl dichloride (103 mg, 0.53 mmol) was 
dissolved in dry dichloromethane (10.0 mL) and added to the reaction mixture. The 
reaction mixture was stirred for 1 hour, then allowed to warm to room temperature and 
was stirred for another hour. The reaction was quenched by adding distilled water (10.0 
mL), and stirring for twenty minutes. The reaction mixture was transferred to a 
separation funnel and the organic and aqueous layers were separated. The organic layer 
was washed with distilled water (10.0 mL X10), then dried over MgSO4 and the 
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solvent was removed in vacuo. This yielded the pure product (50 %, 0.178 g, 0.26 
mmol) as a white solid without the need for further purification.  
1H NMR (CDCl3): δ(ppm) 8.43 (2H, d, J = 7.8 Hz, H2), 8.04 (1H, t, J = 7.8 Hz, H1), 
6.88 (2H, d, J = 8.0 Hz, H6), 6.59 (2H, d, J = 8.0 Hz, H7), 5.73 (2H, d, J = 9.7 Hz, 
H14), 5.24 (2H, d, J = 7.9 Hz, H15), 4.88 (2H, d, J = 3.4 Hz, H11), 4.12 (2H, Broad s, 
H17), 3.35 (2H, dd, J = 7.9, 3.4 Hz, H18), 3.04 (2H, d, J = 18.8 Hz, H21),  2.70 (2H, 
Broad s, H19), 2.54 (2H, dd, J = 15.3, 1.9 Hz, H13), 2.41 (6H, s, H20), 2.35 (2H, dd, J 
= 12.6, 3.5 Hz, H18), 2.27 (2H, dd, J = 15.3, 5.8 Hz, H21), 2.06 (2H, td, J = 12.2, 5.8 
Hz, H22), 1.84 (2H, d(broad), J = 12.2 Hz, H22). 
13C NMR (CDCl3): δ(ppm) 162.16 (C4), 148.73 (C10), 147.61 (C3), 138.57 (C1), 
134.24 (C5), 132.32 (C15), 131.89 (C’s 8 and 9), 129.44 (C14), 127.62 (C2), 121.36 
(C7), 119.99 (C6), 92.49 (C11), 66.03 (C19), 58.96 (C16), 53.47 (C21), 46.41 (C20), 
42.99 (C12), 42.68 (C13), 35.10 (C22), 20.91 (C18).  
IR (KBr disc): σ(cm-1): 3525, 2927, 2361, 2341, 1869, 1844, 1772, 1734, 1700, 1684, 
1653, 1617, 1559, 1540, 1507, 1490, 1456, 1419, 1396, 1318, 1243, 1200, 1121. 
MP: 218-220 oC 
Optical Rotation (0.20 c, CHCl3, 589 nm, 20 oC): -170 o 
Calculated exact mass for product: (C41H39N3O8701.2737 
Calculated exact mass for product: (C41H39N3O8H+) 702.2810 
Found, HRMS (EI, 70 eV):  702.2826 
 
Synthesis of bis(3-morphinyl) 2,2-dimethylmalonate, compound 372:  
 
Morphine hydrochloride (0.339 g, 1.06 mmol) was dissolved in dry dichloromethane 
(10.0 mL) at room temperature under nitrogen and then chilled to -15 oC. Dry 
triethylamine (0.5 mL, 3.6 mmol) was added while stirring and maintaining the 
temperature at -15 oC. Dimethylmalonyl chloride (0.112 mL, 0.53 mmol) was 
dissolved in dry dichloromethane (10.0 mL) and added to the reaction mixture. The 
reaction mixture was stirred for 1 hour, then allowed to warm to room temperature and 
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was stirred for another hour. The reaction was quenched by adding distilled water (10.0 
mL) and stirring for twenty minutes. The reaction mixture was transferred to a 
separation funnel and the organic and aqueous layers were separated. The organic layer 
was washed with distilled water (10.0 mL X10), then dried over MgSO4 and the 
solvent was removed in vacuo. Column chromatography with 15 % methanol and 1 % 
aqueous ammonium hydroxide in dichloromethane yielded the pure product (4.2 %, 16 
mg, 0.02mmol) as a colourless powder.  
1H NMR (CDCl3): δ(ppm) 6.75 (2H, d, J = 8.0 Hz, H5), 6.57 (2H, d, J = 8.0 Hz, H6), 
5.71 (2H, d, J = 10.0 Hz, H13), 5.20 (2H, d, J = 10.0 Hz, H14), 4.86 (2H, d, J = 6.7 Hz, 
H10), 4.10 (2H, Broad s, H15), 3.51 (2H, d, J = 16.1 Hz, H17), 3.42 (2H, Broad s, 
H16), 3.01 (2H, d, J = 16.1 Hz, H20), 2.81 (2H, Broad s, H18), 2.67 (2H, Broad s, 
H12), 2.47 (6H, s, H19), 2.48-2.34 (4H, m, H’s 17 and 20),  2.15 (2H, Broad s, H21), 
1.87 (2H, d(broad), J = 12.2 Hz, H21), 1.64 (6H, s, H1). 
13C NMR (CDCl3): δ(ppm) 171.80 (C3), 147.82 (C9), 133.24 (C4), 131.68 (C14), 
131.24 (C7), 130.80 (C8), 126.40 (C13), 120.03 (C5), 118.96 (C6), 91.22 (C10), 65.75 
(C18), 57.90 (C15), 51.75 (C2), 45.534 (C20), 41.82 (C19), 41.49 (C11), 39.01 (C12), 
33.82 (C21), 21.85 (C1), 19.91 (C17).  
IR (KBr disc) σ(cm-1): 3534, 3450, 2992, 2927, 2878, 2361, 1876, 1843, 1754, 1607, 
1536, 1507, 1459, 1425, 1399, 1312, 1291, 1250, 1211, 1183, 1154, 1098.  
MP: 143-145 oC 
Optical Rotation (0.3 c, CHCl3, 589 nm, 20 oC): -77 o 
Calculated exact mass for product: (C39H42N2O8) 666.2941 
Calculated exact mass for product: (C39H42N2O8H+) 667.3014 
Found: HRMS (EI, 70 eV) 667.3029 
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Attempted Synthesis of bis(3-morphinyl) diglycolate, compound 373:  
 
Morphine hydrochloride (0.339 g, 1.06 mmol) was dissolved in dry dichloromethane 
(10.0 mL) at room temperature under nitrogen and then chilled to -15 oC. Dry 
triethylamine (0.5 mL, 3.6 mmol) was added while stirring and maintaining the 
temperature at -15 oC. Diglycolyl chloride (0.085 mg, 0.495 mmol) was dissolved in 
dry dichloromethane (10.0 mL) and added to the reaction mixture. The reaction 
mixture was stirred for 1 hour, then allowed to warm to room temperature and was 
stirred for another hour. The reaction was quenched by adding distilled water (10.0 
mL), and stirring for twenty minutes. The reaction mixture was transferred to a 
separation funnel and the organic and aqueous layers were separated. The organic layer 
was washed with distilled water (10.0 mL X10), then dried over MgSO4 and the 
solvent was removed in vacuo.  
The mass recovery of the product was 432 %, 1.431 g, and the crude product was 
soluble in the aqueous, not the organic as expected, because of this the crude product 
had almost all the impurities mixed in with it and hence gave a very high crude yield.  
The product was not isolated pure; there are inorganic impurities present which are not 
visible by NMR. But this means the optical rotation, MP and IR spectrum could not be 
recorded. 
1H NMR (CDCl3): δ(ppm) 6.62 (2H, d, J = 8.1 Hz, H4), 6.56 (2H, d, J = 8.1 Hz, H5), 
5.61 (2H, d, J = 10.0 Hz, H12), 5.24 (2H, dd, J = 10.0 Hz, 0.7 Hz, H13), 5.13 (2H, d, J 
= 7.5 Hz, H9), 4.19 (4H, s, H1), 4.07 (2H, broad d, J = 7.5 Hz, H14), 3.2-1.5 (22H, m, 
H’s 11 and 16 to 22). 
13C NMR (CDCl3): δ(ppm) 176.99 (C2), 144.48 (C8), 138.29 (C3), 128.83 (C13), 
128.50 (C7), 126.46 (C6), 122.76 (C12), 120.73 (C4), 117.87 (C5), 85.96 (C9), 69.69 
(C17), 67.48 (C14), 67.25 (C1), 60.77 (C19), 47.74 (C18), 40.80 (C10), 40.34 (C11), 
38.01 (C20), 32.07 (C16).  
Calculated exact mass for product: (C38H40N2O9) 668.2734 
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Attempted synthesis of cyclo[3’-(6’-morphinyl terephthalate)(3-
morphinyl)terephthalate], macrocycle 380  
 
Morphine hydrochloride (0.325 g, 1.01 mmol) was dissolved in dry DCM (10.0 mL) at 
room temperature under nitrogen and then chilled to -15 oC. Dry triethylamine (0.35 
mL, 2.5 mmol) was added. Terephthaloyl dichloride (102 mg, 0.506 mmol) was 
dissolved in dry DCM (5.0 mL) and added to the reaction mixture. The reaction 
mixture was stirred for one hour, then allowed to warm to room temperature and was 
stirred for one hour. DCM (60.0 mL) and triethylamine (0.35 mL, 2.5 mmol) were 
added. The reaction solution was heated to reflux. Terephthaloyl dichloride (102 mg, 
0.506 mmol) was dissolved in dry DCM (50.0 mL) and added dropwise to the reaction 
flask. This reaction mixture was stirred for four hours at reflux. The reaction was 
quenched by adding distilled water (20.0 mL), cooling to room temperature and 
stirring for twenty minutes. The reaction mixture was transferred to a separation funnel 
and the organic and aqueous layers were separated. The organic layer was washed with 
distilled water (20 mL X10), then dried over MgSO4 and the solvent was removed in 
vacuo. Column chromatography using 10 % methanol in dichloromethane followed by 
two consecutive recrystallisations from chloroform:hexane resulted in the product 
(5.48 %, 0.023 g) which was not pure. MS, IR, MP and optical rotation were not 
recorded at this point as it was intended to carry out this analysis once the title 
compound had been isolated pure. By NMR the product appeared to be present, as 
presented in figures 83 and 85. The NMR data given below was from this impure 
product. Further recrystallisations from the same solvent mix did not improve the 
purity of this product. Further attempts of recrystallisations from other solvents and 
solvent mixes proved fruitless. The product was then washed with dilute hydrochloric 
acid (5.0 mL, 0.1 M) with the aim to form the hydrochloride salt of the product which 
would dissolve in the water and could then be extracted pure with the addition of a 
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mild base. The NMR data for each of the products from this did not contain the target 
product, this was either due to decomposition of the product by the alkali and alkaline 
conditions it was exposed to or because the product was not successfully synthesised. 
As such the MS, IR, MP and optical rotation could not be recorded. Repeat synthesis 
of this product failed to isolate the title compound.  
1H NMR (CDCl3): δ(ppm) 8.06 (4H, s, H1), 7.73 (4H, s, H23), 7.08 (2H, d, J = 7.9 Hz, 
H6), 6.64 (2H, d, J = 7.9 Hz, H5), 5.78 (2H, dt, J = 9.3, 2.5 Hz, H13), 5.49 (2H, dt, J = 
9.3, 1.9 Hz, H14), 5.37 (2H, d, J = 7.0 Hz, H10), 5.24 (2H, dd, J = 7.0, 1.9 Hz, H15), 
3.2-1.5 (22H, m, H’s 12 and 16-20).  
13C NMR (CDCl3): δ(ppm) 163.77 (C21), 162.52 (C3), 147.82 (C9), 132.63 (C2), 
132.46 (C4), 131.65 (C8), 130.23(C22), 128.81 (C1), 128.77 (C23), 128.01 (C13), 
127.42 (C7), 120.85 (C6), 119.12 (C14), 118.61 (C5), 87.15 (C10), 68.09 (C15), 45.71 
(C17), 41.81 (C19), 41.35 (C18), 38.97 (C11), 33.71 (C12), 28.68 (C20), 19.73 (C16).  
 
Synthesis of 3-O-triethylsilyl morphine, compound 396:  
 
Morphine hydrochloride (6.620 g, 20.572 mmol) was dissolved in dry dichloromethane 
(62.0 mL) under nitrogen at room temperature. Triethylamine (3.0 mL) was added. 
TES triflate (4.65 mL, 20.572 mmol) was added to the reaction mixture. This was 
stirred overnight at room temperature. The reaction was quenched by the addition of 
water (20.0 mL) and stirring for 20 minutes. The reaction mixture was filtered and the 
liquid transferred to a separation funnel and was then washed with distilled water (30.0 
mL X6). The organic layer was then dried over MgSO4 and the solvent was removed in 
vacuo. Column chromatography with 20 % methanol in dichloromethane was carried 
out on the product isolated from the organic layer to yield pure target product (45 %, 
3.70 g, 9.26 mmol) as a pale yellow liquid. Morphine (50 %, 2.935 g, 10.29 mmol) was 
also recovered as unreacted starting materials. This indicates a 95 % recovery of the 
starting material. 
As this product was an intermediate its infrared spectrum was not recorded.  
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1H NMR (CDCl3): δ(ppm) 6.50 (1H, d, J = 8.0 Hz, H4), 6.40 (1H, d, J = 8.0 Hz, H5), 
5.58 (1H, d quintet, J = 9.9, 2.6 Hz, H12), 5.20 (1H, dt, J = 9.9, 3.1 Hz, H13), 4.77 
(1H, d, J = 1.2 Hz, H9), 4.09 (1H, dt, J = 2.6, 1.2 Hz, H14), 3.29 (1H, q, J = 3.1 Hz, 
H16), 2.94 (1H, d, J = 18.4 Hz, H19), 2.60 (1H, t, J = 3.1 Hz, H17), 2.53 (1H, dd, J = 
12.2, 5.1 Hz, H11), 3.36 (3H, s, H18), 2.37-2.31 (1H, m, H19), 2.23 (1H, dd, J = 18.4, 
3.1 Hz, H16), 2.00 (1H, td, J = 11.6, 5.1 Hz, H20), 1.77  (1H, broad d, J = 11.6 Hz, 
H20), 0.91 (9H, t, J = 7.9 Hz, H1), 0.66 (6H, q, J = 7.9 Hz, H2). 
13C NMR (CDCl3): δ(ppm) 147.32 (C8), 136.14 (C3), 132.33 (C13), 130.12 (C7), 
127.21 (C12), 126.50 (C6) 119.76 (C5), 118.56 (C4), 89.93 (C9), 65.42 (C14), 57.84 
(C17), 45.41 (C19), 41.95 (C18), 41.87 (C10), 39.52 (C11), 32.25 (C20), 19.57 (C16), 
5.57 (C1), 3.96 (C2). 
Calculated exact mass for product: (C23H33NO3Si) 399.2230 
Calculated exact mass for product: (C23H33NO3SiH+) 400.2302 
Found: HRMS (EI, 70 eV) 400.2319 
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Chapter 4 
Metal Picrate Extraction studies with the Synthesised Compounds 
and Metal Templatation reactions 
 
4.1 Introduction: 
This chapter outlines the metal picrate extraction studies carried out on selected 
products synthesized in this project. The aim of this chapter is to establish a general 
view of the binding affinity of the macrocycles and their precursors, to a variety of 
metal cations, indicating which metal cation would bind to the corresponding 
macrocyclic compound. The picrate method is commonly used to determine extracting 
efficiencies of macrocyclic ethers and their precursors by measuring the relative 
distribution of a coloured alkali metal salt (in this case picrate) between water and an 
immiscible organic solvent in the presence of the crown ether.73 If the polyether host is 
a powerful complexing agent, most of the colour will remain in the organic phase, 
whereas a colourless organic phase after extraction, indicates a low binding affinity.  
Attempts to confirm the positive binding results have been made by attempting to force 
the macrocycle to bind to the metal 100 %, by repeating the extraction but using a large 
excess of the metal picrate in the hope of driving the binding to completion. The results 
from this will also determine the stability of the compounds to the extraction 
procedure, as it will be clear in the NMR spectra if the compounds degrade.  
The relationship between the diameter of an alkali cation and the crown ether has been 
noted in earlier literature of crown ethers and this is best referred by Pedersen as the 
“hole-size-rule”.74 The cation diameters of the metals used in this study are shown in 
Table 19.74,75 
 
 
 
 
 
 
 
 
 179 
Group I Group II Group III Group IV 
Metal Diameter 
(Å) 
Metal Diameter 
(Å) 
Metal Diameter 
(Å) 
Metal Diameter 
(Å) 
Li+ 1.36 Mg2+ 1.44 La3+ 2.30 Pb(II) 2.40 
Na+ 1.94 Ca2+ 1.98     
K+ 2.66 Zn2+ 1.48     
Cs+ 3.34 Sr2+ 2.26     
  Cd2+ 1.94     
  Ba2+ 2.68     
Co(II) 1.68   
Cu(II) 1.74 
    
Table 19: Metal Cation diameters 
The results from the binding studies have then been used in macrocyclisation reactions 
using the templatation effect in an attempt to improve the yields of macrocycles 
obtained.  
The results obtained in this investigation will be of use to potential applications of 
sensors, co-catalysts and metal complexation. Although this study did not examine 
these possibilities the work carried out in this chapter will aide the research group in 
the future.  
 
4.2 Results and Discussion: 
4.2.1: Metal Picrate Extraction Tests 
Each of the products successfully isolated as part of this thesis were tested for their 
ability to extract a number of metal picrates. All the metal picrates (sodium, 
magnesium, calcium, zinc, potassium, lithium, barium, caesium, cadmium, cobalt, 
copper, strontium, lead and lanthanum) were synthesised by the same method, the 
example synthetic pathway of Lanthanum picrate is shown in scheme 33.  
 
Scheme 33: Synthetic pathway of Lanthanum picrate 
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This method was agreed to by the head of safety in the department of chemical 
sciences prior to the synthesis being carried out. Under this agreement it was not 
permitted to fully dry the product due to their explosive nature. This meant yields 
could not be calculated. The method for the synthesis was straightforward. A saturated 
solution of picrate was made in DI water at 60 oC with gentle stirring. To this the 
relevant metal carbonate (as a dry powder) was slowly added to the stirring saturated 
picrate solution. As the carbonate was added gaseous carbon dioxide evolved. The 
carbonate was added slowly until the evolution of carbon dioxide ceased. The solution 
was then stirred for a further ten minutes to ensure the reaction had reached 
completion. The stirring bar was removed and the solution was chilled to 0 oC. The 
solution was then gravity filtered and the solid product collected. This synthesis was 
carried out with fourteen metal carbonates: Na2CO3; MgCO3; CaCO3; ZnCO3; K2CO3; 
Li2CO3; BaCO3; Cs2CO3; CdCO3; CoCO3; CuCO3; SrCO3; PbCO3; and La2(CO3)3. 
Before the extractions were carried out a calibration curve was created for each metal 
picrate by making a series of solutions with concentrations over the range 7x10-5 M to 
3.5x10-5 M by dilution from the 7x10-5 M stock solution of the picrate. Each of these 
solutions was made in triplicate and each had its absorbance measured. A calibration 
curve of concentration versus absorbance was drawn up; the coefficient of 
determination (r2 value) for each calibration curve was ≥ 98 %. The calibration curves 
were used to calculate the concentrations of the extracted solutions. This error was 
seen in the blank extraction experiments and therefore results below 2 % extraction 
will be considered as 0 % extraction and will be reported as not successfully 
determined (ND).  
The metal picrate extraction experiments were performed by using host solutions 
(macrocycle or a precursor) in chloroform and guest solutions (picrate) in DI water 
according to the procedure described by Pedersen. To do this a sample of each of the 
metal picrates was thoroughly dried in vacuo (90 oC, 48 h), a solution (7x10-5 M) was 
made up and the extraction tests carried out. Each metal picrate was extracted with 
several of the products. Blank extractions were carried out for each of the picrate 
solutions, extracted with chloroform for comparison to the product solutions. When the 
blank extractions with barium, zinc and calcium picrates were carried out, it was found 
that these products were extracted into chloroform. Therefore the results of the 
extractions of these metal picrates are invalid and are not included in the reported 
results in tables 20 to 40.  
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Binding 
Agent 
Metal 
cation 
% extraction 
Cd2+ ND 
Co2+ ND 
Cu2+ 9.79 
Sr2+ ND 
Pb2+ 4.38 
338 
La3+ 5.32 
Table 20: Results of extractions with 338 
 
 
Binding 
Agent 
Metal 
cation 
% extraction 
Na+ 2.50 
Mg2+ 2.61 
K+ ND 
Li+ 4.76 
Cs+ ND 
Cd2+ 10.35 
Co2+ 7.37 
Cu2+ 50.62 
Sr2+ 3.55 
Pb2+ 8.49 
339 
La3+ 12.66 
Table 21: Results of extractions with 339 
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Binding 
Agent 
Metal 
cation 
% extraction 
Na+ 4.85 
Mg2+ ND 
K+ ND 
Li+ 6.67 
Cs+ 2.64 
Cd2+ 3.40 
Co2+ 3.11 
Cu2+ 66.64 
Sr2+ 26.75 
Pb2+ 21.17 
340 
La3+ 22.47 
Table 22: Results of extractions with 
340 
 
 
Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ ND 
Li+ ND 
Cs+ ND 
Cd2+ 21.17 
Co2+ ND 
Cu2+ 24.76 
Sr2+ ND 
Pb2+ 8.89 
341 
La3+ 12.29 
Table 23: Results of extractions with 
341 
 
O
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Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ ND 
Li+ 17.14 
Cs+ ND 
Cd2+ 9.39 
Co2+ 5.41 
Cu2+ 49.28 
Sr2+ 9.27 
Pb2+ 6.11 
342 
La3+ 13.16 
Table 24: Results of extractions with 
342 
 
 
Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ 2.74 
Li+ 42.86 
Cs+ ND 
Cd2+ ND 
Co2+ ND 
Cu2+ 63.32 
Sr2+ 3.55 
Pb2+ 5.18 
343 
La3+ 10.63 
Table 25: Results of extractions with 
343 
 
 184 
Binding 
Agent 
Metal 
cation 
% extraction 
Na+ 2.24 
Mg2+ 7.47 
K+ 4.37 
Li+ 10.48 
Cs+ ND 
Cd2+ 8.23 
Co2+ 14.03 
Cu2+ 64.19 
Sr2+ 7.39 
Pb2+ 7.03 
344 
La3+ 9.21 
Table 26: Results of extractions with 
344 
 
 
Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ ND 
Li+ 40.00 
Cs+ ND 
Cd2+ 12.09 
Co2+ ND 
Cu2+ 21.26 
Sr2+ 2.38 
Pb2+ 4.91 
346 
La3+ 6.13 
Table 27: Results of extractions with 
346 
 
HO
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Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ 6.72 
K+ 3.59 
Li+ ND 
Cs+ ND 
Cd2+ 13.06 
Co2+ ND 
Cu2+ 48.81 
Sr2+ ND 
Pb2+ 3.99 
351 
La3+ 5.94 
Table 28: Results of extractions with 
351 
 
 
Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ 2.45 
Li+ ND 
Cs+ ND 
Cd2+ ND 
Co2+ ND 
Cu2+ 37.16 
Sr2+ ND 
Pb2+ ND 
352 
La3+ 4.21 
Table 29: Results of extractions with 
352 
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Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ ND 
Li+ ND 
Cs+ ND 
Cd2+ 14.47 
Co2+ ND 
Cu2+ 33.09 
Sr2+ ND 
Pb2+ 4.52 
353 
La3+ 5.57 
Table 30: Results of extractions with 
353 
 
 
Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ ND 
Li+ ND 
Cs+ ND 
Cd2+ ND 
Co2+ ND 
Cu2+ 9.79 
Sr2+ ND 
Pb2+ ND 
354 
La3+ 3.29 
Table 31: Results of extractions with 
354 
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Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ 4.16 
Li+ ND 
Cs+ 2.42 
Cd2+ 17.89 
Co2+ ND 
Cu2+ 29.01 
Sr2+ ND 
Pb2+ 3.72 
357 
La3+ 4.46 
Table 32: Results of extractions with 
357 
 
 
Binding 
Agent 
Metal 
cation 
% extraction 
Na+ 4.59 
Mg2+ 3.36 
K+ 3.57 
Li+ ND 
Cs+ ND 
Cd2+ 12.29 
Co2+ ND 
Cu2+ 38.91 
Sr2+ ND 
Pb2+ 3.85 
358 
La3+ ND 
Table 33: Results of extractions with 
358 
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Binding 
Agent 
Metal 
cation 
% extraction 
Na+ 25.78 
Mg2+ ND 
K+ 13.64 
Li+ ND 
361 
Cs+ 10.43 
Table 34: Results of extractions with 
361 
 
 
Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ 3.11 
Li+ 6.67 
Cs+ ND 
Cd2+ 19.43 
Co2+ ND 
Cu2+ 23.77 
Sr2+ 3.16 
Pb2+ 6.50 
362 
La3+ 5.94 
Table 35: Results of extractions with 
362 
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Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ ND 
Li+ ND 
Cs+ 17.15 
Cd2+ 14.02 
Co2+ ND 
Cu2+ ND 
Sr2+ 2.69 
Pb2+ 9.29 
368 
La3+ 11.68 
Table 36: Results of extractions with 
368 
 
Binding 
Agent 
Metal 
cation 
% extraction 
Na+ 11.79 
Mg2+ 2.61 
K+ 8.58 
Li+ 2.86 
Cs+ 26.07 
Cd2+ 7.84 
Co2+ ND 
Cu2+ ND 
Sr2+ 8.41 
Pb2+ 18.03 
369 
La3+ 14.27 
Table 37: Results of extractions with 
369 
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Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ 17.54 
Li+ 4.76 
370 
Cs+ 20.63 
Table 38: Results of extractions with 
370 
 
Binding 
Agent 
Metal 
cation 
% extraction 
Na+ ND 
Mg2+ ND 
K+ 12.32 
Li+ ND 
Cs+ 8.46 
Cd2+ 12.87 
Co2+ ND 
Cu2+ ND 
Sr2+ ND 
Pb2+ ND 
371 
La3+ 3.47 
Table 39: Results of extractions with 
371 
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Binding 
Agent 
Metal 
cation 
% extraction 
Cd2+ ND 
Co2+ ND 
Cu2+ ND 
Sr2+ 5.90 
Pb2+ 5.97 
372 
La3+ 10.01 
Table 40: Results of extractions with 
372 
 
Pedersen reported extraction values for crown ethers with various ring sizes and 
incorporating both cyclohexyl and benzene rings. The general conclusion according to 
the Table 41 is that crown ethers with benzene rings are more rigid and less flexible 
than their cyclohexyl analogues; therefore macrocycles with the same cavity size but 
with carbocyclic rings would extract the same metal picrate with different efficacies. 
 
Picrate Extracted 
Crown Ether 
Li+ Na+ K+ Cs+ 
Dicyclohexyl-14-crown-4  1.1 0 0 0 
Cyclohexyl-15-crown-5  1.6 19.7 8.7 4.0 
Dibenzo-18-crown-6  0 1.6 25.2 5.8 
Dicyclohexyl-18-crown-6  3.3 25.6 77.8 44.2 
Dicyclohexyl-21-crown-7  3.1 22.6 51.3 49.7 
Dicyclohexyl-24-crown-8  2.9 8.9 20.1 18.1 
Table 41: Extraction results, two-phase liquid extraction: dichloromethane and water 
The macrocycles and their precursors reported in this thesis contain two or more 
aromatic rings or rigid morphine units. Therefore minimal flexibility and minimal 
conformational change is expected on binding to the metal cation; making binding 
more entropically favourable. Additionally, they contain carbonyl groups which are not 
present in the crown ethers Pederson tested, the presence of these groups can change 
the electron density within the ring and as such effect the metal binding ability.  
 192 
Among the compounds tested two macrocycles and four open structures, compounds 
358, 361, 339, 340, 344 and 369, showed significant extraction values for sodium 
picrate. The two macrocycles 358 and 361 are 25 membered rings, with 6 oxygen 
atoms in the ring, 4 carbonyl groups and 4 aromatic groups on the ring, also 361 has a 
nitrogen atom. Pedersen’s crown ethers dibenzo-18-crown-6 and dicyclohexyl-18-
crown-6 exhibit higher affinity towards K+ over Na+. The same trend was observed for 
macrocycles with bigger cavities, dicyclohexyl-21-crown-7 and dicyclohexyl-24-
crown-8, whereas binding studies performed for this project showed the opposite for 
macrocycle 361 with a higher affinity for Na+ and the results for 358 are within error of 
each other. The results for the open structures will be compared to corresponding 
macrocycles later in this chapter for the possibility of utilisation of the metal 
carbonates as templates for the macrocyclisation reaction.  
There are six macrocycles, 351, 352, 357, 358, 361 and 362, and five precursors, 343, 
344, 369, 370 and 371, that successfully extracted potassium picrate from the aqueous 
solution. 370, bis(3-morphinyl)phthalate, extracted the highest percentage of potassium 
picrate from the aqueous layer. Of the macrocycles that extracted potassium picrate the 
most active was compound 361, which also extracted a higher percentage of sodium 
and zinc, than of potassium, and successfully extracted barium, calcium and caesium to 
approximately the same extent as it extracted potassium. None of the macrocycles that 
extracted the potassium exhibited signs of selectivity for potassium, each showed 
higher extraction values for other metal picrates. 
Lithium picrate was only extracted by one macrocycle, 362, but this macrocycle also 
extracted several other metal picrates including zinc and barium, both of which it 
extracted more strongly. It was also extracted by eight precursors, compounds 339, 
340, 342, 343, 344, 346, 369 and 370 to varying degrees. Of the nine compounds that 
extracted lithium picrate compounds 343 and 346 extracted it most effectively, both 
compounds within error of each other, at 42.86 % and 40.00 % respectively. 
357 and 361 are the only two macrocycles that successfully extracted caesium picrate; 
it was also extracted by the precursors 340, 368, 369, 370 and 371. Both macrocycles 
that extracted caesium picrate also extracted other metal picrates at equal or higher 
percentage extraction. Of the seven compounds that extracted caesium picrate, 369 
extracted it most effectively with a result of 26.07 % extraction. 369 extracted other 
picrates but of the metals tested it extracted caesium most strongly.  
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Magnesium picrate was extracted by two macrocycles, 351 and 358, and by three 
precursors, 339, 344 and 369. It was most strongly extracted by 344, with 7.47 % 
extraction recorded, although this is within error of the extraction recorded for 
macrocycle 351 which was shown to have an extraction value of 6.72. Both of these 
compounds extracted other metal picrates more effectively with larger extraction 
values being recorded for calcium and barium picrates by both compounds.  
Cadmium picrate was successfully extracted by fourteen compounds, nine precursors 
(339, 340, 341, 342, 344, 368, 369, and 371) and five macrocycles (346, 351, 353, 357, 
358 and 362). The extraction values with each of the compounds were almost all 
between 10 % and 20 %, with the highest value being 21.17 % and the lowest being 
3.40 %. Although it was successfully extracted by many of the compounds tested it 
was not the most strongly extracted metal picrate by any of these compounds.  
Cobalt picrate was not extracted by any of the macrocycles that were tested for its 
extraction, although it was extracted with four macrocycle precursors, (339, 340, 342 
and 344). 344 was the only compound to extract the cobalt picrate by more than 10 % 
with a percentage extraction of 14.03 % being recorded, although this same compound 
did extract other metal picrates more effectively. Similarly each of the other 
compounds that extracted this metal picrate extracted other metal picrates more 
strongly.  
Fifteen compounds tested successfully extracted copper(II) picrate to varying degrees. 
Of these fifteen compounds eight were precursors (338, 339, 340, 341, 342, 343, 344 
and 346) and six were macrocycles (351, 352, 353, 354, 357, 358 and 362). Each of 
these compounds also extracted other metal picrates. Although 352 did not extract the 
copper(II) picrate most effectively, giving a value of 37.17 % compared to 66.64% for 
340, it only extracted two other metal picrates, potassium picrate (2.45 %) and 
lanthanum picrate (4.21 %), from the aqueous solution. This shows that 352 has a 
strong degree of preferential binding to copper(II) over each of the other metals tested, 
although in mixed solution testing it may differ. The binding of 352 to the copper(II) 
picrate is of interest because copper(II) has been shown to be useful as a catalyst.76 
Although other products synthesised were found to extract copper(II) picrate to a 
higher degree, 352 was the product which extracted copper(II) most preferentially over 
the other metal picrates, with almost tenfold more copper(II) picrate being extracted 
over the other metal picrates. This could be advantageous in the isolation of the 
catalyst at the end of the catalysed reaction and also in increasing the amount of 
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copper(II) in the organic solution, as copper(II) will not be very soluble in organic 
media but will be more soluble in the organic media if in a host-guest complex.  
Strontium picrate was extracted by 339, 340, 342, 343, 344, 346, 362, 368, 369 and 
372. Only one of these, 362, is a macrocycle, the rest being precursors. Of these 
compounds all but one extracted less than 10 %, with 340 being the only compound 
that extracted more, extracting 26.75 %, although 340 did not appear to be selective for 
strontium as it extracted a higher percentage of copper. 
Sixteen compounds, 338, 339, 340, 341, 342, 343, 344, 346, 351, 353, 357, 358, 362, 
368, 369 and 372, extracted lead picrate to differing extents, with 340 extracting the 
highest percentage of it at 27.17 %. The only other compound to extract lead picrate by 
more than 10 % was 369. None of the compounds, either the macrocycles (351, 353, 
357, 358 and 362) or the precursors (338, 339, 340, 341, 342, 343, 344, 346, 368, 369 
and 372) showed selectivity for lead picrate, each one showing either higher or similar 
extraction of other metal picrates.  
There were nineteen compounds that extracted lanthanum picrate, six macrocycles 
(compounds 351, 352, 353, 354, 357 and 362) and thirteen precursors (338, 339, 340, 
341, 342, 343, 344, 346, 368, 369, 371 and 372). Of these, 340 extracted the highest 
percentage (22.47 %) but as before this compound also successfully extracted other 
metal picrates to a similar or better extent. None of the nineteen compounds showed 
selectivity of lanthanum picrate, they each extracted other metal picrates to a higher or 
similar extent.  
 
4.2.2: Metal Picrate Extraction with NMR Tests 
Seven of the compounds, two macrocycles and five precursors, had their best results, 
from section 4.2.1, repeated with a variation on the above method in an attempt to 
obtain an NMR of the host-guest species. Also a selection of the negative results, at 
least one negative result for each compound, had the same test run on them to ensure 
the compounds were not degrading when subjected to the test conditions. In an effort 
to promote binding of the metal picrate to the macrocycle or precursor to its maximum 
level a saturated solution of the metal picrate in water was used in the extraction. Also 
the concentration of the extracting compound was increased to 15 mM so that there 
was enough of the compound in each extraction to obtain a good quality NMR 
spectrum.  
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Extractions were carried out as before, 6 mL of picrate solution shaken with 6 mL of 
macrocycle/precursor solution. All mixtures were shaken on an automatic shaker for 
ten minutes at 600 oscillations per minute. The mixtures were allowed to settle for ten 
minutes and then separated. Previously the aqueous layer had its absorbance recorded 
and the data used to calculate the percent extraction, by this method the organic layer 
was removed and the solvent evaporated in vacuo. The solid was then dissolved in 
deuterated chloroform and its NMR spectrum recorded, as it was the aim of this section 
to prove extraction was taking place by recoding an NMR of as many of the host-guest 
species as possible and not to recalculate the percentage binding. The NMR spectrum 
of each of the host molecules (being tested by this method) was recorded in deuterated 
chloroform on the same day for comparison. 
Each of the recorded spectra of the product/metal picrate mixes in which no extraction 
was recorded (tables 20 to 40) showed no degradation of the products; with each 
spectrum after attempted extraction of the metal picrate matching that of the 
macrocycle or precursor prior to attempted extraction.  
338 had the test carried out with cadmium, strontium and copper. No difference was 
observed in the NMR spectra from the cadmium and strontium extractions, this was the 
expected result. For the extraction of copper(II) picrate using this compound there was 
a change in the NMR. This change in chemical shift varies depending on the peak 
being looked at with some increasing and others decreasing by varying degrees. This 
degree and direction of change can be caused by both the change in electro-negativity 
of the atoms (by attraction of electron density by the copper(II) cation) and also by 
conformational changes as shown by Lee et al.77 In table 42 below the differences for 
each of the peaks in the proton and carbon NMR spectra between compound 338 and 
compound 338 after extraction with copper(II) picrate are listed. Figures 100 and 101 
show the proton and carbon NMR spectra respectively, of the host-guest complex. 
Figure 100a and 101a show the proton and carbon NMR spectra respectively, of the 
free host 338, for visual comparison. 
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Atom  
Number 
338 1H 
NMR 
 
338 1H NMR 
After 
Copper(II) 
Extraction  
Difference 
(ppm) 
338 13C 
NMR 
 
338 13C 
NMR After 
Copper(II) 
Extraction 
Difference 
1 7.630 7.636 +0.006 131.88 131.87 -0.01 
2 7.969 7.9703 +0.004 129.73 129.76 +0.03 
3    131.57 131.61 +0.04 
4    165.46 165.43 -0.03 
5    139.65 139.60 -0.05 
6 7.160 7.164 +0.004 121.11 121.13 +0.02 
7 6.903 6.907 +0.004 122.75 122.74 -0.01 
8 7.095 7.093 -0.002 127.37 127.39 +0.02 
9 6.950 6.954 +0.004 113.60 113.55 -0.05 
10    150.40 150.38 -0.02 
11 4.037 4.039 +0.002 70.36 70.38 +0.02 
12 3.715 3.709 -0.006 61.05 61.03 -0.02 
Table 42: Differences in carbon and proton NMR spectra of 338 and 338-Cu host-
guest complex. 
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Figure 100: Proton NMR of the host-guest complex 338 and Cu(II). 
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Figure 100a: Proton NMR of the free host 338. 
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Figure 101: Carbon NMR of the host-guest complex 338 and Cu(II). 
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Figure 101a: Carbon NMR of the free host, 338. 
The differences in the NMR spectra, both proton and carbon, between 338 (host) and 
338 with copper(II) (host-guest complex) being relatively small, so it was decided to 
test the variation that can occur within the NMR of 338. This was carried out by 
repeating the NMR of this compound, made up originally at 90 mM, in triplicate and 
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also making up three solutions, with varying concentration, for NMR and repeating the 
recording of these NMR spectra in triplicate also. The concentrations used were 20 
mM, 40 mM and 60 mM, and each spectrum was recorded in triplicate. The maximum 
variation at any one peak was ±0.001 ppm in proton NMR (when zero was properly set 
with TMS) and ±0.01 ppm in the carbon NMR (zero also set with TMS). This 
procedure with varying concentrations and triplicate recording of each spectrum was 
carried out on each of the products tested by NMR.  
The method carried out in this investigation, was not used to calculate the binding 
constants or percentage extraction, but instead to try to force the formation as much as 
possible of the host-guest complex and then to obtain an NMR of this complex 
showing it was different from the host in solution by itself. The differences in both 
proton and carbon NMR spectra is significant, being both larger than the difference in 
the repeated NMR spectra of 338 and also varying in magnitude and direction. If all 
differences were equal in magnitude and direction it would suggest that there is no 
significant difference as it would appear as all differences are due to incorrect zeroing 
of the TMS peak. It can be clearly seen from the data that the NMR spectrum of the 
host-guest complex of 338-Cu2+ picrate has been recorded. The atoms showing the 
greatest change are expected to be those closest to the position of the bound metal, as 
the metal cation attracts electron density towards itself and away from the atoms of the 
macrocycle thus shifting these atoms downfield. The largest shift downfield is seen in 
hydrogens 1, 2, 6, 7 and 9 and in carbons 2, 3, 6 and 8 suggesting that the metal has 
bound to the aromatic rings withdrawing electron density from these regions.  
The proton NMR of compound 341 compared to that of 341-copper(II) picrate host-
guest complex is significantly different before the location of the peaks is taken into 
account, as seen in figures 102 and 103.  
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Figure 102: 1H NMR of the host 341. 
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Figure 103: 1H NMR of the host-guest complex, 341 and Cu(II). 
As can be seen in the inset of these two figures, the region of the spectrum representing 
the aromatic protons (H’s 6 to 9), between 6.71 ppm and 6.87 ppm, is completely 
different in shape, with the doublet circa 6.8 ppm showing greater intensity in the host-
guest complex compared to the same doublet in the NMR of compound 341 by itself. 
This alone shows a significant difference between the two NMR spectra, but there is 
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also a difference of +0.031 ppm for the peak representing H11. When these two factors 
have been taken into account it is clear that the host-guest species of 341-copper(II) 
has been formed and an NMR has clearly been recorded of it.  The largest shift 
downfield is seen in hydrogen 11 suggesting that the metal has bound to the oxygen 
atom between C11 and C10. There are also changes in the phenyl rings and the 
pyridine ring, suggesting binding in these locations (to the aromatic rings themselves 
or to the hetero-atoms in and surrounding these rings). 341 also had this test carried out 
using sodium, magnesium, caesium and strontium picrates, each showing no 
significant difference from 341 after extraction, indicating no host guest complex was 
formed and also no decomposition of 341 took place. 
343 was also subjected to these extraction tests with lanthanum, lithium, cobalt, 
caesium and sodium. As expected only lanthanum and lithium showed any difference 
by NMR after extraction. Unlike the 341-copper(II) host-guest complex there is no 
obvious visual difference between the host and host-guest complexes but there are 
slight differences in chemical shift. Table 43 lists the differences in the proton NMR 
spectra between 343 and 343 host-guest species with both lithium and lanthanum 
picrates. 
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Atom  
Number 
343 1H 
 
343 1H NMR 
After 
Lithium 
Extraction  
Difference 
from 343 
343 1H NMR 
After 
Lanthanum 
Extraction 
Difference 
from 343 
1 1.709 1.707 -0.002 1.707 -0.002 
5 7.150 7.147 -0.003 7.148 -0.002 
6 6.923-
6.882 
6.921-6.879 -0.0025 6.920-6.879 -0.003 
7 7.024 7.021 -0.003 7.020 -0.004 
8 6.923-
6.882 
6.921-6.879 -0.0025 6.920-6.879 -0.003 
10 4.041 4.033 -0.008 4.033 -0.008 
11 3.715 3.701 -0.014 3.701 -0.014 
Table 43: Differences in proton NMR spectra of 343 and 343 host-guest complexes. 
From the table above it can be seen that the difference in NMR between each of the 
host-guest species and compound 343 is approximately the same. Again in this case 
compound 343 had its proton NMR spectrum recorded in triplicate and also at varying 
concentrations, as with compound 338. In this case there was more of a difference 
observed between the spectra at the same concentration, a maximum difference of 
0.002 ppm seen between the NMR spectra of 338 at the same concentration. When the 
concentration was varied this difference was not exceeded. So although lanthanum and 
lithium are significantly different metals, (lanthanum is a lanthanoid and lithium is a 
group one metal) they appear to have the same effect on compound 343 when in a 
host-guest species, indicating that the binding interactions are occurring in both the 
same locations and to a similar strength. Figures 104 and 105 show the NMR spectra 
of the 343-lithium picrate host-guest complex and the NMR of 343 for visual 
comparison.  
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Figures 104: NMR of the 343-lithium picrate host-guest complex 
2.02.53.03.54.04.55.05.56.06.57.0 ppm
1.
70
9
3.
70
5
3.
71
5
3.
72
6
4.
03
0
4.
04
1
4.
05
1
6.
88
2
6.
88
5
6.
90
4
6.
92
3
7.
01
2
7.
01
6
7.
03
2
7.
03
5
7.
13
0
6.
00
3.
91
4.
00
4.
00
1.
90
2.
12
3.73.83.94.04.1 ppm6.957.007.057.107.15 ppm
 
Figures 105: NMR of 343 
351 was successfully isolated in host-guest complexes with copper(II) and cadmium 
picrates. It was also tested with lithium, sodium, cobalt and strontium picrates, to 
ensure that the product did not degrade under the test conditions. As was expected, 
each of these did not show any host-guest complex by NMR and also no degradation of 
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351 was observed. Table 44 below shows the difference in the NMR spectra between 
compound 351 and its host-guest species with both cadmium and copper.  
Atom  
Number 
351 1H 
 
351 1H NMR 
After 
Cadmium  
Difference 
from 351 
351 1H NMR 
After 
Copper(II)  
Difference 
from 351 
1 7.17-
7.21 
7.17-7.21 0 7.17-7.21 0 
2 8.159 8.151 -0.008 8.151 -0.008 
4 8.375 8.385 +0.010 8.386 +0.011 
7 7.351 7.342 -0.009 7.343 -0.008 
8 6.97 6.97 0 6.97 0 
9 7.050 7.048 -0.002 7.048 -0.002 
10 6.97 6.97 0 6.97 0 
12 4.305 4.304 -0.001 4.304 -0.001 
13 4.623 4.617 -0.006 4.617 -0.006 
16 8.022 8.018 -0.004 8.012 -0.010 
17 7.17-
7.21 
7.17-7.21 0 7.17-7.21 0 
18 8.067 8.060 -0.007 8.062 -0.005 
Table 44: Differences in 1H NMR spectra of 351 and 351 host-guest complexes. 
 
There are no obvious visual differences between the NMR spectra of 351 and its host-
guest complexes, as seen in figures 106 to 108. The differences in chemical shift are 
significant with individual peaks varying as much as ±0.01 ppm, whereas these peaks 
varied by only ±0.002 ppm when carrying out the NMR of 351 at varying 
concentrations in triplicate. The degree of change to the chemical shift of any 
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individual peak is indicative of the level that the guest cation affects the host in that 
area of the molecule thus indicating where the guest is binding in the host molecule.  
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Figure 106: Proton NMR of 351 
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Figure 107: Proton NMR of 351-Cadmium(II) host-guest complex 
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Figure 108: Proton NMR of 351-Copper(II) host-guest complex 
The NMR spectra of the host-guest complexes of 351 with copper(II) and cadmium are 
similar, thus indicating that these two metals bind to 351 in a similar manner when 
forming the host-guest complex. Although there are significant differences on some 
peaks suggesting that although the effect is similar it is not as close as is seen on the 
host-guest species of 343. The biggest shift downfield was for H4 in both host guest 
complexes, suggesting the cationic guest has bound to the upper half of the macrocycle 
located in a position so as to extract most electron density from H4. 
362 was successfully isolated in host-guest complexes with copper(II) and 
cadmium(II) picrates. It was also tested with caesium, cobalt, magnesium and sodium 
picrates; in each of these cases no change in the NMR was observed indicating that 
there was no host-guest complex formed and no degradation of the macrocycle by this 
extraction technique. For the host-guest species of 362 with copper(II)and cadmium 
there was a visual difference between the NMR spectra of the macrocycle and that of 
the host-guest complexes, as seen in figures 109 to 111. The visual difference is most 
notable in the region of the spectra between 7.9 ppm and 8.1 ppm. Here it can be 
clearly seen that in both host-guest species the triplet and doublet are closer together 
than in the spectrum for 362.  The spectrum of 362 here is different to that reported in 
chapter two as it is recorded in deuterated chloroform, in chapter two it was recorded 
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in deuterated acetonitrile, because in chloroform a solution of high enough 
concentration could not be made to record a carbon spectrum.  
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Figure 109: Proton NMR of 362 
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Figure 110: Proton NMR of 362-Cadmium host-guest complex 
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Figure 111: Proton NMR of 362-Copper(II) host-guest complex 
Beyond the clear visual difference between the spectra there are less obvious 
differences in chemical shift in the spectra which are detailed in table 45 below.  
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Atom  Number 362 1H 
 
362 1H After 
Cadmium  
Difference 
from 351 
362 1H After 
Copper(II)  
Difference 
from 362 
1 7.991 8.014 0.023 8.010 0.019 
2 8.280 8.272 
-0.008 8.274 -0.006 
6 7.167-7.210 7.175-7.219 0.008 7.175-7.218 0.008 
7 6.929-6.967 6.929-6.968 0 6.929-6.968 0 
8 7.092 7.077 -0.015 7.081 -0.011 
9 6.929-6.967 6.929-6.968 0 6.929-6.968 0 
11 4.306 4.314 0.008 4.313 0.007 
12 4.706 4.721 0.015 4.719 0.013 
15 8.053 8.041 -0.012 8.044 -0.009 
16 7.850 7.859 0.009 7.858 0.008 
Table 45: Differences in proton NMR spectra of 362 and 362 host-guest complexes. 
As can be seen both visually in figures 109 to 111 and from the data in table 45 the 
host-guest complexes of macrocycle 362 with both copper(II) and cadmium have been 
successfully identified. Each host-guest species is significantly different from 362 as a 
free macrocycle and they are also different from each other. The difference between 
each other is less apparent than the difference from the free macrocycle but it can be 
seen both visually when looking at the peaks from H1 and H16 and also in the data 
from these peaks. These two peaks are closest in the 362-cadmium host guest species, 
a little further apart in the 362-copper(II) host guest species and further apart again in 
the free macrocycle. The greatest shifts downfield are for hydrogens 1 and 12 and then 
6, 9 and 11 in the host guest complex, this suggests that the cationic guest species are 
extracting electron density from areas that affect these hydrogens most strongly within 
the macrocycle, thus binding in these areas. This suggests that these metal cations are 
binding throughout the entire macrocycle rather than just in one area, extracting 
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electron density from both pyridine rings and each of the oxygens. Copper(II) and 
cadmium(II) are in the same oxidation state and have similar diameters (see table 19) 
so they may have the correct charge and size for efficient binding to 362. Although 
cobalt(II) is only slightly smaller than copper(II), it did not show any detectable levels 
of extraction (table 35) which suggests that it may be too small for effective binding to 
362.  
This testing was carried out with 368 in conjunction with copper, magnesium, caesium, 
potassium and sodium picrates. The host-guest complex of 368 with caesium has been 
isolated by this method; each of the other metal picrates failed to give the host-guest 
complex, as expected, and also did not degrade 368. 
The NMR spectra of the host-guest complex and that of 368 are significantly different, 
both proton and carbon. The difference in both the proton and carbon NMR spectra 
cannot be seen easily by visual inspection of the spectra, mainly because the NMR 
spectra are complicated with numerous peaks close together, as seen in figures 112 to 
115. The differences are highlighted in table 46. In the carbon NMR there appears to 
be a peak missing in the aromatic region of the spectrum, there are also peaks at 30.95 
ppm and at 207.07 ppm. The two peaks at 30.95 ppm and at 207.07 ppm correspond to 
acetone, which must have been residual in the NMR tube as there was no acetone used 
in this procedure. It appears that the peak at 130.52 ppm in the carbon NMR of the 
368-caesium host-guest complex appears to have a very high intensity and is thought to 
be the amalgamation of two peaks from compound 368, those peaks being for C1 and 
C7, which would indicate a significant change in C7 and a less significant change in 
C1. There is a strong change downfield in the position of C2 which is in the same 
subunit as C1. There are also many other significant changes in the chemical shifts 
throughout the spectra which implies that there is strong binding of caesium across the 
entire molecule of 368. 
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Atom  
Number 
368 1H 
 
368-
Caesium 
1H  
Difference 368 
13C  
368-
Caesium 
13C 
Difference 
 
1 8.223 8.242 +0.019 130.50 130.52 +0.02 
2   
 134.20 134.48 +0.28 
3 
   163.22 163.23 +0.01 
4 
   133.39 133.41 +0.02 
5 6.811 6.834 +0.023 120.09 120.15 +0.06 
6 6.595 6.526 -0.069 121.07 121.30 +0.23 
7 
   131.68 130.52 -1.16 
8 
   132.56 131.87 -0.69 
9 
   148.73 148.78 +0.05 
10 4.876 4.908 +0.032 58.87 59.10 +0.23 
11 
   42.69 42.53 -0.16 
12 2.543 2.768 +0.225 40.45 40.03 -0.42 
13 5.732 5.768 +0.036 127.87 127.39 -0.48 
14 5.247 5.261 +0.014 133.29 132.35 +0.06 
15 4.119 4.136 +0.017 92.53 92.40 -0.13 
17 3.307, 
2.290 
3.452, 
2.404 
+0.145, 
+0.114 20.77 21.00 +0.23 
18 2.643 2.705 +0.062 65.86 65.74 -0.12 
19 2.358 2.474 +0.116 43.13 42.91 -0.22 
20 3.015, 
2.290 
3.051, 
2.404 
+0.036, 
+0.114 46.39 46.51 +0.12 
21 2.013, 
1.848 
2.126, 
1.906 
+0.113, 
+0.058 35.24 34.86 -0.38 
Table 46: Differences in NMR spectra of 368 and 368-caesium host-guest complex. 
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Figure 112: Proton NMR of 368 
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Figure 113: Proton NMR of 368-Caesium host-guest complex 
 
 213 
30405060708090100110120130140150160 ppm
20
.
7
7
35
.
24
40
.
45
42
.
69
43
.
13
46
.
06
46
.
39
58
.
87
65
.
86
77
.
33
92
.
53
12
0.
09
12
1.
07
12
7.
87
13
0.
50
13
1.
68
13
2.
56
13
3.
29
13
3.
39
13
4.
20
14
8.
73
16
3.
22
131132133134 ppm 39404142434445464748 ppm
 
Figure 114: Carbon NMR of 368 
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Figure 115: Carbon NMR of 368-Caesium host-guest complex 
As with each of the other examples of the host-guest complexes the NMR of the host, 
368, was recorded in triplicate and at different concentrations in order to ascertain the 
degree of variation of the NMR spectrum of 368. Similarly the variation on the proton 
NMR spectrum was ±0.002 ppm and 0.01 in the carbon spectrum. The NMR spectra, 
both carbon and proton, of the host-guest complex was shown to be significantly 
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different from that of 368, with differences as large as +0.28 ppm to -1.16 ppm in the 
carbon spectra and +0.116 ppm to -0.069 ppm in the proton spectra.  
This testing was carried out on 369 in conjunction with cobalt, copper, lead and 
lanthanum picrates. Both lead and lanthanum picrates caused changes to the spectrum 
of 369 after the extraction, indicating the successful binding of the cation to compound 
369. Cobalt and copper(II) picrates had no effect on the spectrum of 369 after the 
extraction indicating that not only was there no binding but also that 369 is stable to 
the extraction procedure.  
The NMR spectra of each of the host-guest species not only differed from that of 369 
but also from each other, as seen from table 47 and figures 116 to 118. This alludes to 
a differing interaction between each of these metals and 369; the reasoning for this 
could be due to a number of factors, including the different nature of the metal cations, 
the location of binding of the metal to the host (possible binding to the nitrogen atoms, 
oxygen atoms, aromatic rings, or any combination of all three) and also the host to 
guest ratio. As with the host molecules in each of the previous host-guest species in 
this section the NMR of the host was recorded in triplicate and at different 
concentrations, and again the differences seen in the host-guest complexes far exceed 
those seen in the free host. As can be seen in table 47 the 369-lanthanum complex is 
significantly different to unbound 369, with the differences varying in both direction 
and magnitude. Also the 369-lead complex is significantly different to metal free 369, 
with one peak showing a chemical shift change in an upfield direction compared to the 
rest shifting downfield. Although the changes in the NMR spectrum of the 369-
lanthanum complex are varied they are not obvious on inspection of the NMR, figure 
117, whereas there is a marked difference in the spectrum of the 369-lead complex as 
seen in figure 118. The NMR spectrum of the 369-lead complex shows a significant 
broadening of peaks in the region of 2 to 3 ppm. The cause for this is not clear. From 
the clarity of the spectrum across the region of 4.5 to 9 ppm it is indicated that it was 
not the product degrading as multiple extra peaks would have appeared across the 
region nor was it not a problem with the NMR spectrometer. In the 1H-NMR spectrum 
of the 369-Lanthanum host guest complex the change in chemical shift of the 
hydrogens on the isophthaloyl subunit (H’s 1, 2 and 3) are less significant than the 
change in chemical shift for the morphine units, suggesting that the lanthanum interacts 
more strongly with the morphine units and more specifically the B and D rings (figure 
81, chapter 3) as the hydrogens on these rings show the biggest difference in chemical 
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shift. With the 369-lead host guest complex the difference in the hydrogens of the 
isophthaloyl subunit appear to have changed more, but with this complex the 
broadening of the peaks in the spectrum makes it more difficult to infer where the 
strongest interactions are taking place. 
 
Atom  
Number 
369 1H 
 
369-
Lanthanum 1H  
Difference 369-Lead 1H Difference 
 
1 8.934 8.928 -0.006 8.928 -0.006 
2 7.595 7.598 +0.003 7.605 +0.010 
3 8.377 8.378 +0.001 8.382 +0.005 
7 6.836 6.835 -0.001 6.856 +0.020 
8 6.617 6.620 +0.003 6.640 +0.023 
12 4.883 4.884 +0.001 4.914 +0.031 
14 2.689 2.702 +0.013 Peak to broad to determine 
15 5.759 5.762 +0.003 5.790 +0.031 
16 5.249 5.253 +0.003 5.252 +0.003 
17 4.134 4.128 -0.006 4.142 +0.008 
19 
3.427, 
2.43-
2.34 
3.452, 2.45-
2.36 
+0.025, 
+0.02 
3.575, second  
peak to broad to 
determine 
+0.148 
20 2.790 2.765 -0.025 Peak to broad to determine 
21 2.462 2.476 +0.014 2.558 +0.096 
22 
3.043, 
2.43-
2.34 
3.048, 2.45-
2.36 
+0.005, 
+0.02 
3.070, second  
peak to broad to 
determine 
+0.027 
23 2.125, 1.895 2.125, 1.905 
0.000, 
+0.010 
First  peak to 
broad to 
determine, 1.953 
+0.058 
Table 47: Differences in 1H NMR spectra of 369 and 369 host-guest complexes 
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Figure 116: 1H NMR of 369 
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Figure 117: 1H NMR of 369-Lanthanum host-guest complex 
 
 217 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5 ppm
5.56.06.57.07.58.08.5 ppm
5.
23
3
5.
24
0
5.
24
6
5.
25
8
5.
26
3
5.
27
1
5.
7
78
5.
80
3
6.
63
0
6.
65
1
6.
84
6
6.
86
7
7
.
58
5
7
.
60
5
7.
62
5
8.
37
0
8.
37
5
8.
39
0
8.
39
4
8.
84
9
8.
92
8
1.
98
8
2.
00
0
1.
95
8
1.
99
5
2.
00
0
0.
83
1
1.
87
0
1.
19
1
0.
89
9
3.03.23.43.63.84.04.2 ppm
2.
86
5
3.
04
6
3.
09
4
3.
57
5
4.
13
2
4.
13
6
4.
14
8
4.
15
4
2.
12
4
1.
70
1
2.
07
4
2.02.22.42.62.8 ppm
2.
55
8
2.
86
5
2.
14
7
1.
97
5
9.
89
6
3.
78
7
Figure 118: Proton NMR of 369-Lead host-guest complex 
This testing has clearly shown, with seven examples that the products are stable to the 
extraction tests carried out here and in the previous testing, section 4.2.1 page 179. 
Also demonstrated herein is the ability of the products of this project to extract metal 
picrates from the aqueous phase into chloroform solution by binding to them, which in 
turn stabilises the metal cations in organic media.  
 
4.2.3: Metal Templatation reactions 
From the results obtained earlier in this chapter it was decided to attempt to synthesise 
the macrocycles using metal templatation reactions. Each macrocyclisation was 
attempted four times with the selected metal carbonate; in the presence of and absence 
of triethylamine as the active base and each of these (with and without triethylamine) 
both at room temperature and in refluxing dichloromethane. The goal of the 
templatation reactions was to increase the yield of the macrocycle by using a metal 
template in the cyclisation step which should hold the acyclic structure in a 
conformation in which the cyclisation step occurs more readily than without the metal 
template. Another viable option is to use a metal that will not bind to the acyclic 
structure but instead only to the macrocycle and if a large excess of this metal is 
present it may force the equilibrium towards the formation of the host-guest complex 
and hence of the macrocycle. The ideal metal template will bind to the open structure 
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but when the macrocycle has formed it will no longer bind giving the free macrocycle 
as the product rather than the host guest complex. With this ideology in mind the first 
series of macrocyclisation reactions to be attempted using a metal template will use 
metals which showed extraction to the open structures, in section 4.2.1, but not to the 
corresponding macrocycles. For the purposes of this study a value of 10 % extraction 
was deemed acceptable as low enough extraction to be classified as not extracting, i.e. 
if the macrocycles (or their precursors) did not extract the metal picrate by more than 
10 % it was deemed non-extracting (or non-binding) for the purposes of this set of 
experiments and classified in the corresponding series. The next series contained 
metals which were extracted both to the open structure and to the macrocycle and the 
final series contained metals which were extracted to the macrocycles but not by the 
open structures. The structures of the macrocycles being synthesised by the metal 
templatation method are shown in figure 119 below.  
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Figure 119: The macrocycles being synthesised by the metal templatation method 
The combinations of macrocycle-metal attempted in each series are detailed in table 
48. 
 
 
 
 
 
 
 
 220 
Macrocycle being 
synthesised 
Metal Carbonate 
used in Series 1  
Metal Carbonate 
used in Series 2 
Metal Carbonate 
used in Series 3  
351 (from 339) La3+ Cd2+, Cu2+  
352 (from 339) La3+ Cu2+  
353 (from 340) La3+, Pb2+, Sr2+ Cu2+ Cd2+ 
354 (from 342) Cd2+, La3+, Li+, Sr2+ Cu2+  
357 (from 343) La3+, Li+ Cu2+ Cd2+ 
357 (from 346) La3+ Cd2+, Cu2+  
358 (from 340) La3+, Pb2+, Sr2+ Cu2+ Cd2+ 
361 (from 341) Cd2+, Cu2+, La3+  Cs+, K+, Na+ 
362 (from 341) La3+ Cd2+, Cu2+  
Table 48: The combinations of macrocycle-metal attempted in each series 
The metal carbonates were dried in the oven at 120 oC for one week. Each synthesis 
was carried out using the appropriate bis-alcohol (or bis-phenol as in 346) as the 
acyclic starting material. All syntheses were carried out in dry dichloromethane under 
nitrogen and at the same concentration (0.12 M) of bis-alcohol starting material and 6 
equivalents of metal carbonate. If triethylamine was used as the base there were 2.42 
equivalents were added.  
In series one there was seventy-six reactions, each metal carbonate macrocycle 
combination was carried out by the four different methods. There were nineteen 
combinations of metal carbonate to macrocycle; each of these was carried out at room 
temperature, with and without triethylamine as the main base, and also in refluxing 
dichloromethane with and without triethylamine. There was no improvement in yield 
recorded from the seventy six reactions, with the yield of each of the attempts for 
macrocycles 351 (3.8 %), 352 (2.1 %), 353 (1.8 % at room temperature and 12 % in 
refluxing dichloromethane), 354 (8.4 %) and 357 (17 %) from 346 (the bis-phenol) 
with triethylamine present being less than those reported in chapter two, (section 2.3, 
pages 54-57). As in chapter two, the synthesis of 357, 358, 361 and 362 from the bis-
alcohol starting material failed to yield the target product. These results were seen both 
at room temperature and in refluxing dichloromethane. The NMR data for these 
compounds matched that reported in chapter two (pages 118-122 and 129) indicating 
that the products were not bound to the metals. Each of the attempted synthesis in 
series one without triethylamine were unsuccessful, with greater than 90 % of the 
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starting material being recovered, the same result was achieved for the reactions at 
room temperature and in refluxing dichloromethane.  
In series two there were eleven metal carbonate to macrocycle combinations attempted. 
Again each one was carried out using the four varied methods, resulting in forty-four 
synthesis attempts. In this series there was no attempt made at the synthesis of 361. For 
each of the other macrocycles the results were very similar to those obtained from the 
series one combinations. For each of the attempts with triethylamine the yields were 
less than the reported values in chapter two and within experimental variation of those 
obtained from the series one reactions. The synthesis of macrocycles 357, 358, 361 and 
362 from the bis-alcohols failed. The NMR data of the isolated products matched that 
from chapter two, which suggests that there was no, or minimal, binding of the metal 
cation to the macrocycles. The reactions without triethylamine did not yield the target 
macrocycles, as seen in series one, with the bis-alcohol and bis-phenol starting 
materials being obtained in greater than 90 % mass recovery. 
In series three there were six metal carbonate to macrocycle combinations screened 
and each one attempted by the four different methods as previously. As in series one 
and two above, each of the reactions with triethylamine present resulted in yields less 
than those reported in chapter two and within experimental error of those obtained 
from the series one. Again the synthesis of macrocycles 357, 358, 361 and 362 from 
the bis-alcohols failed. As was detailed previously the NMR data of the isolated 
products matched that from chapter two, which suggests that there was no, or minimal, 
binding of the metal cation to the macrocycles. Also the synthesis attempts without 
triethylamine did not yield the target macrocycles with more than 90 % mass recovery 
of the bis-alcohol and bis-phenol starting materials. 
From the investigation in this section it can be seen that the attempts to increase yield 
by templatation using these metal carbonates was unsuccessful. Although this is a 
preliminary study and it is possible with different salts of these metals (to increase 
solubility in the organic media and activity as base), different solvents (both for 
increased temperature and to aide solubility of the metal salts in the organic media) and 
different concentrations, that metal templatation with metal cations could work. It is 
also possible that none of these metal cations can act as a template for the 
macrocyclisation reactions tested and that to use templatation for the synthesis of these 
macrocycles the use of another metal (not tested here) may be necessary. 
 
 222 
4.3 Conclusion:  
A selection of the macrocycles and their precursors synthesised in this project were 
tested for metal extraction ability against a variety of metal picrates. Compounds 359 
and 360 did not extract any of the metal picrates above the error in the calibration 
curves. Each of the other compounds tested showed extraction of several metal picrates 
on an individual basis.  
Although there are many interesting results with percentage extractions above 15 or 
even 20 %, none of the metal picrates showed selectivity, i.e. extracted only one metal 
picrate, instead preferential extraction was observed in many cases, with a higher 
extraction of one metal picrate observed over each of the other metal picrates. The 
most obvious case of preferential extractions is the extraction of copper(II) over 
lanthanum(III) and potassium by 352, in this case copper(II) is extracted almost nine 
times the percentage of lanthanum(III) and 15 times the percentage of potassium. But 
this is not a true test of selectivity as each metal picrate is tested for binding 
individually and to test for selectivity the picrates would have to be in a mixed solution 
when extracted by the macrocycle/precursor as the presence of one metal may interfere 
with the formation of the host-guest complex with another metal. Also to fully 
determine selectivity of the host compounds there has to be a determination of not only 
extraction of the metal picrate into the organic, but determination of whether the guest 
metal is a free cation or is chemically bound to the anion, and on top of that how much 
of the metal picrate is actually bound to the host compound and how much is in the 
organic solution.    
In order to confirm the host-guest complexes were forming rather than the metal 
picrate salts simply transferring from the aqueous to the organic the extraction studies 
were repeated with some modifications. These changes were made to drive the 
formation of the host-guest complex to as high a conversion as possible and then to 
record an NMR of as many of the host-guest complexes as possible. These tests were 
carried out on a variety of compounds with a variety of metal picrates. For each 
compound chosen the test was carried out with multiple picrates which gave either 
high binding or low/no binding. The combinations which gave high extractions values 
were chosen so as to maximise the chances of obtaining an NMR of the host-guest 
complex. Each of the combinations which gave low extraction values, all of which 
gave readings that have been reported as not successfully determined, were chosen to 
show that these results (at or around 0 %) were correct, i.e. no extraction hence no 
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binding occurred, but also that these metal picrates were not degrading the 
macrocycle/precursor being used as the host. In each of the cases the experiment was 
successful showing that not only is the host guest being formed, hence extraction 
occurring, but also the host molecules are stable to the test conditions.  
If this project was to be continued the next stage of testing with these metals would be 
to carry out the separate solution method of electrochemical testing with ion selective 
electrodes. This would be done using an electrode with a membrane impregnated with 
the binding agent. This could then be tested for each metal individually, and the 
difference between the potentials for each metal can be used to calculate the selectivity 
co-efficient.  
Attempts at the synthesis of the macrocycles via metal cation templatation were made 
using the results of the metal binding testing as a guide for metal selection. Each of 
these attempts failed to increase the yields of the macrocycles, with the yields being 
less for those with triethylamine acting as a base and the reactions failing to work 
without triethylamine. This could be for numerous reasons; the most obvious is that it 
is possible that the metals chosen will not act as templates for the macrocycles 
attempted. Also this was only a preliminary study with these metals, it is possible with 
different metal salts, increasing solubility and alkalinity, or different solvents, allowing 
higher temperatures and more metal into solution, that these metals could work as 
templates.  
If this was to be worked on further the use of higher temperatures and higher 
concentrations of both metal and acyclic starting material may lend to better results, 
along with the use of different metals.  
 
Experimental: 
General method for the synthesis of picrate salts: 
Sodium Picrate salt synthesis: 
0.77 g of the picric acid (65 % suspension in water) was dissolved in enough water at 
60 oC with gentle stirring to make a saturated solution. Sodium carbonate was added 
slowly to the hot solution of picric acid with gentle stirring until the evolution of 
carbon dioxide has ceased. The solution was gently stirred for a further 10 minutes and 
then cooled to 0 oC. 
The sodium picrate product was filtered by gravity filtration and washed with ice cold 
water (30 mL). The wet product was then removed from the filter paper and transferred 
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to a storage container. Yields of the products could not be recorded as the agreed 
preparation of the salts stated that the bulk picrate salts were not to be dried.  
 
Remaining Picrate Salt synthesis: 
Each of the other picrate salts, magnesium, calcium, zinc, potassium, lithium, barium, 
caesium, cadmium, cobalt, copper, strontium, lead and lanthanum picrates were carried 
out by the same method as was used for the synthesis of sodium picrate.  
 
Picrate Extraction Studies:78 
A sample of each of the picrate salts was dried in vacuo. 35 µmol of each dry picrate 
salt was accurately weighed, on a 10 µg scale. This was used to accurately make up 
500 mL of a 7 x 10-5 M solution of each picrate in water. 8.75 µmol of each of the 
products to be tested (338-344, 346, 351-354, 357-362 and 368-372) were accurately 
weighed on a 10 µg scale. This was used to accurately make up 0.5 L of a 1.75 x 10-5 
M solution of each of the products in chloroform. Due to insufficient sample being 
isolated and also some of the compounds were not isolated until near the end of the 
project it was not possible to test each of the picrates with each of the products. The 
following table is a list of these exceptions.  
Product Metal in picrate  Product 
Metal in 
picrate 
Cd 
 
Na 
Co 
 
Mg 
Cu 
 
Ca 
Sr 
 
Zn 
Pb 
 
K 
370, 361, 360 
La 
 
Li 
 
  
Ba 
 
  
338, 372  
Cs 
Table 49: List of product: metal picrate combinations that were not tested. 
Calibration curves of each picrate were made in the range of 7 x 10-5 M to 4.6 x 10-5 
M. The absorbance of each solution was measured at 356 nm on a Varian CARY 50 
Scan UV-Visible Spectrophotometer and a calibration curve drawn for each picrate. 
6 mL of each picrate solution was mixed with 6 mL of each of the product solutions. 
All mixtures were shaken on an automatic shaker for ten minutes at 600 oscillations 
per minute. The mixtures were allowed to settle for ten minutes and separated. 
Absorbance readings of the aqueous layer were taken at 356 nm. All extractions were 
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done in triplicate and their UV absorbance readings averaged for the calculations. The 
mean absorbance was then compared to the calibration curve for each picrate and the 
percentage extraction calculated. Percentage extraction was determined by calculating 
the number of moles of metal picrate that transferred to the organic phase and dividing 
by the number of moles of the binding agent (macrocycle or open structure) in the 
organic layer, as shown in the formula below.  
(  ) (  )% 100 (  )
eo
org
M Picrate M PicrateExtraction
Binding Agent
 −
=  
 
 
where (M Picrate)o is the number of moles of metal picrate in the aqueous layer 
originally, (M Picrate)e is the number of moles in the aqueous layer after extraction and 
(Binding agent)org is the number of moles of binding agent in the organic layer. 
Blank tests were carried out by extracting a solution of each of the binding agents in 
chloroform with water and also by extracting an aqueous solution of each of the picrate 
salts with chloroform.  
 
Picrate Extraction NMR Studies: 
Water was added to a sample of cadmium, caesium, cobalt, copper, lanthanum, lead, 
lithium, magnesium, potassium, sodium and strontium picrate salts to make saturated 
solutions of each of the picrates. 0.9 mmoles of each of the products to be tested (338, 
341, 343, 351, 362, 368 and 369) was accurately weighed, on a 10 µg scale. This was 
used to accurately make up 60 mL of a 15 mM solution of each of the products in 
chloroform.  
6 mL of the appropriate picrate solution was mixed with 6 mL of the appropriate 
product solutions, detailed in table 50 below. All mixtures were shaken on an 
automatic shaker for ten minutes at 600 oscillations per minute. The mixture were 
allowed to settle for ten minutes and then separated. 
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Macrocycle/Precursor Metal Picrate 
338 Cd, Sr, Cu 
341 Cu, Mg, Cs, Sr 
343 La, Li, Co, Cs, Na 
351 Cu, Cd, Li, Na, Co, Sr 
362 Cu, Cd, Cs, Co, Mg, Na 
368 Cu, Mg, Cs, K, Na 
369 Co, Co, Pb, La 
Table 50: Combinations of Macrocycles/Precursors with metal picrates 
The chloroform was removed under vacuum and the solid was dissolved in 1.5 mL 
deuterated chloroform and then its proton NMR was recorded, and in some cases its 
carbon NMR was also recorded. For the comparison NMR spectra; 6 mL of each 
product solution, in chloroform, had the solvent removed in vacuo; were then dissolved 
in deuterated chloroform and had their NMR spectra were recorded in triplicate. Each 
of the products should have been approximately 60 mM in the deuterated chloroform. 
20 mM and 40 mM solutions in deuterated chloroform were made by dilution of the 60 
mM solution in deuterated chloroform. Their NMR spectra were also recorded at 20 
mM and 40 mM in triplicate. 
The NMR spectra of the hosts before and after extraction with the metal picrates were 
then compared to ascertain if the host-guest complex had formed.  
 
General method for the synthesis of macrocycles using metal templatation at 
room temperature without triethylamine: 
The appropriate bis-alcohol or bis-phenol (2.4 mmol) was dissolved in dry 
dichloromethane (5.0 mL) at room temperature under nitrogen. Dry metal carbonate 
(14.4 mmol) was added. The appropriate dichloride (2.4 mmol) was dissolved in dry 
dichloromethane (15.0 mL) and added slowly to the reaction mixture. The reaction 
mixture was then left stirring for 16 hour at room temperature. After this time had 
elapsed the reaction was quenched by adding distilled water (10.0 mL) and stirring for 
ten minutes. The reaction mixture was transferred to a separation funnel and the 
organic and aqueous layers were separated. The organic layer was washed with 
distilled water (50.0 mL X3), saturated ammonium chloride solution (50.0 mL) and 
saturated sodium chloride solution (50.0 mL). The organic layer was dried over 
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magnesium sulphate and the solvent was removed in vacuo yielding the crude product. 
The products were purified by the same method as reported in the experimental section 
of chapter two, pages 118-122 and 129.  
 
General method for the synthesis of macrocycles using metal templatation in 
refluxing dichloromethane without triethylamine: 
The appropriate bis-alcohol or bis-phenol (2.4 mmol) was dissolved in dry 
dichloromethane (5.0 mL) at room temperature under nitrogen. Dry metal carbonate 
(14.4 mmol) was added. The solution was then heated to reflux. The appropriate 
dichloride (2.4 mmol) was dissolved in dry dichloromethane (15.0 mL) and added 
slowly to the reaction mixture. The reaction mixture was left stirring for 16 hour at 
reflux. After this time had elapsed the reaction was allowed to cool to room 
temperature and quenched by the addition of distilled water (10.0 mL) and stirred for 
ten minutes. The reaction mixture was transferred to a separation funnel and the 
organic and aqueous layers were separated. The organic layer was washed with 
distilled water (50.0 mL X3), saturated ammonium chloride solution (50.0 mL) and 
saturated sodium chloride solution (50.0 mL). The organic layer was dried over 
magnesium sulphate and the solvent was removed in vacuo to leave behind the crude 
product. The products were purified by the same method as reported in the 
experimental section of chapter two, pages 118-122 and 129.  
 
 
General method for the synthesis of macrocycles using metal templatation at 
room temperature with triethylamine: 
The appropriate bis-alcohol or bis-phenol (2.4 mmol) was dissolved in dry 
dichloromethane (5.0 mL) at room temperature under nitrogen. Dry metal carbonate 
(14.4 mmol) and dry triethylamine (5.8 mmol) were added. The appropriate dichloride 
(2.4 mmol) was dissolved in dry dichloromethane (15.0 mL) and added slowly to the 
reaction mixture. The reaction mixture was left stirring for 16 hour at room 
temperature. After this time had elapsed the reaction was quenched by adding distilled 
water (10.0 mL) and stirred for ten minutes. The reaction mixture was transferred to a 
separation funnel and the organic and aqueous layers were separated. The organic layer 
was washed with distilled water (50.0 mL X3), saturated ammonium chloride solution 
(50.0 mL) and saturated sodium chloride solution (50.0 mL). The organic layer was 
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dried over magnesium sulphate and the solvent was removed in vacuo to yield the 
crude product. The products were purified by the same method as reported in the 
experimental section of chapter two, pages 118-122 and 129.  
 
General method for the synthesis of macrocycles using metal templatation in 
refluxing dichloromethane with triethylamine: 
The appropriate bis-alcohol or bis-phenol (2.4 mmol) was dissolved in dry 
dichloromethane (5.0 mL) at room temperature under nitrogen. Dry metal carbonate 
(14.4 mmol) and dry triethylamine (5.8 mmol) were added. The solution was heated to 
reflux. The appropriate dichloride (2.4 mmol) was dissolved in dry dichloromethane 
(15.0 mL) and added slowly to the reaction mixture. The reaction mixture was left 
stirring for 16 hour at reflux. After this time had elapsed the reaction was allowed to 
cool to room temperature and quenched by adding distilled water (10.0 mL) and 
stirring for ten minutes. The reaction mixture was transferred to a separation funnel 
and the organic and aqueous layers were separated. The organic layer was washed with 
distilled water (50.0 mL X3), saturated ammonium chloride solution (50.0 mL) and 
saturated sodium chloride solution (50.0 mL). The organic layer was then dried over 
magnesium sulphate and the solvent was removed in vacuo yielding the crude product. 
The products were purified by the same method as reported in the experimental section 
of chapter two, pages 118-122 and 129.  
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Chapter 5:  
Biological screening of selected products successfully isolated in this 
project. 
5.1 Introduction: 
Crown ethers have been developed which show potent inhibition of cell proliferation 
and new systems are being exploited to kill microbial organisms.79 Functionalized 
crowns have also been synthesized to bind and cleave DNA and have led to 
investigative drug studies in cancer research. Also some natural crown ethers, such as 
Nonactin 1, are antimicrobial agents. As it has been shown that crown ethers act as 
antimicrobial agents by a variety of methods it was decided to test a sample of the 
water soluble macrocycles synthesised in this project for their antibacterial properties. 
This investigation was carried out prior to the metal binding in chapter four as a 
preliminary screening and therefore it was unknown at that stage if the macrocycles 
bind to any biologically active metal cations.  
There is a large diversity of structures of known p-gp inhibitors; with examples ranging 
from polyethylene glycol to more rigid structures e.g. progesterone. Some macrocycles 
have been shown to be P-gp inhibitors e.g. 270 and 271 (chapter 1).55, 57, 58 The P-gp 
inhibitors can act in a number of ways, from being high-affinity substrates of the 
pump; efficient inhibitors of ATP hydrolysis coupled P-gp transport and; partial 
substrates/inhibitors. High-affinity substrates of the pump will be expelled from the 
cell at a high rate and this will reduce the rate at which P-gp can remove other 
compounds from the cell. Efficient inhibitors of ATP hydrolysis coupled P-gp 
transport decrease the rate of ATP hydrolysis, therefore P-gp will not obtain the energy 
required to pump it’s substrates from the cell. Partial substrates/inhibitors bind to P-gp 
but P-gp cannot pump these molecules out of the cell and so P-gp is inhibited from 
eliminating other compounds from the cell. With the knowledge that some 
macrocycles have been shown to inhibit P-gp, and the fact that there are multiple ways 
in which P-gp inhibition can occur, it was decided to test each of the water soluble 
macrocycles for P-gp inhibition.  
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5.2 Results: 
5.2.1 Antibacterial testing 
343, 344, 346, 351-353, 357-359 and 362 (figure 119) were tested for minimum 
inhibitory concentration against Pseudomonas aeruginosa, Escherichia coli, Klebsiella 
spp., Staphylococcus aureus, Salmonella spp., Enterococcus spp. and Bacillus subtilis 
over the concentration range 0-2000 µg/mL.  
Minimum inhibitory concentrations (MICs) for the compounds were determined by 
serial two-fold dilutions in Mueller-Hinton broth using the broth micro-dilution method 
described by Amsterdam.80 
The bacterial strains were grown in Mueller-Hinton broth overnight. The compound to 
be tested was dissolved in sterile water and diluted in the test medium to twice the top 
concentration desired in the test, i.e., the highest desired concentration was 2000 
µg/mL, so the compound to be tested was diluted to 4000 µg/mL. Ten serial two-fold 
dilutions of the compound to be tested were made. Into each of the diluted solutions 
was added a sample of the bacteria to be tested. The plates were then incubated and 
checked after 18 and 36 hours, with the MIC being reported as the lowest 
concentration of the compound that completely inhibited growth of the organism as 
detected by the unaided eye.  
Compounds that were water-insoluble were diluted in methanol. The MICs for these 
compounds were obtained using the same procedure described above. However, 
instead of diluting the compound directly in Mueller-Hinton broth, 20 µL of the 
solution (to give a final concentration of 2000 µg/mL) was added to the first well in the 
row. The methanol was allowed to evaporate and then 200 µL of Mueller-Hinton broth 
was added, mixed and diluted using serial two-fold dilutions as described above. 
All tested compounds showed no activity at the tested concentration range, with MIC 
values >2000 µg/mL. 
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Figure 119: Compounds tested for their antibacterial properties. 
At the same time these compounds were tested for antibacterial activity a number of 
samples were undergoing testing as P-gp inhibitors. Initial results from the P-gp 
inhibition testing gave positive results so no more work was undertaken examining and 
developing antibacterial properties.  
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5.2.2 P-gp inhibition testing 
The first two compounds that were examined for inhibition of P-gp were 357 and 359, 
structures shown in figure 121.  
 
Figure 121: Structures of 357 and 359 
The compounds were studied for their anti-proliferative effectiveness against DLKP 
and DLKP-A cell lines, alone and in combination with the widely used 
chemotherapeutic drug Epirubicin. The DLKP cell line is a poorly differentiated 
squamous cell lung carcinoma. The main mechanism of MDR for DLKP is via 
multidrug resistance associated protein 1 (MRP1) while it poorly expresses P-gp. 
DLKP-A cell line is a daughter cell line of DLKP and highly expresses P-gp while 
expressing very low levels of MRP1.  
Epirubicin was shown to have an IC50 of 0.017 ±0.0008 µM on the DLKP cell line and 
2.1 µM ±0.24 on the DLKP-A cell line. Initial testing of 357 at concentrations of 40 
µM with Epirubicin (0.3 µM) a significant increase in cell kill occurred in DLKP-A, a 
5-fold increase as seen in graph 1 below. Under the same conditions but with DLKP no 
significant increase occurred, as shown in graph 2.  
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Graph 1: Double combination of 357 with epirubicin on the DLKP-A cell line. 
 
Graph 2: Double combination of 357 with epirubicin on the DLKP cell line. 
At this concentration of Epirubicin (0.3 µM) without 357 the survival of cell line 
DLKP-A was not significantly affected, i.e. the cell kill from Epirubicin was close to 
zero. Also 357 in the absence of Epirubicin had no significant effect on cell survival. 
357 was further examined with 5-flourouracil (5-FU) and taxotere on the DLKP-A cell 
line. The IC50 values of 5-FU and taxotere on the DLKP-A cell line are 59 ±1.9 µM 
and 87 ±6.7 nM respectively. 5-FU is not affected by P-gp and as such no 
improvement in cell kill occurred when 357 was added as shown in graph 3. Taxotere 
is pumped from the cell by P-gp and at a concentration of 0.23 nM taxotere and 30 µM 
357 an improved cell kill was recorded as shown in graph 4.  
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Graph 3: Double combination of 357 with 5-FU on the DLKP-A cell line. 
 
Graph 4: Double combination of 357 with taxotere on the DLKP-A cell line. 
Initial testing on 359 also indicated that this compound lead to decreased cell survival 
when used in combination with epirubicin as seen in graph 5.  
 
Graph 5: Double combination of 359 with epirubicin on the DLKP-A cell line. 
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As the apparent activity of 359 was not as pronounced as that of 357 it was decided, in 
consultation with the biologists, who carried out the testing, not to pursue this product 
for its potential as a P-gp inhibitor. Instead it was decided to focus on the potential 
decomposition products of 357. Macrocycle 357 could decompose both in the media 
and in the cell. The decomposition of 357 in the aqueous biological media would most 
likely be caused by the hydrolysis of the ester bonds and may be catalysed by the 
buffers in the media. If it is in the cell that the decomposition takes place the ester 
bonds could hydrolyse chemically within the cell or in an enzymatic reaction by an 
esterase or hydrolase enzyme.  
On analysis of the structure of 357 it was concluded there were four most probable 
decomposition products of 357 with further decomposition products possible such as 
ortho-catechol by breaking the ether bond in 2-(2-hydroxyethoxy)phenol. The four 
decomposition products deemed most feasible were 343, 346, 2-(2-
hydroxyethoxy)phenol and dimethylmalonic acid (figure 122). This was concluded 
because the ester bonds in 357 are susceptible to hydrolysis and the likely products of 
the hydrolysis of the ester bonds are 343, 346 and the starting materials for the 
synthesis of 357. 
 
Figure 122: Structures of 357 and its most probable decomposition products. 
For the next round of testing 2-(2-hydroxyethoxy)phenol (336), dimethylmalonic acid, 
2,2'-(2,2'-(propane-1,3-diylbis(oxy))bis(2,1-phenylene))bis(oxy)diethanol (399), 2,2'-
(2,2'-(2,2'-(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(oxy)bis(2,1-phenylene))-
bis(oxy)diethanol (400), 2,2'-(2,2'-(1,2-phenylenebis(methylene))bis(oxy)bis(2,1-
phenylene))bis(oxy)diethanol (401), 2,2'-(2,2'-(1,3-phenylenebis(methylene))bis(oxy)-
bis(ethane-2,1-diyl))bis(oxy)diphenol (402) and  343 were submitted. Products 399-
402 (figure 123) were synthesised by another member of the group and any further 
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testing and results on these compounds are contained in their work.84 399-402 were 
included in the testing in an effort towards the identification of the pharmocophore.  
 
Figure 123: Structures of 399-402. 
346 at this stage had not been synthesised and its synthesis was carried out and then the 
product was submitted for testing. The results from this round of testing indicated that 
336 and dimethylmalonic acid showed no inhibition of P-gp. The results, graphs 6 and 
7, also show that both 343 and 346 had a significant effect on cell survival in 
conjunction with epirubicin. This indicates that 343 and 346 are effective P-gp 
inhibitors. The results, shown in graph 8, indicate that 399 also inhibits P-gp but less 
effectively than 357, 343 and 346.  
The testing showed that 343 at a concentration of 25 µM with Epirubicin (0.3 µM) a 
significant decrease in cell survival occurred in DLKP-A, a 10-fold decrease as seen in 
graph 6. When the epirubicin concentration is increased to 1.4 µM the lower 
concentration of 12 µM 343 is sufficient to achieve the same cell survival rate. 
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Graph 6: Double combination of 343 with epirubicin on the DLKP-A cell line. 
The testing of 346 at concentrations of 12 µM with Epirubicin (0.3 µM) showed a 
significant increase in cell kill occurred in DLKP-A, with only 20 % cell survival as 
seen in graph 7, and 346 at concentrations of 25 µM with Epirubicin (0.3 µM) a further 
decrease in cell survival occurs, with less than 10 % of the cells surviving.  
 
Graph 7: Double combination of 346 with epirubicin on the DLKP-A cell line. 
343 and 346 had similar activity except with concentrations of epirubicin (0.3 µM) and 
12 µM of the compound being tested. At these concentrations cell survival for 346 was 
approximately 20 % but using 343 was approximately 80 %. For each of the other 
concentrations of 343 and 346 with epirubicin at 0.3 µM the cell survival levels were 
comparable. With epirubicin at the more concentrated 1.4 µM the cell survival were 
similar for concentrations 12, 25 and 27 µM of 343 and 346, but at the 49 µM of 346 
the cell survival was approximately half of the cell survival with 343 at the same 
concentration.  
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The testing showed that 399 at concentrations of 57 µM with 0.3 µM Epirubicin a 
significant increase in cell kill occurred in DLKP-A, with only 40 % cell survival as 
seen in graph 8 below, and 399 at concentrations of 43 µM with 1.4 µM  Epirubicin a 
further decrease in cell survival occurs, with only 15 % now surviving. 
 
Graph 8: Double combination of 399 with epirubicin on the DLKP-A cell line 
Compound 400 did not show any synergy with epirubicin, thus suggesting it did not 
inhibit P-gp (graph 9).  
 
Graph 9: Double combination of 400 with epirubicin on the DLKP-A cell line. 
In graph 10 the synergistic effect was observed with 401 at a concentration of 2µM and 
epirubicin at 0.5µM. With a lower concentration of 401, 0.5µM, and a slightly higher 
concentration of epirubicin, 1.4µM, synergy was also observed.  
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Graph 10: Double combination of 401 with epirubicin on the DLKP-A cell line. 
Graph 11 below shows the effects of 402 on the DLKP-A cell line when used in 
combination with epirubicin. It was seen to have a slight antagonistic effect at the 
higher concentration of epirubicin with both concentrations of 402 that were tested on 
the DLKP-A cell line. 
 
Graph 11: Double combination of 349 with epirubicin on the DLKP-A cell line. 
At this stage in the development of a P-gp inhibitor three lead compounds had been 
identified, 343, 346 and 401. It was decided to concentrate efforts on the optimisation 
of the synthesis of 346, the most promising lead compound of this project. The reason 
for this was to produce sufficient material for full analysis of the compound as a P-gp 
inhibitor. Optimisation would also lead to a high throughput synthesis to isolate more 
material for any further testing which may be deemed necessary depending on the 
outcome of the P-gp inhibition testing. The optimisation process is outlined in chapter 
2, page 68.  
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When samples from the optimised method of synthesis were submitted for continued 
testing issues arose with the solubility of 346. The product would not dissolve at the 
same concentrations in the same media as was previously possible. Previously 10 mg 
of 346 had been dissolved in 1.0 mL ethanol and then added to the aqueous media for 
biological testing. However the product of the optimised synthesis of 346 would not 
dissolve at same concentration 10 mg/mL in ethanol. From the evidence available, 
NMR (carbon and proton), MP, Rf and IR, the product could not be differentiated from 
that which was originally synthesised. This shows that the structure of the product is 
the same as that originally generated. The evidence thus indicates that the issue arose 
either due to a low level impurity in the originally synthesised 346 which aided 
solubility or to a low level impurity in 346 from the optimised synthesis which 
hindered solubility. The possibility of different crystal structures of the product could 
also explain different solubilities of the compound in solution as different crystal 
matrices can have different solubilities in varying solvents.81 Ordinarily different 
crystal structures would lead to different melting points, however this possibility 
cannot be ruled out. Also different crystal forms can lead to different biological 
activity82 due to the different shape of the molecule in the crystal and this varied shape 
can then interact differently with the target species.  
A thorough investigation of 346 and its synthesis was then undertaken as a priority. 
This study started by synthesising 346 multiple times using the original method 
developed, each time changing the work up of the product at each step in an attempt to 
isolate 346 that had comparable solubility to the original batch of 346. The original 
batch of 346 was soluble in ethanol at 10 mg/mL and remained in solution when added 
to the biological media. The work in this project was carried out in two laboratories in 
two separate buildings. The initial synthesis of 346 was carried out in laboratory X249 
in the School of Chemical Sciences, but due to the relocation of the research group to 
the National Institute of Cellular Biotechnology building all the other syntheses were 
carried out in laboratory G23. In the different laboratories the DI water came from 
different sources, in X249 the DI water is obtained from a Millipore system and in G23 
there is a building wide DI water system. So when this work was undertaken it was 
important to use the water from X249 in some of the attempts. Table 51 outlines the 
attempts made.  
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Work up of TES 
protection stage 
Work up of synthesis of 
triethylsilyl protected 
bis(2-(2-
hydroxyphenoxy)ethyl) 
2,2-dimethylmalonate 
Work up of deprotection 
step 
Original work up: quenched 
with H2O, Washed with 
water and then saturated 
NH4Cl, Dried over MgSO4, 
Column chromatography 
for purification 
Original work up: quench 
with H20, wash with water, 
dry over MgSO4, Column 
chromatography 
Original work up: quenched 
with Na2CO3, washed with 
water and then saturated 
NaHCO3, dried over 
MgSO4, Chromatography 
and recrystallisation for 
purification 
Same as original but also an 
added NaCl wash 
Same as original but with 
added an added NaCl wash 
Same as original but 
quenched with K2CO3 
Same as original but NaCl 
wash instead of NH4Cl 
wash 
Same as original but with 
added NaCl and NH4Cl 
wash 
Same as original but 
quenched with 
triethylamine 
Same as original but with 
added KCl wash 
Same as original but with 
an added KCl wash 
Same as original but 
quenched with sodium 
hydroxide 
Same as original but also an 
added KCl wash and NaCl 
wash 
Same as original but also an 
added KCl wash and NaCl 
wash 
Same as original but 
quenched with potassium 
hydroxide 
Same as original but with 
KCl wash and NaCl wash 
instead of NH4Cl 
Same as original but with 
KCl wash and NaCl wash 
and NH4Cl 
Same as original but with 
KCl wash and NaCl wash 
and NH4Cl wash 
Same as each above but 
dried over Na2SO4 
Same as original but with 
added NH4Cl wash 
Same as original but with 
added KCl wash 
Same as each above but 
using tap water instead of 
DI water 
Same as original but with 
KCl wash and NH4Cl was 
Same as original but with 
added KCl wash and NaCl 
wash 
Same as original but with 
NH4Cl wash 
Same as each above but 
using water from X249 
instead of water G23 
Same as each above but 
using water from X249 
instead of water G23 Same as original but with 
added NaCl wash 
 Same as each above but 
using tap water instead of 
DI water 
Same as original but with 
NaCl wash and NH4Cl 
wash 
 Same as each above but 
dried over Na2SO4 
Same as original but with 
KCl wash and NH4Cl wash 
  Same as each above but 
dried over Na2SO4 
  Same as each above but 
using tap water instead of 
DI water 
  Same as each above but 
using water from X249 
instead of water G23 
Table 51: Attempts at working up 346 to make soluble in the biological media 
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Each of the work-ups in table 51 were carried out in conjunction with each of the 
work-ups from the other columns. So for example from column “work up of TES 
protection stage” the original work-up was split into nine samples, one sample for each 
of the work-ups in the “work-up of synthesis of triethylsilyl protected bis(2-(2-
hydroxyphenoxy)ethyl) 2,2-dimethylmalonate” column, then each sample from this 
was split into fifteen samples to be worked up by each method in the “work up of 
deprotection step” column. This gave one thousand, four hundred and eighty five 
samples each of which were tested for solubility in ethanol at 10 mg/mL. A sample of 
each solution in ethanol was added to biological media to test if the 346 would stay in 
solution in the media. All of the attempts to synthesise 346 again with different work-
ups failed to give a sample which would stay in solution when added to the media.  
The next step was an attempt to make a solution of 346 at the required concentration, 
10 mg/mL, in such a way that 346 would stay in solution when added to the biological 
media. This was examined both directly using heat and sonication and indirectly by 
making a solution in an organic solvent (e.g. ethanol) then mixing this solution with 
the media. Table 52 below shows the attempts to solublise 346 in the biological media.  
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Solvent (mixture) Additive Successful (yes or no) 
Ethanol none no 
Ethanol : water a none no 
DMSO none no 
DMSO : water a  none no 
DMSO : Ethanol a none no 
DMSO : Ethanol : water a none no 
Ethanol NaCl, KCl, NH4Cl b no 
Ethanol : water a NaCl, KCl, NH4Cl b no 
DMSO NaCl, KCl, NH4Cl b no 
DMSO : water a NaCl, KCl, NH4Cl b no 
DMSO : Ethanol a NaCl, KCl, NH4Cl b no 
DMSO : Ethanol : water a NaCl, KCl, NH4Cl b no 
Ethanol Cremophor EL®, NaCl, 
KCl, NH4Cl b 
no 
Ethanol : water a Cremophor EL®, NaCl, 
KCl, NH4Cl b 
no 
DMSO Cremophor EL®, NaCl, 
KCl, NH4Cl b 
no 
DMSO : water a Cremophor EL®, NaCl, 
KCl, NH4Cl b 
no 
DMSO : Ethanol a Cremophor EL®, NaCl, 
KCl, NH4Cl b 
no 
DMSO : Ethanol : water a Cremophor EL®, NaCl, 
KCl, NH4Cl b 
no 
Ethanol Tween 80®, NaCl, KCl, 
NH4Cl b 
yes, 15 % tween 80® in 
ethanol dissolved 346 and 
also it stayed in solution 
for biological screening. c  
Ethanol : water a Tween 80®, NaCl, KCl, 
NH4Cl b 
no 
DMSO Tween 80®, NaCl, KCl, 
NH4Cl b 
no 
DMSO : water a Tween 80®, NaCl, KCl, 
NH4Cl b 
no 
DMSO : Ethanol a Tween 80®, NaCl, KCl, 
NH4Cl b 
no 
DMSO : Ethanol : water a Tween 80®, NaCl, KCl, 
NH4Cl b 
no 
Table 52: Attempts at solublising 346 in the biological media. 
a
: various different ratios of these solvents were used. b: each of these additives were 
used individually and in conjunction with each other. c: also worked at higher 
concentrations of tween 80® but lower concentrations of additives lead to less 
complications in the biological screening.  
Each mixture was heated and sonicated as necessary to dissolve 346. No sonication or 
heating above 35 oC was allowed when added to the biological media, as this could not 
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be done when the P-gp inhibition testing was preformed. In table 52 “successful” 
means that a solution was made which when added to the biological media no solid 
crashed out of solution. A sample of 346 was then submitted which was to be dissolved 
in ethanol with 15 % tween 80®. This sample would then be added to the biological 
media containing DLKP-A cells. Tween 80® has previously been shown to inhibit P-
gp83 therefore a blank test with the 15 % tween 80® in ethanol without 346 was carried 
out. The results of these tests are shown in graphs 12 and 13.  
 
Graph 12: 346 in ethanol with 15 % tween 80® 
 
Graph 13: 15 % tween 80® in ethanol 
The synergistic effect of the solution of 346 in ethanol with 15 % tween 80® could not 
be distinguished from that of the blank test, as seen in graphs 12 and 13. From these 
results it was evident that 346 was not giving the same synergistic effect as was seen in 
the initial synthesis of the product. This indicates that the initial batch of 346 
synthesised was different to each of the repeat synthesis. The inconsistency between 
DLKP-A: The combination of epirubicin and 346 in ethanol + 15% tween 80® 
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DLKPA: The combination of epirubicin and 15%tween 80 ®/ethanol. 
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the original result and repeat syntheses is currently unknown, the NMR spectra of the 
products from the original synthesis and that of the optimised show the products to be 
alike as seen in figures 124 and 125 below. Although in the NMR spectrum of the 
initial synthesis the peaks are less well defined than those from the optimised synthesis 
and there are small variations in the chemical shifts this seems to be more likely due to 
error in the NMR spectrum. Most likely these minor variations arise from temperature 
variations and/or concentration differences in the samples. Each of the peaks are in the 
correct location in the spectra with small variations. They are not identical but are not 
significantly different from each other and they are each significantly different from 
the NMR spectrum of 343. 
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Figure 124: 1H-NMR of 346 from initial synthesis 
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Figure 125: 1H-NMR of 346 from optimised synthesis 
This meant that the results originally obtained from the P-gp inhibition testing of 346 
could not be reproduced, and hence could not be confirmed.  
In an effort to confirm that 343 and 346 were not confused with each other on testing a 
new sample of 343 was synthesised and the P-gp inhibition testing with this new batch 
was repeated on the DLKP-A cell line. Also the test was carried out in combination 
with taxotere, which had not been reported previously. The results of this test showed 
that this new batch of 343, the same compound as confirmed by X-ray crystallography 
in chapter 2 (page 80) inhibited P-gp and thus increased the cell kill rate when acting in 
combination with Epirubicin and in combination with Taxotere (graph 14). 
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Graph 14: Repeat 343 on DLKP-A with Epirubicin and Taxotere. 
Although the method had remained the same, the concentrations of the test compound, 
in this case 343, and of Epirubicin used had been altered in the standard operating 
procedure. The solubility of 343 had not changed when using the same concentration 
of stock solution used as before, 10 mg/mL. The results of this examination provided 
two valued pieces of information; the first is that 343 and 346 had not been mixed 
when the first tests with these samples were carried out, as the results for this new 
batch of 343 are in agreement with those obtained from the original testing. Secondly 
is that 343 has been shown to work in combination with Taxotere which had not 
previously been carried out.  
While the work was being carried out on 346 in an effort to obtain a solution of 10 
mg/mL, a series of commercially available crown ethers and polyethylene glycols were 
also tested for their inhibition of P-gp. This was carried out for inclusion in the initial 
stages of a structure activity relationship study. The tested compounds were triethylene 
glycol, tetraethylene glycol, pentaethylene glycol, hexaethylene glycol, 15-crown-5 
and benzo-18-crown-6 (non-toxic according to MSDS supplied by sigma-aldrich®). Of 
these compounds only benzo-18-crown-6 was seen to display a synergistic effect with 
epirubicin on the DLKP-A cell line. When the extent of the interaction is compared to 
that of 343, 346 (original batch) and 357 in combination with epirubicin on the same 
cell line, it is clear that these have a much greater effect. Benzo-18-crown-6 only acts 
synergistically at 160 µM and above, whereas the required concentration of 357 is 40 
µM and of 346 (original batch) lies between 2.5 µM and 12.5 µM. Graphs 15 to 20 
illustrate the results of the testing of these six commercially available compounds.  
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Graph 15: Double combination of triethylene glycol with epirubicin on the DLKP-A 
cell line 
 
Graph 16: Double combination of tetraethylene glycol with epirubicin on the DLKP-A 
cell line 
 
Graph 17: Double combination of pentaethylene glycol with epirubicin on the DLKP-A 
cell line 
DLKP-A: Triethylene glycol and epirubicin double combination 
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Graph 18: Double combination of hexaethylene glycol with epirubicin on the DLKP-A 
cell line 
 
Graph 19: Double combination of 15-crown-5 with epirubicin on the DLKP-A cell line 
 
Graph 20: Double combination of benzo-18-crown-6 with epirubicin on the DLKP-A 
cell line 
 
The data obtained in this investigation is not a complete structure activity relationship 
study, nevertheless important information guiding future studies has been gained. It 
can be seen that the aromatic rings in the acyclic P-gp inhibitors are an important 
feature, although alone it does not indicate that similar compounds will act as P-gp 
inhibitors. The commercially available ethylene glycols tested do not have the aromatic 
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rings and show no effect on P-gp. 400, which was synthesised within the group, also 
has no effect on P-gp. Each of the other acyclic products synthesised within the group 
that have been tested (343, 346, 399, 401 and 402) had an effect on P-gp. 343, 399 and 
401 each displayed inhibition of P-gp. Although further testing proved the results from 
the initial testing of 346 were unreliable, it is still important to have aromatic rings in 
the structures of compounds within this group of P-gp inhibitors.  
It also appears that the aromatic ring is important in the cyclic P-gp inhibitors; this is 
seen mainly with 15-crown-5 not inhibiting P-gp and benzo-18-crown-6 inhibiting P-
gp although this difference could also be partly or entirely due to the difference in size 
of the ring.  
Thus far in the SAR study it appears that the open structures are more effective as P-gp 
inhibitors than the macrocycles. Although to prove this conclusively it would be 
necessary to isolate and test 363 and a number of other macrocycles of varying size 
and constituents. Included in the testing of macrocycles should be analogues of 357 
and 359 as well as macrocycles made from 399 and 401. 
Also the initial results from 343 compared to 346 point towards the finding that the 
structures being linked between the primary alcohols being more active than those 
linked between the phenols. However this is only a preliminary finding as can be seen 
in the difference in activity between 348 and 349 suggests the opposite to be true. 
These results taken together suggest that the position of the linker is important but 
which position is preferable depends on the linker molecule used. Therefore it is 
advisable when developing new acyclic P-gp inhibitors as part of the further work on 
this SAR study that each linker to be used should be tested when linked between the 
primary alcohols and when linked between the phenols.  
 
5.3 Conclusion: 
All compounds tested are non-toxic over the concentration ranges tested against 
Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp., Staphylococcus aureus, 
Salmonella spp., Enterococcus spp. and Bacillus subtilis. This is a good indication that 
these compounds are relatively non-toxic to microbial life.  
357 was shown to inhibit P-gp in DLKP-A cell line. From these results 343 was tested 
and 346 was synthesised and also investigated. 346 proved to be the most interesting 
potential P-gp inhibitor at this stage, due to its higher activity at lower concentrations. 
No further testing was carried out on 343 and 357 although they did exhibit inhibition 
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of P-gp on the DLKP-A cell line. The synthesis of 346 was then optimised so the 
confirmation studies could be carried out and also an investigation into how it inhibits 
P-gp. Each of the repeated synthesis of 346 lead to products that were insoluble at the 
required concentration in the biological media. In order to solve this problem a solution 
of 346 in ethanol with 15 % tween 80® was made, which stayed in solution on 
addition to the biological media. When this was analysed the activity of 346 could not 
be separated from the activity of the tween 80®.  
It is apparent that the initial synthesis of 346 gave a product that differed in some way 
to each of the following syntheses, although all the data available suggests that the 
products are the same. The reason for this could be any number of factors including: a 
low level impurity: a difference in the structure of the product that is not evident: a 
difference in the crystal matrix of the product: or a difference in the biological media. 
The difference cannot be inspected any further as there is no remaining sample from 
the original synthesis of 346, it was all consumed in the testing carried out. 
If this project was to be continued in this direction the next step to be taken would be 
to have the analysis on 357 and 343 repeated to confirm the results. Then, using these 
two compounds as the starting point, carry out a structure activity relationship study to 
both identify the pharmocophore and to develop a product with higher activity as a P-
gp inhibitor. The information obtained from the testing of each of the commercially 
available compounds and compounds 346-349 can also be added to the structure 
activity relationship study. Included in this study should be the synthesis and isolation 
of 363 (chapter 2) and any possible decomposition products from 357. As the results 
from the initial batch of 346 could not be repeated there is no information from this 
compound to aide in the structure activity relationship study. As these products are 
made and tested further information on structural characteristics which help increase P-
gp inhibition will be gained. This information can be used to aide the development of a 
more effective P-gp inhibitor.  
 
Experimental: 
Synthesis of 346 was carried out using two methods, the original method used and the 
optimised method. The original synthesis was repeated multiple times, each time 
changing the work up as detailed in table 51. The product of each different work up 
was characterised by NMR and MP before attempts were made to dissolve these 
products in ethanol at 10 mg/mL. 
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Minimum inhibitory concentration (toxicity) testing was carried out by Dr. Brid Quilty 
in the school of biotechnology, Dublin City University.  
P-gp inhibition testing carried out by Aoife Devery, under the supervision of Dr Robert 
O’Connor of the National Institute of Cellular Biotechnology, Dublin City University.  
 
Minimum inhibitory concentration testing: 
Minimum inhibitory concentrations (MICs) for the compounds were determined by 
serial two-fold dilutions in Mueller-Hinton broth using the broth micro-dilution method 
described by Amsterdam.80 
The bacterial strains were grown in Mueller-Hinton broth overnight. The compound to 
be tested was dissolved in sterile water and diluted in the test medium to 4000 µg/mL. 
100 µL of Mueller-Hinton broth was dispensed into all wells of a microtitre plate. 100 
µL of the compound solution was measured into the wells in column 1 (far left of 
plate). The compound was mixed into the wells in column 1 by pumping the pipette up 
and down 6-8 times. 100 µL was withdrawn from column 1 and added to column 2. 
This made column 2 a two-fold dilution of column 1 and again was mixed by pumping 
the pipette up and down 6-8 times. 100 µL was transferred to column 3. This procedure 
was repeated down to column 10 only. 100 µL was discarded from column 10 rather 
than putting it in column 11. 5 µL of (2 x 104 CFU/mL) the strain to be tested was 
dispensed into wells in the columns 11 to 1 in that order. Column 12 was used as a 
sterility control. The plates were incubated at 37 °C. Growth on the plates was noted 
and recorded after 18-36 hours. The MIC was the lowest concentration of the 
compound that completely inhibited growth of the organism in the micro-dilution wells 
as detected by the unaided eye. 
Compounds that were water-insoluble were diluted in methanol. The MICs for these 
compounds were obtained using the same procedure described above. However, 
instead of diluting the compound directly in Mueller-Hinton broth, 20 µL of the 
solution (to give a final concentration of 20000 µg/mL) was added to the first well in 
the row. The methanol was allowed to evaporate and then 200 µL of Mueller-Hinton 
broth was added, mixed and diluted using serial two-fold dilutions as described above. 
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P-gp inhibition testing: 
Solubilisation of the compounds: 
The test compound (10 mg) was placed into a vial. DMSO (1 mL), ethanol (1 mL) or 
water (1 mL) was added and the vial was shaken vigorously. The vial was then 
sonicated at 37 oC for 1 hour.  
If the compound was dissolved at this stage it was tested for its solubility in cell culture 
complete media (10 µL of the test solution in 40 µL of complete media or a dilution to 
make up 100 µM was carried out). 
 
Assessment of cell number by the acid phosphatase assay 
Following the incubation period of 6-7 days, media was removed from the plates. Each 
well was washed twice with phosphate buffered saline (100 µL). This was then 
removed and freshly prepared phosphatase substrate (100 µL) (10 mM p-nitrophenol 
phosphate in 0.1 M sodium acetate, 0.1 % triton X-100 (pH 5.5)) was added to each 
well. The plates were then incubated in the dark at 37 oC for 2 hours. The enzymatic 
reaction was stopped by the addition of 1N NaOH (50 µL). The plate was read in a 
dual beam plate reader (Synergy HT, Bio-Tek, USA) at 450nm with a reference 
wavelength of 620 nm. 
 
Initial combination toxicity assays 
Each compound to be tested was diluted to the relevant concentrations for testing. The 
first double combination to be carried out was with epirubicin and if an interesting 
result was found the double combinations was repeated with taxotere and 5-FU.  
The plates were incubated for 6 days, at which time the acid phosphatase assay was 
carried out in order to determine the cell density. 
Results from this method gave information on the compounds short term stability in 
culture conditions, of its general toxicity and whether a synergistic combination with 
epirubicin was possible on either the DLKP or DLKP-A cell lines. 
 
In vitro toxicity assays 
Cell suspensions containing 104 cell/mL were prepared in a cell culture medium. These 
cell suspensions (100 µL/well) were added to 96-well plates. Plates were agitated 
gently in order to ensure even dispersion of cells over a given well. Cells were then 
incubated overnight at 37 oC in an atmosphere containing 5 % CO2. Cytotoxic drug 
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dilutions were prepared at double their final concentration in cell culture medium. 
Volumes of the drug dilutions (100 µL) were then added to each well. Plates were then 
mixed gently as above. Cells were incubated for a further 5 days at 37 oC and 5 % CO2 
until the control wells had reached approximately 80-90 % confluency. Assessment of 
cell survival in the presence of drug was determined by the acid phosphatase assay.  
 
Combination toxicity assays 
The 96-well plates were seeded as described above and incubated overnight at 37 oC 
with 5 % CO2. Dilutions of cytotoxic drugs and other agents were prepared at 4X their 
final concentration in media. The drug solution (50 µL) and the combination drug 
solution (50 µL) were then added to each relevant well so that each well had a final 
volume of 200 µL. All potential toxicity-enhancing agents were dissolved in DMSO, 
ethanol or media. Stock solutions (approximately 1.5 mg/mL) were prepared in media; 
the filter was sterilised with a 0.22 µm filter and then used to prepare all subsequent 
dilutions. Cells were incubated for a further 5 days at 37 oC in an atmosphere of 5 % 
CO2. At this point the control wells would have reached approximately 80-90 % 
confluency. Cell number was assessed using acid phosphatase assay. 
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Conclusion 
 
In conclusion a number of new precursors to macrocycles, each containing 2-(2-
hydroxyethoxy)phenol, were synthesised. These precursors were then successfully 
used in the synthesis of novel macrocycles. The possibility of the optimisation of the
synthesis of these macrocycles was shown with the optimisation of 353. 
A number of new precursors to macrocycles, each containing morphine in place of 2-
(2-hydroxyethoxy)phenol, were also synthesised. These precursors were then used in 
the attempted generation of novel macrocycles. Although the isolation of the 
macrocycles containing morphine was unsuccessful, steps were taken that will 
contribute to the research of the group as further efforts are made at the isolation of 
these compounds.  
Each of the synthesised compounds were tested for metal extraction with some 
success. Cobalt picrate was only extracted by compound 344 and strontium picrate was 
only extracted by compound 340. The most interesting result from this analysis was the 
selective extraction of copper picrate by 352. 
A selection of the macrocycles and their precursors containing 2-(2-
hydroxyethoxy)phenol were subjected to toxicity testing against Pseudomonas 
aeruginosa, Escherichia coli, Klebsiella spp., Staphylococcus aureus, Salmonella spp., 
Enterococcus spp. and Bacillus subtilis. All compounds were found to be non-toxic 
over the concentration range 0-2000 µg per mL.  
A number of the products of this project were tested for inhibition of P-gp. There were 
preliminary positive results. 346 gave the most impressive result of these but its results 
were not repeatable. There were other positive results but due to the thorough 
investigation of 346 these results were not fully scrutinised. This work will be the basis
of a structural activity study which will be continued within the research group.  
The initial goal of this project was the synthesis of the macrocycles containing 
morphine. Although the attempts at this were not successful the study will be 
continued within the research group using the results in this project as a guide. New P-
gp inhibitors have been developed and investigation of this will also be continued 
within the research group in an effort to develop a more efficient inhibitor.  
 
  
 
 
 
 
 
APPENDIX 1 
 
NMR spectra
  
 
 
Compound: 337 
Furan-2,5-dicarbonyl dichloride 
1H and 13C NMR 
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Compound: 338 
Bis(2-(2-Hydroxyethoxy)phenyl)phthalate  
1H and 13C NMR 
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Compound: 339 
Bis(2-(2-Hydroxyethoxy)phenyl)isophthalate  
1H and 13C NMR 
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Compound: 340 
Bis(2-(2-Hydroxyethoxy)phenyl)terephthalate  
1H and 13C NMR 
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Compound: 341 
Bis(2-(2-Hydroxyethoxy)phenyl)pyridine-2,6-
dicarboxylate  
1H and 13C NMR 
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Compound: 342 
Bis(2-(2-Hydroxyethoxy)phenyl)furan-2,5-dicarboxylate 
1H and 13C NMR 
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Compound: 343 
Bis(2-(2-Hydroxyethoxy)phenyl)-2,2-dimethylmalonate 
1H and 13C NMR 
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Compound: 344 
Bis(2-(2-Hydroxyethoxy)phenyl)diglycolate 
1H and 13C NMR 
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Compound: 348 
2,3,6,7,10,11,17,18-tetrabenzo-1,4,9,12,15,20-
hexaoxacyclodoeicosa-2,6,10,17-tetraene-5,8,16,19-
tetraone 
1H and 13C NMR 
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Compound: 349 
2,3,6,7,10,11,17,19-tetrabenzo-1,4,9,12,15,21-
hexaoxacyclotrieicosa-2,6,10,17-tetraene-5,8,16,20-
tetraone 
1H and 13C NMR 
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Compound: 350 
2,3,6,7,10,11,17,20-tetrabenzo-1,4,9,12,15,22-
hexaoxacyclotetraeicosa-2,6,10,17,19-pentaene-
5,8,16,21-tetraone 
1H and 13C NMR 
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Compound: 351 
2,3,6,8,11,12,18,20-tetrabenzo-1,4,10,13,16,22-
hexaoxacyclotetraeicosa-2,6,11,18-tetraene-5,9,17,21-
tetraone 
1H and 13C NMR 
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Compound: 352 
2,3,6,8,11,12,18,21-tetrabenzo-1,4,10,13,16,23-
hexaoxacyclopentaeicosa-2,6,11,18,20-pentaene-
5,9,17,22-tetraone 
1H and 13C NMR 
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Compound: 353 
2,3,6,9,11,12,13,19,22-tetrabenzo-1,4,11,14,17,24-
hexaoxacyclohexaeicosa-2,6,8,12,19,21-hexaene-
5,10,18,23-tetraone 
1H and 13C NMR 
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Compound: 354 
2,3,11,12,-dibenzo-6,8,18,20-difurano-
1,4,7,10,13,16,19,22-octaoxacyclohexaeicosa-2,11-
diaene-5,9,17,21-tetraone 
1H and 13C NMR 
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4
.
2
9
0
4
.
3
0
1
4
.
3
1
2
4
.
5
6
2
4
.
5
6
9
4
.
5
7
3
4
.
5
8
0
4
.
5
8
4
6
.
9
2
9
6
.
9
3
6
6
.
9
3
9
6
.
9
5
7
6
.
9
7
6
7
.
0
5
2
7
.
0
5
6
7
.
0
7
3
7
.
0
7
7
7
.
1
5
8
7
.
1
6
5
7
.
1
8
0
7
.
1
8
4
7
.
2
0
4
7
.
2
1
9
7
.
2
2
3
7
.
2
8
2
4
.
0
0
3
.
9
9
4
.
0
5
1
.
9
9
2
.
0
6
2
1
.
0
1
2
.
0
1
Furan Macro
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Compound: 345 
2-(2-(Triethylsilyloxy)phenoxy)ethanol  
1H and 13C NMR 
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Compound: 346 
Bis(2-(2-Hydroxyphenoxy)ethyl)-2,2-dimethylmalonate 
1H and 13C NMR 
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Dimethyl Bottom Linked
With TES protection
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Compound: 347 
Bis(2-(2-Hydroxyphenoxy)ethyl)terephthalate  
1H and 13C NMR 
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Compound: 355 
Bis(2-(2-Hydroxyphenoxy)ethyl)isophthalate  
1H and 13C NMR 
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Compound: 356 
Bis(2-(2-hydroxyphenoxy)ethyl)furan-2,5-dicarboxylate 
1H and 13C NMR 
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Compound: 357 
2,3,9,10-dibenzo-6,16-tetramethyl-1,4,8,11,14,18-
hexaoxacyclohexaeicosa-2,9-diene-5,7,15,17-tetraone 
1H and 13C NMR 
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Compound: 358 
2,3,6,9,11,12,13,19,21-tetrabenzo-1,4,11,14,17,23-
hexaoxacyclopentaeicosa-2,6,8,12,19-pentaene-
5,10,18,22-tetraone 
1H and 13C NMR 
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4
.
3
6
1
4
.
3
7
1
4
.
3
8
2
4
.
5
2
0
4
.
5
3
1
4
.
5
4
1
6
.
9
6
9
6
.
9
7
2
6
.
9
8
8
6
.
9
9
2
7
.
0
0
7
7
.
0
1
1
7
.
0
3
2
7
.
0
3
6
7
.
0
5
3
7
.
0
5
6
7
.
0
8
1
7
.
0
8
5
7
.
1
0
1
7
.
1
0
5
7
.
1
9
6
7
.
2
0
1
7
.
2
1
6
7
.
2
1
7
7
.
2
1
9
7
.
2
2
1
7
.
2
3
6
7
.
2
4
0
7
.
4
4
1
7
.
4
6
3
7
.
4
8
2
7
.
7
2
7
8
.
1
2
0
8
.
1
2
4
8
.
1
3
6
8
.
1
4
1
4
.
1
0
3
.
9
7
6
.
2
7
1
.
9
8
1
.
0
5
4
.
0
0
2
.
9
8
 
 65707580859095100105110115120125130135140145150155160165170 ppm
6
2
.
9
5
6
6
.
9
1
7
6
.
7
2
7
7
.
0
4
7
7
.
2
4
7
7
.
3
5
1
1
4
.
6
7
1
2
2
.
0
8
1
2
3
.
0
9
1
2
7
.
1
6
1
2
8
.
5
4
1
2
9
.
6
7
1
3
0
.
1
3
1
3
0
.
7
4
1
3
2
.
8
5
1
3
3
.
9
1
1
4
0
.
9
0
1
4
9
.
6
5
1
6
3
.
8
3
1
6
5
.
3
1
 
  
 
 
Compound: 359 
2,3,11,12-dibenzo-1,4,7,10,13,16,19,22-
octaoxacyclotetraeicosa-2,11-diene-5,9,17,21-tetraone 
1H and 13C NMR 
 
 
 
 
 
 4.55.05.56.06.57.07.58.0 ppm
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Compound: 360 
2,3,6,9,12,13,19,21-tetrabenzo-20-aza-1,4,11,14,17,23-
hexaoxacyclopentaeicosa-2,6,8,12,19-pentaene-
5,10,18,22-tetraone 
1H and 13C NMR 
 
 
 
 
 
 4.55.05.56.06.57.07.58.0 ppm
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Compound: 361 
2,3,6,8,11,12,18,21-tetrabenzo-7-aza-1,4,10,13,16,23-
hexaoxacyclopentaeicosa-2,6,11,18,20-pentaene-
5,9,17,21-tetraone 
1H and 13C NMR 
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Compound: 362 
2,3,6,8,11,12,18,20-tetrabenzo-7,19-diaza-
1,4,10,13,16,22-hexaoxacyclotetraeicosa-2,6,11,18-
tetraene-5,9,17,21-tetraone 
1H and 13C NMR 
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Compound: 368 
bis(3-morphinyl) terephthalate 
1H and 13C NMR 
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Compound: 369 
bis(3-morphinyl) isophthalate 
1H and 13C NMR 
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Compound: 370 
bis(3-morphinyl) phthalate 
1H and 13C NMR 
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Compound: 371 
bis(3-morphinyl) pyridine-2,6-dicarboxylate 
1H and 13C NMR 
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Compound: 372 
bis(3-morphinyl) 2,2-dimethylmalonate 
1H and 13C NMR 
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Dimethyl opiate
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Compound: 373 
bis(3-morphinyl) diglycolate 
1H and 13C NMR 
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Compound: 380 
cyclo[3’-(6’-morphinyl terephthalate)(3-
morphinyl)terephthalate] 
1H and 13C NMR 
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Compound: 396 
3-O-triethylsilyl morphine 
1H and 13C NMR 
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